

FORM PTO-1390 (REV. 3-90)		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER PPT-20479-US	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)					
INTERNATIONAL APPLICATION NO. PCT/DK99/00118		INTERNATIONAL FILING DATE March 9, 1999		PRIORITY DATE CLAIMED March 9, 1998	
TITLE OF INVENTION PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS					
APPLICANT(S) FOR DO/EO/US Bjarne Due Larsen					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3. <input checked="" type="checkbox"/> This express request to immediately begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).					
<input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.					
<input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))					
a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input type="checkbox"/> has been transmitted by the International Bureau.					
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).					
<input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
<input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))					
a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).					
b. <input type="checkbox"/> have been transmitted by the International Bureau.					
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.					
d. <input checked="" type="checkbox"/> have not been made and will not be made.					
<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
<input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
<input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
11. <input type="checkbox"/> Documents forming the basis for the examination of the present application					
a. <input type="checkbox"/> the documents of the international application published by the International Bureau.					
b. <input type="checkbox"/> the documents of the international application published by the International Bureau as amended under Article 19 PCT before the International Bureau.					
<input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 are transmitted herewith.					
<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
c. <input type="checkbox"/> the documents of the international application published by the International Bureau as amended under Article 34 PCT in the procedure before the International Preliminary Examining Authority.					
<input type="checkbox"/> Amendments under Article 34 PCT which are the Annexes to the International Preliminary Examination Report (35 U.S.C. 371(c)(5)) are transmitted herewith.					
<input type="checkbox"/> A translation of the Annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 12. to 17. below concern other document(s) or information included:					
12. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
13. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
14. <input checked="" type="checkbox"/> A FIRST Preliminary Amendment.					
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
15. <input type="checkbox"/> A substitute specification.					
16. <input type="checkbox"/> A change of power of attorney and/or address letter.					
17. <input type="checkbox"/> Other items or information:					

Attorney Docket No.: PPT-20479-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Larsen

Serial No.: To Be Decided Group Art Unit: To be Decided

Filed: Examiner: To Be Decided

For: PHARMACOLOGICALLY ACITVE PEPTIDE CONJUGATES HAVING A
REDUCED TENDENCY TOWARDS ENZYME HYDROLYSISVERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c))-Small Business ConcernAssistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
- ☒ an official of the small business concern empowered to act on behalf of the
concern identified below:

Name of ConcernZealand Pharmaceuticals A/S.....

Address of ConcernAgern Allé 3.....

.....DK-2970 Hørsholm.Denmark.....

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 2.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For

09-07-99 15:49

purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern and/or there is an obligation under contract or law by the inventor(s) to convey rights to the small business concern with regard to the invention

entitled.....PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A
REDUCED TENDENCY TOWARDS ENZYME HYDROLYSIS.....

by inventor(s).....Bjarne Due Larsen.....

described in

☒ the specification filed herewith

☐ application serial no., filed

☐ patent no., issued

SECRET 20 0654460

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

FULL NAME

ADDRESS

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT

ORGANIZATION

FULL NAME

ADDRESS

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT

ORGANIZATION

FULL NAME

ADDRESS

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT

ORGANIZATION

FULL NAME

ADDRESS

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT

ORGANIZATION

662720"06574260

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Send correspondence to:

CHERYL H. AGRIS, PH.D.
Attorney at Law
P.O. Box 806
Pelham, N.Y. 10803

Direct Telephone calls to:

CHERYL H. AGRIS, PH.D.
(914) 738-7921

Attorney at La

Name of person signing.....EVA STEJNESS

Title of person other than owner.....MD, CEO

Address of person signing..Agern Allé 3.....
.....DK-2970 Hørsholm, Denmark.....

Signature.....

Date.....9/7/98

* NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities.
(37 CFR 1.27)

66E720 06574650

Attorney Docket No.: PPT-20479-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Larsen

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: Concurrently Herewith

Examiner: To Be Assigned

For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES
HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC
HYDROLYSIS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Before the above-captioned application is taken up for examination,
entry of the following amendment is respectfully requested:

IN THE CLAIMS:

Please cancel claims 33-36 and 38, 40, 42, 44, 46, 48, 50 and 51
without prejudice.

Please amend claims 1, 6, 7, 9, 13, 16, 20, 21, 31, and 32 as follows:

1. (amended) A pharmaceutically active peptide conjugate having a
reduced tendency towards enzymatic cleavage comprising X and Z,

wherein X is a pharmaceutically active peptide sequence, and

wherein Z is a stabilising peptide sequence, of 4-20 amino acid units covalently
bound to X, wherein each amino acid unit in said stabilising peptide sequence,
Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln,

666720"0654E60

Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



wherein R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} -alkyl, phenyl, and phenyl-methyl, wherein C_{1-6} -alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C_{1-6} -alkyl, C_{2-6} -alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R^1 and R^2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

wherein the ratio between the half-life of said peptide conjugate and the half-life of the corresponding pharmaceutically active peptide sequence, X, when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when said pharmaceutically active peptide X is not orally absorbed, said conjugate is absorbed,

or a salt thereof, [with the proviso that said pharmaceutically active peptide conjugate is not selected from

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH,

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Glu)₆-OH,

H-Tyr-Gly-Gly-Phe-Leu-(Glu)₆-OH and

H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH].

In claim 6, line 1, please delete “any of the preceding claims” and insert –claim 1--.

In claim 7, line 1, please delete “claim 5 or 6” and insert –claim 1--.

In claim 9, line 1, please delete “any of claims 5 to 8” and insert –claim 1--.

In claim 13, line 1, please delete “any of claims 5 to 9” and insert –claim 1--.

In claim 16, line 1, please delete “any of claims 5 to 9” and insert –claim 1--.

In claim 20, line 1, please delete “any of claims 5 to 18” and insert –claim 1--.

In claim 21, line 1, please delete “any of claims 5-7” and insert –claim 1--.

In claim 25, line 1, please delete “any of the preceding claims” and insert –claim 1--.

In claim 31, please delete “or claim 30”.

In claim 32, please delete “as defined in any of the claims 1-25” and insert –according to claim 1--.


REMARKS

This amendment is made to more clearly define the subject matter which Applicants regard as their invention and to remove multiple

dependencies. This amendment contains no new matter and is supported by the specification. Entry of the amendment is respectfully requested.

Respectfully submitted,

Date: July 12, 1999



Cheryl H. Agris, Reg. No. 34,086

P.O. Box 806

Pelham, N.Y. 10803

(914) 712-0093

666770089760



101 Rec'd PCT/PTO 21 OCT 1999

09/341560

Attorney Docket No. PPT-20479-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Larsen

Appln. Serial No.: 09/341,590

Examiner: To Be Decided

Filed: July 12, 1999

Group Art Unit: To Be Decided

For: Pharmacologically Active Peptide Conjugates Having a Reduced Tendency Towards Enzymatic Hydrolysis

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the application as follows:

IN THE SPECIFICATION

Please amend the specification as follows:

On page 3, line 30, please insert after "(DPLCE)", --(SEQ ID NO. 1)--.

On page 3, lines 30-31, please insert after "DPLCE-Arg-Pro-Ala", --(SEQ ID NO. 2)--.

On page 3, line 31, please insert after "DPDPE-Phe", --(SEQ ID NO. 3)--.

On page 3, line 31, please insert after "DPLCE-Phe", --(SEQ ID NO. 4)--.

On page 3, line 31, please insert after "DPDPE-Arg-Gly", --(SEQ ID NO. 5)--.

On page 3, line 31, please insert after "DPLCE-Arg-Gly", --(SEQ ID NO. 6)--.

09/341560

On page 3, line 31 to page 4, line 1, please insert after "DPDPE-Phe-Ala-NH-C₆H₁₃", --(SEQ ID NO. 7)--.

On page 4, line 1, please insert after "DPDPE-Phe-Ala-CONH₂", --(SEQ ID NO. 7)--.

On page 4, line 2, please insert after "DPDPE-Arg-Gly", --(SEQ ID NO. 5)--.

On page 4, line 17, please insert after "DSIP-(Lys-Glu)₃", --(SEQ ID NO. 8)--.

On page 4, lines 17-18, please insert after "DSIP-(Glu)₆", --(SEQ ID NO. 9)--.

On page 4, line 18, please insert after "Leu-enkephalin-(Glu)₆", --(SEQ ID NO. 10)--.

On page 4, line 18, please insert after "Leu-enkephalin-(Lys)₆", --(SEQ ID NO. 11)--.

On page 6, line 9, please insert after "H-Tyr-Gly-Gly-Phe-Leu-(Glu)₆-OH", --(SEQ ID NO. 10)--.

On page 6, line 10, please insert after "H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 9, line 15, please insert after "(H-Tyr-Gly-Gly-Phe-Leu-OH)", --(SEQ ID NO. 12)--.

On page 9, line 16, please insert after "(Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂)", --(SEQ ID NO. 13)--.

On page 10, lines 9-10, please insert after "(Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala)", --(SEQ ID NO. 14)--.

On page 10, lines 10-11, please insert after “(Ala-Leu-Leu-Glu-Thr-Tyr-Cys-Ala-Thr-Pro-Ala-Lys-Ser-Glu)”, --(SEQ ID NO. 15)--.

On page 10, lines 11-12, please delete “insulin growth factor 1(30-40)” and insert in its place, --insulin growth factor I(30-41)(Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr) (SEQ ID NO. 16)--.

On page 10, lines 12-13, please delete “insulin growth factor 1(24-41)” and insert in its place, --insulin growth factor I(24-41)(Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr) (SEQ ID NO. 17)--.

On page 10, lines 13-14, please insert after “(Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg)”, --(SEQ ID NO. 18)--.

On page 10, lines 14-15, please insert after “(Tyr-Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg)”, --(SEQ ID NO. 19)--.

On page 10, lines 15-16, please delete “(Asp-Val-Ser-Thr-Pro-Pro-Thr-Val-Leu-Pro-Asp-Asn-Phe-Pro-Arg-Tyr)” and insert in its place, --(Asp-Val-Ser-Thr-Pro-Pro-Thr-Val-Leu-Pro-Asp-Asn-Phe-Pro-Arg-Tyr) (SEQ ID NO. 20)--.

On page 10, line 17, please delete “(His-DTrp-Ala-Trp-DPhe-Lys-NH₂)” and insert in its place, --(His-DTrp-Ala-Trp-DPhe-Lys-NH₂) (SEQ ID NO. 21)--.

On page 10, lines 17-18, please insert after “(Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys)”, --(SEQ ID NO. 22)--.

On page 10, lines 18-19, please insert after “(Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu)”, --(SEQ ID NO. 23)--.

On page 10, lines 19-20, please insert after “(Leu-Thr-Phe-Lys-Phe-Tyr-Met-Pro-Lys-Lys-Ala)”, --(SEQ ID NO. 24)--.

On page 10, lines 20-22, please delete “(His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂)” and insert in its place, -- (His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂) (SEQ ID NO. 25)--.

On page 10, lines 22-24, please insert after “(His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser)”, --(SEQ ID NO. 26)--.

On page 10, line 25, please insert after “Cys(Acm)-Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys(Acm)”, --(SEQ ID NO. 27)--.

On page 10, lines 26-27, please delete “(D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu)” and insert in its place, --(D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu) (SEQ ID NO. 28)--.

On page 10, lines 27-28, please delete “D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Tyr-Leu”, and insert in its place, --(D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Tyr-Leu) (SEQ ID NO. 29)--.

On page 10, lines 28-31, please insert after “(Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys; Disulfide bridge: Cys37-Cys53)”, --(SEQ ID NO. 30)--.

On page 10, line 31 to page 11, line 1, please insert after “(Met-Cys-His-cyclohexylAla-Gly-Gly-Arg-Met-Asp-Arg-Ile-Ser-Cys-Tyr-Argü disulfide bridge cys2-cys13)”, --(SEQ ID NO. 31)--.

On page 11, lines 1-2, please insert after “(also known as MT-II, alpha-MSH4-10-NH₂, or Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10)”, --(SEQ ID NO. 32)--.

On page 11, lines 2-4, please insert after “(Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn)”, --(SEQ ID NO. 33)--.

On page 11, lines 4-6, please delete “(also known as 8-ornithine-vasopressin, (POR-8), [Phe2,Ile3,Orn8]vasopressin), Cys-Phe-Ile-Gln-Asn-Cys-Pro-Orn-Gly-NH₂, Disulfide bridge: Cys1-Cys6)” and replace with --(also known as 8-ornithine-vasopressin, (POR-8), [Phe2,Ile3,Orn8]vasopressin or Cys-Phe-Ile-Gln-Asn-Cys-Pro-Orn-Gly-NH₂, Disulfide bridge: Cys1-Cys6) (SEQ ID NO. 34)--.

On page 11, lines 6-7, please insert after “(DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr-ol; disulfide bridge: Cys2-Cys7)”, --(SEQ ID NO. 35)--.

On page 11, lines 8-10, please insert after “(Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH₂; Disulfide bridge: Cys2-Cys7)”, --(SEQ ID NO. 36)--.

On page 11, line 10, please delete “Tyr-Pro-Trp-Phe-NH₂”, and insert in its place, --(Tyr-Pro-Trp-Phe-NH₂) (SEQ ID NO. 37)--.

On page 11, lines 10-11, please delete “Tyr-Pro-Phe-Phe-NH₂”, and insert in its place, --(Tyr-Pro-Phe-Phe-NH₂) (SEQ ID NO. 38)--.

On page 11, lines 11-12, please insert after “(also known as Orphanin FQ, Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln)”, --(SEQ ID NO. 39)--.

On page 11, lines 12-13, please insert after “(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His)”, --(SEQ ID NO. 40)--.

On page 11, lines 13-14, please insert after “(Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg)”, --(SEQ ID NO. 41)--.

On page 11, lines 14-15, please insert after “(Gly-Pro-Hyp-Gly-Ala-Gly)”, --(SEQ ID NO. 42)--.

On page 11, lines 15-16, please insert after “(Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH₂)”, --(SEQ ID NO. 43)--.

On page 11, lines 16-17, please insert after “(Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val)”, --(SEQ ID NO. 44)--.

On page 11, lines 17-18, please delete “(Glp)-Glu-Arg-Pro-Pro-Leu-Gln-Gln-Pro-Pro-His-Arg-Asp)”, and insert – ((Glp)-Glu-Arg-Pro-Pro-Leu-Gln-Gln-Pro-Pro-His-Arg-Asp) (SEQ ID NO. 45)--.

On page 11, lines 18-19, please delete “Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys; Disulfide bridge: Cys2-Cys13”, and insert (Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys; Disulfide bridge: Cys2-Cys13) (SEQ ID NO. 46)--.

On page 11, lines 19-20, please insert after “(Ac-D-Bhg-Leu-Asp-Ile-Ile-Trp)”, --(SEQ ID NO. 47)--.

On page 11, line 20, please insert after “(Ac-D-Dip-Leu-Asp-Ile-Ile-Trp)”, --(SEQ ID NO. 48)--.

On page 11, line 21, please insert after “(His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val)”, --(SEQ ID NO. 49)--.

On page 11, lines 21-22, please insert after “(Asn-Val-Ile-Gln-Ile-Ser-Asn-Asp-Leu-Glu-Asn-Leu-Arg)”, --(SEQ ID NO. 50)--.

On page 11, lines 22-23, please insert after “(Boc-Arg-Ala-DTrp-Phe-DPro-Pro-Nle-NH₂)”, --(SEQ ID NO. 51)--.

On page 11, line 23, please insert after “(Tyr-Pro-Trp-Gly-NH₂)”, --(SEQ ID NO. 52)--.

On page 11, line 24, please insert after “(Thr-Arg-Ser-Ala-Trp)”, --(SEQ ID NO. 53)--.

On page 11, lines 24-25, please delete “Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn”, and insert --(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn) (SEQ ID NO. 54)--.

On page 14, line 14, please insert after “Lys-Lys-Lys-Lys”, --(SEQ ID NO. 55)--.

On page 14, line 17, please insert after “Lys-Lys-Lys-Lys-Lys”, --(SEQ ID NO. 56)--.

On page 14, line 17, please insert after “Xaa-Lys-Lys-Lys-Lys”, --(SEQ ID NO. 57)--.

On page 14, lines 17-18, please insert after “Lys-Xaa-Lys-Lys-Lys”, --(SEQ ID NO. 58)--.

On page 14, line 18, please insert after “Lys-Lys-Xaa-Lys-Lys”, --(SEQ ID NO. 59)--.

On page 14, line 18, please insert after “Lys-Lys-Lys-Xaa-Lys”, --(SEQ ID NO. 60)--.

On page 14, line 18, please insert after "Lys-Lys-Lys-Lys-Xaa", --(SEQ ID NO. 61)--.

On page 14, line 25, please insert after "Lys-Lys-Lys-Lys-Lys-Lys", --(SEQ ID NO. 62)--.

On page 14, lines 25-26, please insert after "Xaa-Lys-Lys-Lys-Lys-Lys", --(SEQ ID NO. 63)--.

On page 14, line 26, please insert after "Lys-Xaa-Lys-Lys-Lys-Lys", --(SEQ ID NO. 64)--.

On page 14, line 26, please insert after "Lys-Lys-Xaa-Lys-Lys-Lys", --(SEQ ID NO. 65)--.

On page 14, lines 26-27, please insert after "Lys-Lys-Lys-Xaa-Lys-Lys", --(SEQ ID NO. 66)--.

On page 14, line 27, please insert after "Lys-Lys-Lys-Lys-Xaa-Lys", --(SEQ ID NO. 67)--.

On page 14, line 27, please insert after "Lys-Lys-Lys-Lys-Lys-Xaa", --(SEQ ID NO. 68)--.

On page 14, lines 27-28, please insert after "Xaa-Xaa-Lys-Lys-Lys-Lys", --(SEQ ID NO. 69)--.

On page 14, line 28, please insert after "Xaa-Lys-Xaa-Lys-Lys-Lys", --(SEQ ID NO. 70)--.

On page 14, line 28, please insert after "Xaa-Lys-Lys-Xaa-Lys-Lys", --(SEQ ID NO. 71)--.

On page 14, line 28, please insert after "Xaa-Lys-Lys-Lys-Xaa-Lys", --(SEQ ID NO. 72)--

On page 14, line 29, please insert after "Xaa-Lys-Lys-Lys-Lys-Xaa", --(SEQ ID NO. 73)--

On page 14, line 29, please insert after "Lys-Xaa-Xaa-Lys-Lys-Lys", --(SEQ ID NO. 74)--

On page 14, line 29, please insert after "Lys-Xaa-Lys-Xaa-Lys-Lys", --(SEQ ID NO. 75)--

On page 14, lines 29-30, please insert after "Lys-Xaa-Lys-Lys-Xaa-Lys", --(SEQ ID NO. 76)--.

On page 14, line 30, please insert after "Lys-Xaa-Lys-Lys-Lys-Xaa", --(SEQ ID NO. 77)--

On page 14, line 30, please insert after "Lys-Lys-Xaa-Xaa-Lys-Lys", --(SEQ ID NO. 78)--

On page 14, lines 30-31, please insert after "Lys-Lys-Xaa-Lys-Xaa-Lys", --(SEQ ID NO. 79)--.

On page 14, line 31, please insert after "Lys-Lys-Xaa-Lys-Lys-Xaa", --(SEQ ID NO. 80)--

On page 14, line 31, please insert after "Lys-Lys-Lys-Xaa-Xaa-Lys", --(SEQ ID NO. 81)--

On page 14, lines 31-32, please insert after "Lys-Lys-Lys-Xaa-Lys-Xaa", --(SEQ ID NO. 82)--.

On page 14, line 32, please insert after "Lys-Lys-Lys-Lys-Xaa-Xaa", --(SEQ ID NO. 83)--.

On page 16, line 11, please insert after "(Lys-Glu)₃", --(SEQ ID NO. 84)--.

On page 16, line 11, please insert after "(Glu-Lys)₃", --(SEQ ID NO. 85)--.

On page 16, line 18, please insert after "Lys₃-Glu₃", --(SEQ ID NO. 86)--.

On page 16, line 18, please insert after "Glu₃-Lys₃", --(SEQ ID NO. 87)--.

On page 19, line 21, please insert after "(GHRH(1-44)(Human)-Lys₆-NH₂)", --(SEQ ID NO. 88)--.

On page 19, line 25, please insert after "(GHRH (1-44)(Human)-Glu₆-NH₂)", --(SEQ ID NO. 89)--.

On page 19, lines 28-29, please insert after "(Lys₆-PTH(1-34)(Human)-OH)", --(SEQ ID NO. 90)--.

On page 20, lines 2-3, please insert after "(PTH(1-34)(Human)-Lys₆-OH)", --(SEQ ID NO. 91)--.

On page 20, line 6, please insert after "(GLP-1-(7-36)(Human)-Lys₆-OH)", --(SEQ ID NO. 92)--.

On page 20, line 9, please insert after "(EMP-1-Lys₆-OH)", --(SEQ ID NO. 93)--.

On page 20, line 12, please insert after “(Lys₆-EMP-1-OH)”, --(SEQ ID NO. 94)--.

On page 20, line 15, please insert after “(Lys₆-EMP-1-Lys₆-OH)”, --(SEQ ID NO. 95)--.

On page 20, line 18, please insert after “(GHRP-(Lys)₆-NH₂)”, --(SEQ ID NO. 96)--.

On page 20, lines 20-21, please insert after “(Leu-enkephalin-Lys-Lys-Glu-Glu-Glu-Lys-OH)”, --(SEQ ID NO. 97)--.

On page 20, lines 23-24, please insert after “(Leu-enkephalin-Lys-Glu-Glu-Glu-Glu-Lys-OH)”, --(SEQ ID NO. 98)--.

On page 20, line 26, please delete “H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys-OH (Leu-enkephalin-(Lys-Glu)₃) and insert –H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Lys-Glu-Lys-Glu-OH(Leu-enkephalin-(Lys-Glu)₃) (SEQ ID NO. 99)--.

On page 20, line 28, please insert after “(Leu-enkephalin-(Dpr)₆-OH)”, --(SEQ ID NO. 100)--.

On page 20, line 30, please insert after “(H-Lys₆-Leu-enkephalin)”, --(SEQ ID NO. 101)--.

On page 21, line 3, please insert after “(H-Lys₆-Leu-enkephalin-Lys₆-OH)”, --(SEQ ID NO. 102)--.

On page 21, line 5, please insert after “(GnRH-Lys₆-OH)”, --(SEQ ID NO. 103)--.

On page 21, line 7, please insert after “(GnRH-(Lys-Glu)₃-OH)”, --(SEQ ID NO. 104)--.

On page 21, lines 10-11, please insert after “(PTH 1-34 human-(Lys-Glu)₃-OH)”, --(SEQ ID NO. 105)--.

On page 44, line 18, please insert after “(Leu-enkephalin-Glu₆-OH)”, --(SEQ ID NO. 10)--.

On page 44, line 22, please insert after “Glu₆”, --(residues 6-12 in SEQ ID NO. 10)--.

On page 45, line 5, please insert after “(Leu-enkephalin-Lys₆-OH)”, --(SEQ ID NO. 11)--

On page 45, line 9, please insert after “Lys₆”, --(SEQ ID NO. 62)--.

On page 45, line 24, please insert after “(H-Lys₆-Leu-enkephalin)”, --(SEQ ID NO. 101)--.

On page 45, lines 29-30, please insert after “H-Lys₆-enkephalin sequence”, --(SEQ ID NO. 101)--.

On page 46, lines 10-11, please insert after “(H-Lys₆-Leu-enkephalin-Lys₆-OH)”, --(SEQ ID NO. 102)--.

On page 46, line 14, please insert after “Lys₆”, --(SEQ ID NO. 62)--.

On page 46, line 15, please insert after “H-Lys₆-enkephalin sequence”, --(SEQ ID NO. 101)--.

On page 46, line 27, please insert after “(Leu-enkephalin-Lys-Lys-Glu-Glu-Glu-Lys-OH)”, --(SEQ ID NO. 97)--.

On page 47, line 10, please insert after “(Leu-enkephalin-Lys-Glu-Glu-Glu-Lys-OH)”, --(SEQ ID NO. 98)--.

On page 47, line 26, please insert after “(Leu-enkephalin-(Orn)₆-OH)”, --(SEQ ID NO. 106)--.

On page 48, line 11, please insert after “(Leu-enkephalin-(Dbu)₆-OH)”, --(SEQ ID NO. 107)--.

On page 48, line 27, please insert after “(Leu-enkephalin-(Dpr)₆-OH)”, --(SEQ ID NO. 108)--.

On page 49, line 10, please insert after “(Leu-enkephalin-Lys₁₀-OH)”, --(SEQ ID NO. 109)--.

On page 49, line 27, please insert after “(DSIP-Glu₆-OH)”, --(SEQ ID NO. 9)--.

On page 49, line 30, please insert after “Glu₆”, -- (residues 10-15 of SEQ ID NO. 9)--.

On page 49, line 31, please insert after “DSIP sequence”, --(SEQ ID NO. 110)--.

On page 50, lines 13-14, please insert after “(DSIP-(Lys-Glu)₃-OH)”, --(SEQ ID NO. 8)-

On page 50, line 17, please insert after “(LysGlu)₃”, --(SEQ ID NO. 84)--.

On page 50, line 18, please insert after “DSIP sequence”, --(SEQ ID NO. 110)--.

On page 51, line 1, please insert after “(DSIP)”, --(SEQ ID NO. 110)--.

On page 51, line 8, please insert after “DSIP sequence”, --(SEQ ID NO. 110)--.

On page 51, lines 22-23, please insert after “H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-Lys₆-OH (Substance P-Lys₆-OH)”, --(SEQ ID NO. 111)--.

On page 51, line 25, please insert after “Lys₆”, --(SEQ ID NO. 62)--.

On page 51, line 26, please insert after “Substance P sequence”, --(SEQ ID NO. 112)--.

On page 52, line 7, please insert after “(Substance-P-NH₂)”, --(SEQ ID NO. 112)--.

On page 52, line 23, please insert after “(Substance-P-Lys₆-NH₂)”, --(SEQ ID NO. 111)--.

On page 53, line 8, please insert after “(K₆-Substance-P-NH₂)”, --(SEQ ID NO. 113)--.

On page 53, line 23, please insert after “(GHRP-(Lys)₆-NH₂)”, --(SEQ ID NO. 96)--.

On page 54, line 22, please insert after “(K₆-GHRP-NH₂)”, --(SEQ ID NO. 114)--.

On page 55, line 7, please insert after “(GnRH-Lys₆-OH)”, --(SEQ ID NO. 103)--.

On page 55, line 10, please insert after “Lys₆”, --(SEQ ID NO. 62)--.

On page 55, line 11, please insert after “GnRH sequence”, --(SEQ ID NO. 115)--.

On page 55, lines 24-25, please insert after “pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys-Glu)₃-OH (GnRH-(Lys-Glu)₃-OH)”, --(SEQ ID NO. 104)--.

On page 55, line 28, please insert after “(Lys-Glu)₃”, --(SEQ ID NO. 84)--.

On page 55, line 29, please insert after “GnRH sequence”, --(SEQ ID NO. 115)--.

On page 56, lines 11-12, please delete “pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (GnRH-NH₂) NH₂” and insert in its place --pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (GnRH-NH₂) (SEQ ID NO. 115)--.

On page 56, lines 26-27, please delete “(K₆-GnRH-NH₂) NH₂”, and insert in its place, --(K₆-GnRH-NH₂) (SEQ ID NO. 116)--.

On page 57, lines 9-10, please insert after “(EMP-1-OH)”, --(SEQ ID NO. 117)--.

On page 57, lines 26-27, please insert after “(EMP-1-Lys₆-OH)”, --(SEQ ID NO. 93)--.

On page 58, lines 13-14, please insert after “(K₆-EMP-1-OH)”, --(SEQ ID NO. 94)--.

On page 58, lines 30-32, please insert after “(GLP-1-(7-36)(Human)-OH)”, --(SEQ ID NO. 118)--.

On page 59, lines 14-16, please insert after “(GLP-1-(7-36)(Human)-Lys₆-OH)”, --(SEQ ID NO. 92)--.

On page 60, lines 1-3, please insert after “(PTH(1-34)(Human)-OH)”, --(SEQ ID NO. 119)--.

On page 60, lines 17-19, please insert after “(PTH(1-34)(Human)-Lys₆-OH)”, --(SEQ ID NO. 91)--.

On page 61, lines 2-4, please insert after “(PTH 1-34 human-(Lys-Glu)₃-OH)”, --(SEQ ID NO. 105)--.

On page 61, line 7, please insert after “(Lys-Glu)₃”, --(SEQ ID NO. 84)--.

On page 61, line 8, please insert after “PTH sequence”, --(SEQ ID NO. 119)--.

On page 61, lines 21-23, please insert after “OH (Lys₆-PTH(1-34)(Human)-OH)”, --(SEQ ID NO. 90)--.

On pages 62-65, please delete

“Table 1

HPLC Gradient	Peptide / Peptide Conjugate
25 – 40% B in 15 minutes	H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (PTH(1-34)(Human)-OH)
25 – 40% B in 15 minutes	H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys) ₆ -OH (PTH(1-34)(Human)-(Lys) ₆ -OH)
25 – 40% B in 15 minutes	H-(Lys) ₆ -Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH ((Lys) ₆ -PTH(1-34)(Human)-OH)

25 – 50% B in 15 minutes	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu- Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg- OH (GLP-1(7-36)(Human)-OH)
25 – 50% B in 15 minutes	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu- Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg- (Lys) ₆ -OH (GLP-1(7-36)(Human)-(Lys) ₆ -OH)
5 – 50% B in 15 minutes	H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val- Cys-Lys-Pro-Gln-Gly-Gly-OH (EMP-1-OH)
5 – 50% B in 15 minutes	H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val- Cys-Lys-Pro-Gln-Gly-Gly-(Lys) ₆ -OH (EMP-1-(Lys) ₆ -OH)
10 – 50% B in 15 minutes	H-(Lys) ₆ -Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr- Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH ((Lys) ₆ -EMP-1-OH)
10 – 50% B in 15 minutes	H-(Lys) ₆ -Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr- Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys) ₆ -OH ((Lys) ₆ -EMP-1-(Lys) ₆ -OH)
5 – 40% B in 15 minutes	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂ (Substance P-NH ₂)
5 – 40% B in 15 minutes	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys) ₆ -NH ₂ (Substance P-(Lys) ₆ -NH ₂)

25 – 40% B in 15 minutes	H-(Lys) ₆ -Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂ <i>((Lys)₆-Substance P-NH₂)</i>
40 – 100% B in 15 minutes	H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH <i>(DSIP)</i>
40 – 100% B in 15 minutes	H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu) ₃ -OH <i>(DSIP-(Lys-Glu)₃-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-OH <i>(Leu-Enkephalin)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Lys) ₆ -OH <i>(Leu-Enkephalin-(Lys)₆-OH)</i>
10 – 35% B in 15 minutes	H-(Lys) ₆ -Tyr-Gly-Gly-Phe-Leu-OH <i>((Lys)₆-Leu-Enkephalin-OH)</i>
10 – 35% B in 15 minutes	H-(Lys) ₆ -Tyr-Gly-Gly-Phe-Leu-(Lys) ₆ -OH <i>((Lys)₆-Leu-Enkephalin-(Lys)₆-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Lys) ₁₀ -OH <i>(Leu-Enkephalin-(Lys)₁₀-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Orn) ₆ -OH <i>(Leu-Enkephalin-(Orn)₆-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Dbu) ₆ -OH <i>(Leu-Enkephalin-(Dbu)₆-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Dpr) ₆ -OH <i>(Leu-Enkephalin-(Dpr)₆-OH)</i>

5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-Lys(Glu) ₄ -Lys-OH <i>(Leu-Enkephalin-Lys-(Glu)₄-Lys-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu) ₃ -(Lys) ₂ -OH <i>(Leu-Enkephalin-Lys-(Glu)₃-(Lys)₂-OH)</i>

and insert in its place,

--Table 1

HPLC Gradient	Peptide / Peptide Conjugate
25 – 40% B in 15 minutes	H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu- Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp- Val-His-Asn-Phe-OH <i>(PTH(1-34)(Human)-OH)</i> (SEQ ID NO. 119)
25 – 40% B in 15 minutes	H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu- Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp- Val-His-Asn-Phe-(Lys) ₆ -OH <i>(PTH(1-34)(Human)-(Lys)₆-OH)</i> (SEQ ID NO. 91)
25 – 40% B in 15 minutes	H-(Lys) ₆ -Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys- His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu- Gln-Asp-Val-His-Asn-Phe-OH <i>((Lys)₆-PTH(1-34)(Human)-OH)</i> (SEQ ID NO. 90)
25 – 50% B in 15 minutes	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu- Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg- OH <i>(GLP-1(7-36)(Human)-OH)</i> (SEQ ID NO. 118)

25 – 50% B in 15 minutes	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu- Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg- (Lys) ₆ -OH (GLP-1(7-36)(Human)-(Lys) ₆ -OH) (SEQ ID NO. 92)
5 – 50% B in 15 minutes	H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val- Cys-Lys-Pro-Gln-Gly-Gly-OH (EMP-1-OH) (SEQ ID NO. 117)
5 – 50% B in 15 minutes	H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val- Cys-Lys-Pro-Gln-Gly-Gly-(Lys) ₆ -OH (EMP-1-(Lys) ₆ -OH) (SEQ ID NO. 93)
10 – 50% B in 15 minutes	H-(Lys) ₆ -Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr- Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH ((Lys) ₆ -EMP-1-OH) (SEQ ID NO. 94)
10 – 50% B in 15 minutes	H-(Lys) ₆ -Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr- Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys) ₆ -OH ((Lys) ₆ -EMP-1-(Lys) ₆ -OH) (SEQ ID NO. 95)
5 – 40% B in 15 minutes	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂ (Substance P-NH ₂) (SEQ ID NO. 112)
5 – 40% B in 15 minutes	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys) ₆ -NH ₂ (Substance P-(Lys) ₆ -NH ₂) (SEQ ID NO. 111)
25 – 40% B in 15 minutes	H-(Lys) ₆ -Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂ ((Lys) ₆ -Substance P-NH ₂) (SEQ ID NO. 113)

40 – 100% B in 15 minutes	H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH (<i>DSIP</i>) (SEQ ID NO. 110)
40 – 100% B in 15 minutes	H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu) ₃ -OH (<i>DSIP-(Lys-Glu)₃-OH</i>) (SEQ ID NO. 8)
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-OH (<i>Leu-Enkephalin</i>) (SEQ ID NO. 12)
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Lys) ₆ -OH (<i>Leu-Enkephalin-(Lys)₆-OH</i>) (SEQ ID NO. 11)
10 – 35% B in 15 minutes	H-(Lys) ₆ -Tyr-Gly-Gly-Phe-Leu-OH (<i>(Lys)₆-Leu-Enkephalin-OH</i>) (SEQ ID NO. 101)
10 – 35% B in 15 minutes	H-(Lys) ₆ -Tyr-Gly-Gly-Phe-Leu-(Lys) ₆ -OH (<i>(Lys)₆-Leu-Enkephalin-(Lys)₆-OH</i>) (SEQ ID NO. 102)
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Lys) ₁₀ -OH (<i>Leu-Enkephalin-(Lys)₁₀-OH</i>) (SEQ ID NO. 109)
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Orn) ₆ -OH (<i>Leu-Enkephalin-(Orn)₆-OH</i>) (SEQ ID NO. 106)
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Dbu) ₆ -OH (<i>Leu-Enkephalin-(Dbu)₆-OH</i>) (SEQ ID NO. 107)
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Dpr) ₆ -OH (<i>Leu-Enkephalin-(Dpr)₆-OH</i>) (SEQ ID NO. 108)
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-Lys(Glu) ₄ -Lys-OH (<i>Leu-Enkephalin-Lys-(Glu)₄-Lys-OH</i>) (SEQ ID NO. 98)

5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu) ₃ -(Lys) ₂ -OH <i>(Leu-Enkephalin-Lys-(Glu)₃-(Lys)₂-OH)</i> (SEQ ID NO. 120)
----------------------------	---

--

On page 65, lines 19-20, please insert after “(PTH(1-34)(Human)-OH)”, --(SEQ ID NO. 119)--.

On page 65, lines 23-24, please insert after “H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH”, --(SEQ ID NO. 119)--.

On page 66, lines 5-6, please insert after “H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH”, --(SEQ ID NO. 119)--.

On page 66, line 14, please insert after “(PTH(1-34)(Human)-(Lys)₆-OH)”, --(SEQ ID NO. 91)--.

On page 66, lines 17-19, please insert after “H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys)₆-OH”, --(SEQ ID NO. 91)--.

On page 66, lines 25-27, please insert after “H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys)₆-OH”, --(SEQ ID NO. 91)--.

On page 67, line 3, please insert after “((Lys)₆-PTH(1-34)(Human)-OH)”, --(SEQ ID NO. 90)--.

On page 67, lines 6-8, please insert after "H-(Lys)₆-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH", --(SEQ ID NO. 90)--.

On page 67, line 14, please insert after "(GLP-1(7-36)(Human)-OH) ", --(SEQ ID NO. 118)--.

On page 67, lines 17-18, please insert after "H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-OH", --(SEQ ID NO. 118)--.

On page 67, lines 25-26, please insert after "H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-OH", --(SEQ ID NO. 118)--.

On page 68, line 3, please insert after "(GLP-1(7-36)(Human)-(Lys)₆-OH)", --(SEQ ID NO. 92)--.

On page 68, lines 6-7, please insert after "H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-(Lys)₆-OH", --(SEQ ID NO. 92)--.

On page 68, lines 14-15, please insert after "H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-(Lys)₆-OH", --(SEQ ID NO. 92)--.

On page 68, line 22, please insert after "(EMP-1-OH)", --(SEQ ID NO. 117)--.

On page 68, lines 25-26, please insert after "H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH", --(SEQ ID NO. 117)--.

On page 69, lines 2-3, please insert after "H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH", --(SEQ ID NO. 117)--.

On page 69, line 8, please insert after "(EMP-1-(Lys)₆-OH)", --(SEQ ID NO. 93)--.

On page 69, lines 11-12, please insert after "H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH", --(SEQ ID NO. 93)--.

On page 69, lines 17-18, please insert after "H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH", --(SEQ ID NO. 93)--.

On page 69, line 23, please insert after "((Lys)₆-EMP-1-OH)", --(SEQ ID NO. 94)--.

On page 69, lines 26-27, please insert after "H-(Lys)₆-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH", --(SEQ ID NO. 94)--.

On page 70, line 2, please insert after "((Lys)₆-EMP-1-(Lys)₆-OH)", --(SEQ ID NO. 95)--.

On page 70, lines 5-6, please insert after "H-(Lys)₆-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH", --(SEQ ID NO. 95)--.

On page 70, line 10, please insert after "(Substance P)", --(SEQ ID NO. 112)--.

On page 70, line 13, please insert after "H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂", --(SEQ ID NO. 112)--.

On page 70, line 20, please insert after "H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂", --(SEQ ID NO. 112)--.

On page 70, line 27, please insert after "H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys)₆-NH₂ (Substance P-(Lys)₆-NH₂)", --(SEQ ID NO. 111)--.

On page 70, line 30, please insert after "H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys)₆-NH₂", --(SEQ ID NO. 111)--.

On page 71, line 5, please insert after "H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys)₆-NH₂", --(SEQ ID NO. 111)--.

On page 71, line 12, please insert after "((Lys)₆-Substance P-NH₂)", --(SEQ ID NO. 113)--.

On page 71, line 15, please insert after "H-(Lys)₆-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂", --(SEQ ID NO. 113)--.

On page 71, line 21, please insert after "H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH (DSIP)", --(SEQ ID NO. 110)--.

On page 71, line 24, please insert after "H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH", --(SEQ ID NO. 110)--.

On page 72, line 1, please insert after "(DSIP-(Lys-Glu)₃-OH)", --(SEQ ID NO. 8)--.

On page 72, line 4, please insert after "H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH", --(SEQ ID NO. 8)--.

On page 72, line 9, please insert after “H-Tyr-Gly-Gly-Phe-Leu-OH (Leu-Enkephalin)”, --(SEQ ID NO. 12)--.

On page 72, line 12, please insert after “H-Tyr-Gly-Gly-Phe-Leu-OH”, --(SEQ ID NO. 12)--.

On page 72, line 18, please insert after “H-Tyr-Gly-Gly-Phe-Leu-OH”, --(SEQ ID NO. 12)--.

On page 72, line 23, please insert after “(Leu-Enkephalin-(Lys)₆-OH)”, --(SEQ ID NO. 11)--.

On page 72, line 26, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH”, --(SEQ ID NO. 11)--.

On page 73, line 3, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH”, --(SEQ ID NO. 11)--.

On page 73, line 8, please insert after “((Lys)₆-Leu-Enkephalin-OH)”, --(SEQ ID NO. 101)--.

On page 73, line 11, please insert after “H-(Lys)₆-Tyr-Gly-Gly-Phe-Leu-OH”, --(SEQ ID NO. 101)--.

On page 73, line 17, please insert after “((Lys)₆-Leu-Enkephalin-(Lys)₆-OH)”, --(SEQ ID NO. 102)--.

On page 73, line 20, please insert after “H-(Lys)₆-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH”, --(SEQ ID NO. 102)--.

On page 73, line 25, please insert after “(Leu-Enkephalin-(Lys)₁₀-OH)”, --(SEQ ID NO. 109)--.

On page 73, line 28, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Lys)₁₀-OH”, --(SEQ ID NO. 109)--.

On page 74, line 3, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Lys)₁₀-OH”, --(SEQ ID NO. 109)--.

On page 74, line 8, please insert after “(Leu-Enkephalin-(Orn)₆-OH)”, --(SEQ ID NO. 106)--.

On page 74, line 11, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Orn)₆-OH”, --(SEQ ID NO. 106)--.

On page 74, line 18, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Orn)₆-OH”, --(SEQ ID NO. 106)--.

On page 74, line 22, please insert after “(Leu-Enkephalin-(Dbu)₆-OH)”, --(SEQ ID NO. 107)--.

On page 74, line 25, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Dbu)₆-OH”, --(SEQ ID NO. 107)--.

On page 75, line 2, please insert after “H-Tyr-Gly-Gly-Phe-Leu-(Dbu)₆-OH”, --(SEQ ID NO. 107)--.

On page 75, line 7, please insert after “(Leu-Enkephalin-(Dpr)₆-OH)”, --(SEQ ID NO. 108)--.

On page 75, line 10, please insert after "H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH", --(SEQ ID NO. 108)--.

On page 75, line 17, please insert after "H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH", --(SEQ ID NO. 108)--.

On page 75, line 22, please insert after "(Leu-Enkephalin-Lys-(Glu)₄-Lys-OH)", --(SEQ ID NO. 98)--.

On page 75, line 25, please insert after "H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₄-Lys-OH", --(SEQ ID NO. 98)--.

On page 76, line 2, please insert after "H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₄-Lys-OH", --(SEQ ID NO. 98)--.

On page 76, lines 8-9, please insert after "H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₃-(Lys)₂-OH (Leu-Enkephalin-Lys-(Glu)₃-(Lys)₂-OH)", --(SEQ ID NO. 120)--.

On page 76, line 12, please insert after "H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₃-(Lys)₂-OH", --(SEQ ID NO. 120)--.

On page 76, line 19, please insert after "H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₃-(Lys)₂-OH", --(SEQ ID NO. 120)--.

On page 76, line 27, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 76, line 27, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 76, line 30, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 76, line 31, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 77, line 5, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 77, line 5, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 77, line 19, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 77, lines 19-20, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 77, line 22, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 77, line 22, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 77, line 23, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 78, please delete

“Table 2: Functional activity in serum after p.o. or i.v. administration of Leu-enkephalin-(Lys)6-OH in mice (n=6-8 serum samples per time point; mean \pm S.E.M.).

p.o. administration		i.v. administration	
Time, min	Activity Leu-enkephalin-(Lys)6-OH (nM)	Time, min	Activity Leu-enkephalin-(Lys)6-OH (nM)
0	0	5	15900 2400
15	< Detection Limit	15	8500 1200
30	3000 800	30	6000 950
60	6000 1300	60	1600 340
90	10900 3800	180	440 110
240	10700 230	240	2500 320
480	5000 580	370	31200 8620
960	2800 780	720	< Detection Limit
1380	< Detection Limit	1080	< Detection Limit
N/A	N/A	1440	< Detection Limit

N/A: Non Applicable”

On page 78, please insert

--**Table 2:** Functional activity in serum after p.o. or i.v. administration of Leu-enkephalin-(Lys)6-OH (SEQ ID NO. 11) in mice (n=6-8 serum samples per time point; mean \pm S.E.M.).

p.o. administration		i.v. administration	
Time, min	Activity Leu-enkephalin-(Lys)6-OH (nM) (SEQ ID NO. 11)	Time, min	Activity Leu-enkephalin-(Lys)6-OH (nM) (SEQ ID NO. 11)
0	0	5	15900 2400
15	< Detection Limit	15	8500 1200
30	3000 800	30	6000 950
60	6000 1300	60	1600 340
90	10900 3800	180	440 110
240	10700 230	240	2500 320
480	5000 580	370	31200 8620
960	2800 780	720	< Detection Limit
1380	< Detection Limit	1080	< Detection Limit
N/A	N/A	1440	< Detection Limit

N/A: Non Applicable --

On page 78, line 6, please insert after “Leu-enkephalin-(Lys)6-OH”, --(SEQ ID NO. 11)-

--.

On page 78, line 11, please insert after “Leu-enkephalin-(Lys)6-OH”, --(SEQ ID NO. 11)--.

On page 78, line 12, please insert after “Leu-enkephalin-(Lys)6-OH”, --(SEQ ID NO. 11)--.

On page 78, line 15, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 78, line 16, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 78, line 18, please insert after "Leu-enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)--.

On page 78, line 20, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 78, line 20, please insert after "Leu-enkephalin", --(SEQ ID NO. 12)--.

On page 79, line 2, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 79, line 2, please insert after "Leu-Enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)-

-.

On page 79, line 4, please insert after "Leu-enkephalin-OH", --(SEQ ID NO. 12)--.

On page 79, line 4, please insert after "Leu-Enkephalin-(Lys)₆-OH", --(SEQ ID NO. 11)-

-.

On page 79, lines 4-5, please insert after "Leu-Enkephalin-(Glu₂-Lys-Glu₃)-OH", --(SEQ ID NO. 121)--.

On page 79, line 5, please insert after "Leu-Enkephalin-(Lys-Glu₄-Lys)-OH", --(SEQ ID NO. 98)--.

On page 79, line 5, please delete "Leu-Enkephalin-(ORN)₆-OH" and insert in its place, -- (Leu-Enkephalin-(Orn)₆-OH) (SEQ ID NO. 106)--.

On page 79, lines 5-6, please delete “Leu-Enkephalin-(DBU)₆-OH” and insert in its place, --(Leu-Enkephalin-(Dbu)₆-OH) (SEQ ID NO. 107)--.

On page 79, line 6, please delete “Leu-Enkephalin-(DPR)₆-OH”, and insert in its place --(Leu-Enkaphalin-(Dpr)₆-OH) (SEQ ID NO. 108)--.

On page 79, line 6, please insert after “Leu-Enkephalin-(Lys)₁₀-OH”, --(SEQ ID NO. 109)--.

On page 80, please delete

“**Table 3:** EC50 and T1/2 values for various enkephalin analogues (n=3-4/test substance; mean).

Compound	EC50 value (nM)	T 1/2 min
Leu-Enkephalin-OH	65	6.3
Leu-Enkephalin-(Lys)6-OH	160	18.7
Leu-Enkephalin-(Glu)6-OH	140	ND
Leu-Enkephalin-(Lys-Glu)3-OH	350	ND
Leu-Enkephalin-(Lys2-Glu3-Lys)-OH	680	ND
Leu-Enkephalin-(Lys-Glu4-Lys)-OH	357	84.5
Leu-Enkephalin-(orn)6-OH	>20000	ND
Leu-Enkephalin-(Dbu)6-OH	20000	ND
Leu-Enkephalin-(Dpr)6-OH	200	19.8
Leu-Enkephalin-(Lys)10-OH	2500	ND

ND: Not determined.”

and insert in its place,

--Table 3: EC50 and T1/2 values for various enkephalin analogues (n=3-4/test substance; mean).

Compound	EC50 value (nM)	T 1/2 min
Leu-Enkephalin-OH (SEQ ID NO. 12)	65	6.3
Leu-Enkephalin-(Lys)6-OH (SEQ ID NO. 11)	160	18.7
Leu-Enkephalin-(Glu)6-OH (SEQ ID NO. 10)	140	ND
Leu-Enkephalin-(Lys-Glu)3-OH (SEQ ID NO. 101)	350	ND
Leu-Enkephalin-(Lys2-Glu3-Lys)-OH (SEQ ID NO. 99)	680	ND
Leu-Enkephalin-(Lys-Glu4-Lys)-OH (SEQ ID NO. 98)	357	84.5
Leu-Enkephalin-(Orn)6-OH (SEQ ID NO. 106)	>20000	ND
Leu-Enkephalin-(Dbu)6-OH (SEQ ID NO. 107)	20000	ND
Leu-Enkephalin-(Dpr)6-OH (SEQ ID NO. 100)	200	19.8
Leu-Enkephalin-(Lys)10-OH (SEQ ID NO. 109)	2500	ND

ND: Not determined. --

On page 80, line 5, please insert after “Leu-Enkephalin-OH”, --(SEQ ID NO. 12)--.

On page 80, line 8, please delete “Leu-enkephalin-OH” and insert in its place, --(Leu-Enkephalin-OH) (SEQ ID NO. 12)--.

On page 80, line 21, please delete “Leu-enkephalin-OH” and insert in its place, --(Leu-Enkephalin-OH) (SEQ ID NO. 12)--.

On page 81, please delete,

Table 4: Affinity of Leu-Enkephalin-OH analogues at μ opioid receptors measured as ^3H -DAMGO binding (IC₅₀ values (mean \pm SD)).

Compound	IC ₅₀ values (nM)	IC ₅₀ values (nM)
	Time 0 hours	Time 18 hours
Leu-Enkephalin-OH	97 \pm 9	80
Leu-Enkephalin-(Lys) ₆ -OH	17 \pm 7	32
Leu-Enkephalin-(Glu) ₆ -OH	10,000	5,000
Leu-Enkephalin-(Lys-Glu) ₃ -OH	450 \pm 130	900
Naloxone	9.2 \pm 1.0	7

--

and insert in its place,

Table 4: Affinity of Leu-Enkephalin-OH (SEQ ID NO. 12) analogues at μ opioid receptors measured as ^3H -DAMGO binding (IC₅₀ values (mean \pm SD)).

Compound	IC ₅₀ values (nM)	IC ₅₀ values (nM)
	Time 0 hours	Time 18 hours
Leu-Enkephalin-OH (SEQ ID NO. 12)	97 \pm 9	80
Leu-Enkephalin-(Lys) ₆ -OH (SEQ ID NO. 11)	17 \pm 7	32
Leu-Enkephalin-(Glu) ₆ -OH (SEQ ID NO. 10)	10,000	5,000
Leu-Enkephalin-(Lys-Glu) ₃ -OH (SEQ ID NO. 101)	450 \pm 130	900
Naloxone	9.2 \pm 1.0	7

--

On page 81, line 5, please insert after "Leu-Enkephalin-(Glu)₆-OH", --(SEQ ID NO. 10)-

On page 81, lines 6-7, please insert after “Leu-Enkephalin-(Glu)₆-OH”, --(SEQ ID NO. 10)--.

On page 81, line 9, please insert after “EMP-1-K₆”, --(SEQ ID NO. 93)--.

On page 81, line 10, please insert after “EMP-1”, --(SEQ ID NO. 117)--.

On page 81, line 10, please insert after “EMP-1-K₆”, --(SEQ ID NO. 93)--.

On page 81, line 11, please insert after “EMP-1”, --(SEQ ID NO. 117)--.

On page 81, line 12, please insert after “EMP-1-K₆”, --(SEQ ID NO. 93)--.

On page 81, line 17, please insert after “EMP-1”, --(SEQ ID NO. 117)--.

On page 81, line 17, please insert after “EMP-1- K₆”, --(SEQ ID NO. 93)--.

On page 82, please delete,

“**Table 5:** Changes in body weight and in hematological parameters 4 days after p.o. administration of 956 nmol EMP-1 or EMP-1-K6. Relative changes are presented in parenthesis (mean \pm SEM).”

	EMP-1 p.o.	EMP-1-K6 p.o.
BW (g)	3.4 \pm 0.2 (16 \pm 1%)	3.4 \pm 0.3 (15 \pm 2%)
P-hgb (mM)	+1.5 \pm 0.5 (+8 \pm 1%)	+2.4 \pm 0.3* (+15 \pm 2%*)
Hematocrit (%)	0.3 \pm 0.8 (0.8 \pm 1.8%)	4.5 \pm 0.9* (12.3 \pm 2.3%*)
RBC (10 ¹² cells/l)	0.6 \pm 0.2 (9 \pm 3%)	1.0 \pm 0.1* (17 \pm 2%*)
MCHC (mM)	2.9 \pm 1.5 (4 \pm 2%)	0.2 \pm 1.5 (0 \pm 2%)

*: p<0.05 vs. EMP-1 p.o.”

and insert in its place,

--Table 5: Changes in body weight and in hematological parameters 4 days after p.o. administration of 956 nmol EMP-1 (SEQ ID NO. 117) or EMP-1-K₆ (SEQ ID NO. 93). Relative changes are presented in parenthesis (mean ± SEM).

	EMP-1 p.o. (SEQ ID NO. 117)	EMP-1-K ₆ p.o. (SEQ ID NO. 93)
BW (g)	3.4±0.2 (16±1%)	3.4±0.3 (15±2%)
P-hgb (mM)	+1.5±0.5 (+8±1%)	+2.4±0.3* (+15±2%*)
Hematocrit (%)	0.3±0.8 (0.8±1.8%)	4.5±0.9* (12.3±2.3%*)
RBC (10 ¹² cells/l)	0.6±0.2 (9±3%)	1.0±0.1* (17±2%*)
MCHC (mM)	2.9±1.5 (4±2%)	0.2±1.5 (0±2%)

*: p<0.05 vs. EMP-1 p.o.--

On page 82, line 6, please insert after “EMP-1-K₆”, --(SEQ ID NO. 93)--.

On page 82, line 8, please insert after “EMP-1-K₆”, --(SEQ ID NO. 93)--.

On page 83, line 6, please insert after “human PTH (1-34)”, --(SEQ ID NO. 119)--.

On page 83, line 16, please insert after “hPTH(1-34)”, --(SEQ ID NO. 119)--.

On page 83, lines 17-18, please insert after “H-hPTH(1-34)-K₆-OH”, --(SEQ ID NO. 91)--.

On page 83, line 18, please insert after “H-K₆-PTH(1-34)-OH”, --(SEQ ID NO. 90)--.

On page 83, line 19, please insert after “hPTH(1-34)”, --(SEQ ID NO. 119)--.

On page 83, line 19, please insert after “hPTH(1-34)”, --(SEQ ID NO. 119)--.

On page 83, please delete

“Table 6

Compound / Assay	Retraction assay % Retracted cells	EIA Relative recovery %
Parathyroid Hormone	63.7	-
hPTH (1-34)	58.2	90.8
H-hPTH(1-34)-K ₆ -OH	37.4	61.8
H-K ₆ -PTH(1-34)-OH	34.7	79.1
Blank	11.8	-

“

and insert in its place,

--Table 6

Compound / Assay	Retraction assay % Retracted cells	EIA Relative recovery %
Parathyroid Hormone	63.7	-
hPTH (1-34) (SEQ ID NO. 119)	58.2	90.8
H-hPTH(1-34)-K ₆ -OH (SEQ ID NO. 91)	37.4	61.8
H-K ₆ -PTH(1-34)-OH (SEQ ID NO. 90)	34.7	79.1
Blank	11.8	-

--

On page 83, line 24, please insert after “Substance P-NH₂”, --(SEQ ID NO. 112)--.

On page 83, line 24, please insert after “(Lys)₆-Substance P-NH₂”, --(SEQ ID NO. 113)-

..

On page 83, line 25, please insert after “Substance P-NH₂”, --(SEQ ID NO. 112)--.

On page 83, line 25, please insert after “(Lys)₆-Substance P-NH₂”, --(SEQ ID NO. 113)-

..

On page 83, line 9, please insert after “Substance P-NH₂”, --(SEQ ID NO. 112)--.

On page 83, line 9, please delete “(Lys)₆-SubstanceP-NH₂” and insert in its place, --
((Lys)₆-SubstanceP-NH₂) (SEQ ID NO. 113)--.

IN THE CLAIMS

Please amend claims 11, 12, 15, 18, 19, 24, and 25 as follows:

11. (amended) A peptide conjugate according to claim 10, wherein Z is Lys₄ (SEQ ID NO. 55), Lys₅ (SEQ ID NO. 56) or Lys₆ (SEQ ID NO. 62).

12. (amended) A peptide conjugate according to claim 11, wherein Z is Lys₆ (SEQ ID NO. 62) .

15. (amended) A peptide conjugate according to claim 14, wherein Z is (Lys-Glu)₃ (SEQ ID NO. 84) or (Glu-Lys)₃ (SEQ ID NO. 85).

18. (amended) A peptide conjugate according to claim 17, wherein Z is Lys₃-Glu₃ (SEQ ID NO. 86) or Glu₃-Lys₃ (SEQ ID NO. 87).

19. (amended) A peptide conjugate according to [claims 5-18] claim 1, wherein Z is Lys-Lys-Lys-Lys (SEQ ID NO. 55), Xaa-Lys-Lys-Lys, Lys-Xaa-Lys-Lys, Lys-Lys-Xaa-Lys, Lys-

Lys-Lys-Xaa, Xaa-Xaa-Lys-Lys, Xaa-Lys-Xaa-Lys, Xaa-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys, Lys-Xaa-Lys-Xaa, Lys-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Xaa, Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Xaa-Xaa, Lys-Lys-Lys-Lys-Lys (SEQ ID NO. 56), Xaa-Lys-Lys-Lys-Lys (SEQ ID NO. 57), Lys-Xaa-Lys-Lys-Lys (SEQ ID NO. 58), Lys-Lys-Xaa-Lys-Lys (SEQ ID NO. 59), Lys-Lys-Lys-Xaa-Lys (SEQ ID NO. 60), Lys-Lys-Lys-Lys-Xaa (SEQ ID NO. 61), Xaa-Xaa-Lys-Lys-Lys, Xaa-Lys-Xaa-Lys-Lys, Xaa-Lys-Lys-Xaa-Lys, Xaa-Lys-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys-Lys, Lys-Xaa-Lys-Xaa-Lys, Lys-Xaa-Lys-Lys-Xaa, Lys-Lys-Xaa-Xaa-Lys, Lys-Lys-Xaa-Lys-Xaa, Lys-Lys-Lys-Xaa-Xaa, Lys-Lys-Xaa-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Lys-Xaa, Lys-Xaa-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Lys-Xaa, Xaa-Xaa-Lys-Xaa-Lys, Xaa-Xaa-Xaa-Lys-Lys, Lys-Xaa-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Xaa, Xaa-Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Xaa-Xaa-Xaa, Lys-Lys-Lys-Lys-Lys (SEQ ID NO. 62), Xaa-Lys-Lys-Lys-Lys-Lys (SEQ ID NO. 63), Lys-Xaa-Lys-Lys-Lys-Lys (SEQ ID NO. 64), Lys-Lys-Xaa-Lys-Lys-Lys (SEQ ID NO. 65), Lys-Lys-Lys-Xaa-Lys-Lys (SEQ ID NO. 66), Lys-Lys-Lys-Lys-Xaa-Lys (SEQ ID NO. 67), Lys-Lys-Lys-Lys-Lys-Xaa (SEQ ID NO. 68), Xaa-Xaa-Lys-Lys-Lys-Lys (SEQ ID NO. 69), Xaa-Lys-Xaa-Lys-Lys-Lys (SEQ ID NO. 70), Xaa-Lys-Lys-Xaa-Lys-Lys (SEQ ID NO. 71), Xaa-Lys-Lys-Lys-Xaa-Lys (SEQ ID NO. 72), Xaa-Lys-Lys-Lys-Lys-Xaa (SEQ ID NO. 73), Lys-Xaa-Xaa-Lys-Lys-Lys (SEQ ID NO. 74), Lys-Xaa-Lys-Xaa-Lys-Lys (SEQ ID NO. 75), Lys-Xaa-Lys-Lys-Xaa-Lys (SEQ ID NO. 76), Lys-Xaa-Lys-Lys-Lys-Xaa (SEQ ID NO. 77), Lys-Lys-Xaa-Xaa-Lys-Lys (SEQ ID NO. 78), Lys-Lys-Xaa-Lys-Xaa-Lys (SEQ ID NO. 79), Lys-Lys-Xaa-Lys-Lys-Xaa (SEQ ID NO. 80), Lys-Lys-Lys-Xaa-Xaa-Lys (SEQ ID NO. 81), Lys-Lys-Lys-Xaa-Lys-Xaa (SEQ ID NO. 82), Lys-Lys-Lys-Lys-Xaa-Xaa (SEQ ID NO. 83), Xaa-Xaa-Xaa-Lys-Lys-Lys, Xaa-Xaa-Lys-Xaa-Lys-Lys, Xaa-Xaa-Lys-Lys-Xaa-Lys, Xaa-Xaa-Lys-Lys-Lys-Xaa, Xaa-Lys-Xaa-Xaa-Lys-Lys, Xaa-Lys-Xaa-Lys-Xaa-Lys, Xaa-Lys-Xaa-Lys-Lys-Xaa, Xaa-Lys-Lys-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Lys-Xaa, Xaa-Lys-Lys-Lys-Xaa-Xaa, Lys-Lys-Lys-Xaa-Xaa-Xaa, Lys-Lys-Xaa-Lys-Xaa-Xaa, Lys-Lys-Xaa-Xaa-Lys-Xaa, Lys-Lys-Xaa-Xaa-Xaa-Lys, Lys-Xaa-Lys-Lys-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Lys-Xaa, Lys-Xaa-Lys-Xaa-Xaa-Lys, Lys-Xaa-Xaa-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys-Xaa-Lys, Lys-Xaa-Xaa-Xaa-Lys-Lys, Lys-Lys-Xaa-Xaa-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Xaa-Xaa, Lys-Xaa-Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Xaa-Lys-

Xaa, Lys-Xaa-Xaa-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Lys-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Lys-Xaa, Xaa-Lys-Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Lys-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Lys-Xaa, Xaa-Xaa-Lys-Xaa-Xaa-Lys, Xaa-Xaa-Xaa-Lys-Lys-Xaa, Xaa-Xaa-Xaa-Lys-Xaa-Lys, Xaa-Xaa-Xaa-Xaa-Lys-Lys, Lys-Xaa-Xaa-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Xaa-Lys-Xaa, Xaa-Xaa-Xaa-Xaa-Xaa-Lys, or Xaa-Xaa-Xaa-Xaa-Xaa-Xaa, wherein each Xaa is independently selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Met, Orn, and amino acids of the formula I



wherein R^1 and R^2 are selected from the group consisting of hydrogen, C₁-6-alkyl, phenyl, and phenyl-methyl, wherein C₁-6-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁-6-alkyl, C₂-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R^1 and R^2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid (Dab) and 2,3-diaminopropanoic acid (Dapa).

24. (amended) The peptide conjugate according to claim 16, wherein X is selected from the group consisting of enkephalin, Leu-enkephalin, Met-enkephalin, angiotensin I, angiotensin II, vasopressin, endothelin, vasoactive intestinal peptide, substance P, neurotensin, endorphins, insulin, gramicidin, paracelsin, delta-sleep inducing peptide, Gonadotropin-Releasing hormone, human parathyroid hormone (1-34), truncated erythropoietin analogues, specifically EMP-1, Atrial natriuretic peptide (ANP, ANF), human brain natriuretic peptide (hBNP), cecropin, kinetensin, neurophysins, elafin, guamerin, atriopeptin I, atriopeptin II, atriopeptin III, deltorphin I, deltorphin II, vasotocin, bradykinin, dynorphin, dynorphin A, dynorphin B, growth hormone release factor, growth hormone, growth hormone releasing peptide, oxytocin, calcitonin, calcitonin gene-related peptide, calcitonin gene-related peptide II, growth hormone releasing peptide, tachykinin, adrenocorticotrophic hormone (ACTH), brain natriuretic polypeptide,

cholecystokinin, corticotropin releasing factor, diazepam binding inhibitor fragment, FMRF-amide, galanin, gastric releasing polypeptide, gastric inhibitory polypeptide, gastrin, gastrin releasing peptide, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, LHRH, melanin concentrating hormone, melanocyte stimulating hormone (MSH), alpha-MSH, morphine modulating peptides, motilin, neurokinin A, neurokinin B, neuromedin B, neuromedin C, neuromedin K, neuromedin N, neuromedin U, neuropeptide K, neuropeptide Y, pituitary adenylate cyclase activating polypeptide (PACAP), pancreatic polypeptide, peptide YY, peptide histidine-methionine amide (PHM), secretin, somatostatin, substance K, , thyrotropin-releasing hormone (TRH), kyotorphin, melanostatin (MIF-1), thrombopoeitin analogs, in particular AF 12505 (Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala) (SEQ ID NO. 14), insulin-like growth factor I (57-70) (Ala-Leu-Leu-Glu-Thr-Tyr-Cys-Ala-Thr-Pro-Ala-Lys-Ser-Glu) (SEQ ID NO. 15), [insulin-like growth factor I(30-41)] insulin-like growth factor I(30-41) (Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr) (SEQ ID NO. 16), insulin-like growth factor I(24-41)(Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr) (SEQ ID NO. 17), insulin-like growth factor II (33-40) (Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg) (SEQ ID NO. 18), insulin-like growth [tyro] factor II (33-40) (Tyr-Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg) (SEQ ID NO. 19), insulin-like growth factor II (69-84) [Asp-Val-Ser-Thr-Pro-Pro-Thr-Val-Leu-Pro-Asp-Asn-Phe-Pro- Arg-Tyr)] Asp-Val-Ser-Thr-Pro-Pro-Thr-Val-Leu-Pro-Asp-Asn-Phe-Pro-Arg-Tyr) (SEQ ID NO. 20), growth hormone (GH)-releasing peptide-6 (GHRP-6) [(His-DTrp-Ala-Trp-DPhe-Lys-NH₂)] (His-DTrp-Ala-Trp-DPhe-Lys-NH₂) (SEQ ID NO. 21), beta-Interleukin I (163-171) (Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys) (SEQ ID NO. 22), beta-Interleukin II (44-56) (Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu) (SEQ ID NO. 23), Interleukin II (60-70) (Leu-Thr-Phe-Lys-Phe-Tyr-Met-Pro-Lys-Lys-Ala) (SEQ ID NO. 24), exendin-4 (GLP-1 analog) [(His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂)] (His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂) (SEQ ID NO. 25), exendin-3 (GLP-1 analog) (His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser) (SEQ ID NO. 26),

[Cys(Acm)20,31] epidermal growth factor (20-31) Cys(Acm)-Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys(Acm) (SEQ ID NO. 27), bivalirudin (Hirulog) [(D-Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu)] (D-Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu) (SEQ ID NO. 28), hirulog-1 D-Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Tyr-Leu (SEQ ID NO. 29), C-type natriuretic peptide (1-53) (CNP) (Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys; Disulfide bridge: Cys37-Cys53) (SEQ ID NO. 30), "Mini ANP" (Met-Cys-His-cyclohexylAla-Gly-Gly-Arg-Met-Asp-Arg-Ile-Ser-Cys-Tyr-Arg) disulfide bridge cys2-cys13) (SEQ ID NO. 31), Melanotan II (also known as MT-II, alpha-MSH4-10-NH₂, or Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10) (SEQ ID NO. 32), thymosin alpha1 (TA1) (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) (SEQ ID NO. 33), ornipressin (also known as 8-ornithine-vasopressin, (POR-8), [Phe2,Ile3,Orn8]vasopressin), Cys-Phe-Ile-Gln-Asn-Cys-Pro-Orn-Gly-NH₂, Disulfide bridge: Cys1-Cys6) (SEQ ID NO. 34), octreotide (201-995) (DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr-ol; disulfide bridge: Cys2-Cys7) (SEQ ID NO. 35), eptifibatide (INTEGRILIN), calcitonin gene-related peptide (CGRP) (Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH₂; Disulfide bridge: Cys2-Cys7) (SEQ ID NO. 36), endomorphin-1 Tyr-Pro-Trp-Phe-NH₂ (SEQ ID NO. 37); endomorphin-2 Tyr-Pro-Phe-Phe-NH₂ (SEQ ID NO. 38), nociceptin (also known as Orphanin FQ, Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln) (SEQ ID NO. 39), angiotensinogen (1-13) (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His) (SEQ ID NO. 40), adrenomodullin (1-12) (Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg) (SEQ ID NO. 41), antiarrhythmic peptide (AAP) (Gly-Pro-Hyp-Gly-Ala-Gly) (SEQ ID NO. 42), Antagonist G (Arg-DTrp-(nMe)Phe-DTrp-Leu-Met-NH₂), indolicidin (Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH₂) (SEQ ID NO. 43), osteocalcin (37-49) (Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val) (SEQ ID NO. 44), cortistatin 29 (1-13) (Glp-Glu-Arg-Pro-Pro-Leu-Gln-Gln-Pro-Pro-His-Arg-Asp) (SEQ ID NO. 45), cortistatin 14 Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys; Disulfide

bridge: Cys2-Cys13 (SEQ ID NO. 46), PD-145065 (Ac-D-Bhg-Leu-Asp-Ile-Ile-Trp) (SEQ ID NO. 47), PD-142893 (Ac-D-Dip-Leu-Asp-Ile-Ile-Trp) (SEQ ID NO. 48), fibrinogen binding inhibitor peptide (His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val) (SEQ ID NO. 49), leptin (93-105) (Asn-Val-Ile-Gln-Ile-Ser-Asn-Asp-Leu-Glu-Asn-Leu-Arg) (SEQ ID NO. 50), GR 83074 (Boc-Arg-Ala-DTrp-Phe-DPro-Pro-Nle-NH₂) (SEQ ID NO. 51), Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH₂) (SEQ ID NO. 52), parathyroid hormone related peptide (107-111) (Thr-Arg-Ser-Ala-Trp) (SEQ ID NO. 53), angiotensinogen (1-14) Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn (SEQ ID NO. 54), Leupeptin (Ac-Leu-Leu-Arg-CHO), sandostatin and any modified or truncated analogue thereof.

25. (amended) A peptide conjugate according to claim 1 wherein the conjugate is

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Lys₆-NH₂ (GHRH(1-44)(Human)-Lys₆-NH₂) (SEQ ID NO. 88);

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Glu₆-NH₂ (GHRH (1-44)(Human)-Glu₆-NH₂) (SEQ ID NO. 89);

H- Lys₆-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Lys₆-PTH(1-34)(Human)-OH) (SEQ ID NO. 90);

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Lys₆-OH (PTH(1-34)(Human)-Lys₆-OH) (SEQ ID NO. 91);

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys₆-OH (GLP-1-(7-36)(Human)-Lys₆-OH) (SEQ ID NO. 92);

H-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly-Lys₆-OH (EMP-1-Lys₆-OH) (SEQ ID NO. 93);

H-Lys₆-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly-OH (Lys₆-EMP-1-OH) (SEQ ID NO. 94);

H-Lys₆-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly-Lys₆-OH (Lys₆-EMP-1-Lys₆-OH) (SEQ ID NO. 95);

H-Aib-His-2-D-Nal-D-Phe-Lys-(Lys)₆-NH₂ (GHRP-(Lys)₆-NH₂) (SEQ ID NO. 96);

H-Tyr-Gly-Gly-Phe-Leu-Lys-Lys-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Lys-Glu-Glu-Glu-Lys-OH) (SEQ ID NO. 97);

H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Glu-Glu-Glu-Glu-Lys-OH) (SEQ ID NO. 98);

H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-(Lys-Glu)₃) (SEQ ID NO. 99);

H-Tyr-Gly-Gly-Phe-Leu-(Dapa)₆-OH (Leu-enkephalin-(Dapa)₆-OH) (SEQ ID NO. 100);

H-Lys₆-Tyr-Gly-Gly-Phe-Leu-OH (H-Lys₆-Leu-enkephalin) (SEQ ID NO. 101);

H-Tyr-Gly-Gly-Phe-Leu- Lys₆-OH (H-Leu-enkephalin-Lys₆) (SEQ ID NO. 11);

H-Lys₆-Tyr-Gly-Gly-Phe-Leu-Lys₆-OH (H-Lys₆-Leu-enkephalin-Lys₆-OH) (SEQ ID NO. 102);

Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys)₆-OH (GnRH-Lys₆-OH) (SEQ ID NO. 103);

Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys-Glu)₃-OH (GnRH-(Lys-Glu)₃-OH) (SEQ ID NO. 104); and

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys-Glu)₃-OH (PTH 1-34 human-(Lys-Glu)₃-OH) (SEQ ID NO. 105).


REMARKS

The specification and claims have been amended to correct editorial errors which have heretofore gone unnoticed and to incorporate Sequence ID Nos. No new matter has been added. Applicant asserts that the application is in condition for examination.

Respectfully submitted,

Date:

10/19/99



Cheryl H. Agris, Reg. No. 34,086
Attorney at Law
P.O. Box 806
Pelham, N.Y. 10803
(914) 712-0093

1

**PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A
REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS**

FIELD OF THE INVENTION

5

The present invention relates to pharmacologically active peptide conjugates having a reduced tendency towards enzymatic cleavage.

BACKGROUND OF THE INVENTION

10

There exist a large number of pharmacologically active peptides, e.g., naturally occurring in man or in animals, or synthetic analogues of such peptides. An illustrative example of such a peptide is the analgetically active peptide enkephalin that has given rise to a vast number of synthetic analogues. However, due to precisely their peptic nature, the routes of
15 administration thereof have been rather limited. Thus, peptides are rapidly and very effectively degraded by enzymes, generally with half-lives in the range of minutes. Proteases and other proteolytic enzymes are ubiquitous, particularly in the gastro-intestinal tract, and therefore peptides are usually susceptible to degradation in multiple sites upon oral administration, and to some extent in the blood, the liver, the kidney, and the vascular
20 endothelia. Furthermore, a given peptide is usually susceptible to degradation at more than one linkage within the backbone; each locus of hydrolysis is mediated by a certain protease. Even if such obstacles are overcome, for neuropeptides in particular, difficulties have been encountered in their transport across the blood-brain barrier.

25 There has been a number of attempts to protect peptides against premature degradation (reviewed in Prokai, 1997, Exp. Opin. Ther. Patent 7:233-245, Tamai et al., 1996, Adv. Drug Delivery Rev. 19:401-424 and Zhou et al., 1991, Int. J. Pharm. 75:97-115). One approach includes osmotically altering the blood-brain barrier by infusion of hypertonic solutions of mannitol, arabinose, lactamide, saline, urea, glycerol and radiographic contrast
30 agents. However, there could be toxic side effects.

09/341590 06514E50

Another approach involves the use of protease inhibitors (reviewed in Zhou et al., 1991, Int. J. Pharm. 75:97-115). This approach has yielded mixed results.

A third approach has involved the use of absorption enhancers in peptide formulations (reviewed in Zhou et al., 1991, Int. J. Pharm. 75:97-115). Examples include fatty acids and bile salts. However, varying results have been obtained regarding efficacies and the value of a particular enhancer is dependent on the route of administration used.

Another approach for enhancing the absorption of peptides involves chemically modifying the peptide by, for example, attaching a lipophilic moiety. It has also been found that attaching a pyroglutamyl residue at the N-terminal end can render a compound relatively resistant to hydrolysis. Tamai et al., 1996, Adv. Drug Delivery Rev. 19:401-404, discloses that E2078, a dynorphin analog was chemically modified to make it more stable to enzyme degradation by adding an N-methyl group at the amino-terminus of Arg and replacing D-Leu with L-Leu and adding ethylamine at the carboxy-terminal.

A different approach involves the formation of chimeric peptides. This approach involves coupling the peptide that is not normally transported through the blood-brain barrier to peptide or protein 'vectors' that undergo receptor-mediated or adsorptive-mediated transcytosis.

WO 98/22577 discloses a method for increasing the resistance of a "core protein" to proteolytic degradation by linking or inserting a "stabilizing polypeptide" having the formula $[(\text{Gly}_a)\text{X}(\text{Gly}_b)\text{Y}[(\text{Gly}_c)\text{Z}]_n$. X, Y, and Z may be alanine, serine, valine, isoleucine, leucine, methionine, phenylalanine, proline, and threonine.

U.S. Patent No. 5,545,719 discloses molecules comprising protein fragments homologous to an active region of protein fragments capable of stimulating nerve growth (neuronotrophic proteins such as epidermal growth factor, tubulin, nerve growth factor, laminin, fibronectin, ncam and ependymin) no greater than 80 amino acids long connected to a secondary molecule which can be a second protein fragment derived from the original protein, from

06574E60-0120-ET06

- WO 97/24445 discloses fusion proteins of albumin and growth hormone or variants thereof. It is stated in the specification that variants of albumin should have the oncotic, ligand-binding and non-immunogenic properties of full length albumin and that variants of growth hormone should have its non-immunogenicity and ability to bind and activate the growth hormone receptor.

A further approach involves preparing peptide analogs with increased stability and/or activity by adding a peptide tail. Greene et al., J. Pharm. Exp. Therap. 277:1366-1375, discloses results of studies with various enkephalin analog prodrugs of [D-Pen², D-Pen⁵] enkephalin (DPDPE) and [D-Pen², L-Cys⁵] enkephalin (DPLCE), specifically DPLCE-Arg-Pro-Ala, DPDPE-Phe, DPLCE-Phe, DPDPE-Arg-Gly, DPLCE-Arg-Gly, DPDPE-Phe-Ala-

NH-C₆H₁₃, DPDPE-Phe-Ala-CONH₂. The half lives of most of the analogs, except for DPDPE-Arg-Gly are less than the parent compounds. It is stated on page 1372, column 2 that "the ideal CNS-targeted prodrug would have a long half-life in the serum and a short half-life in the brain." U.S. Patent No. 4,724,229 discloses vasopressin antagonists which have a tripeptide side chain having three basic amino acids, such as arginine, lysine or ornithine which have potent antagonistic activity. U.S. Patent No. 4,542,124, discloses vasopressin antagonists which have a dipeptide side chain having two amino acids, one of which is basis which has potent vasopressin antagonistic activity.

- 10 In the international patent application PCT/DK97/00376 (Bjarne Due Larsen and Arne Holm) prodrugs of pharmacologically active peptides are described, wherein the pharmacologically active peptide is coupled at its C-terminal to a peptide pre-sequence via a linker, the linker typically being an α -hydroxy carboxylic acid. These special peptide derivatives were found to have a prolonged half-life in the presence of proteolytic enzymes
- 15 such as carboxypeptidase A, leucine aminopeptidase, pepsin A and α -chymotrypsin. In addition, PCT/DK97/00376 discloses (as reference compounds) four different peptides equipped with a peptide pre-sequence but without linker, namely DSIP-(Lys-Glu)₃, DSIP-(Glu)₆, Leu-enkephalin-(Glu)₆ and Leu-enkephalin-(Lys)₆.
- 20 It is evident that there is a need for a peptide conjugate which contains a pharmacologically active peptide and a stabilising protein that is relatively simple to synthesize, retains its activity even without removing the stabilising peptide, is stable in plasma or serum and is relatively resistant to enzyme degradation. Therefore, it is an object of the invention to provide a peptide conjugate comprising a pharmacologically active peptide and stabilising
- 25 peptide that is relatively resistant to enzyme degradation.

SUMMARY OF THE INVENTION

- It has now surprisingly been found that by conjugating a pharmacologically active peptide, for example, at its C-terminal, at its N-terminal or at its C- and N-terminal, with a suitable stabilising peptide sequence, it is possible to render the resulting peptide conjugate significantly less susceptible to degradation by proteases compared to the corresponding
- 30

0944590.071399
66ET20.0654650

free pharmacologically active peptide. Without being bound to any specific model for this effect, it is believed that the presence of the stabilising peptide sequence induces a degree of structuring, based on hydrogen bonds, of the pharmacologically active peptide, whereby the peptide conjugate is less susceptible to proteases in contrast to peptides in the random-coil
 5 conformation. As a result of the structuring, the peptide conjugate is much more difficult for a protease to degrade. Moreover, the resulting peptide conjugate is still pharmacologically active, i.e. the peptide conjugate possesses the ability to exert the pharmacological function of the free pharmacologically active peptide.

10 Thus, in a first aspect the invention relates to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage, said peptide conjugate comprises: a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X, each amino acid residue in said stabilising peptide sequence (Z) being independently selected from the group consisting of Ala, Leu,
 15 Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid residues of the general formula I



20 wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and
 25 carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g., 2,4-diaminobutanoic acid (Dbu) and 2,3-diaminopropanoic acid (Dpr); and

wherein the ratio between the half-life of said peptide conjugate and the half-life of the
 30 corresponding pharmacologically active peptide sequence, X, when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in plasma or serum is at least about 2, preferably at least

about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g., at least about 10 and the ratio between the half-life of said peptide conjugate or when the pharmacologically active peptide is not orally absorbed, said conjugate is orally absorbed or a salt thereof.

5

In one embodiment, the pharmacologically active peptide is not selected from the group consisting of H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH,

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Glu)₆-OH,

H-Tyr-Gly-Gly-Phe-Leu-(Glu)₆-OH and

10 H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH.

The present invention also relates to a composition, e.g., a pharmaceutical composition, comprising said pharmacologically active peptide conjugate and a pharmaceutically acceptable carrier, to a pharmacologically active peptide conjugate for use in therapy, a
 15 method of treating a disorder and to the use of a pharmacologically active peptide conjugate for the manufacture of a pharmaceutical composition for use in therapy. Specifically, the invention is directed to a method for inhibiting neurons from transmitting pain impulses to the spinal cord, comprising administering to a subject in need thereof a conjugate comprising enkephalin and Z in an amount effective to inhibit neurons from transmitting
 20 pain impulses, as well as the use of said conjugate for the manufacture of a pharmaceutical composition for use in treatment of pain; a method for stimulating the release of growth hormone from the pituitary comprising administering to a subject in need thereof a conjugate comprising growth hormone releasing hormone or growth hormone releasing peptide and Z in an amount effective to stimulate the release of growth hormone as well as
 25 the use of said conjugate for the manufacture of a pharmaceutical composition for use in stimulating the release of growth hormone; a method for increasing hemoglobin levels comprising administering to a subject in need thereof a conjugate comprising EMP-1 (erythropoietin mimetic protein-1) and Z in an amount effect to increase hemoglobin levels as well as the use of said conjugate for the manufacture of a pharmaceutical composition for
 30 use in increasing treating anemia by increasing hemoglobin levels; a method for treating or preventing bone loss by altering the balance between osteoclastic (bone resorption) and osteoblast activity comprising administering to a patient in need thereof a conjugate

comprising parathyroid hormone and Z in an amount effective to treat or prevent bone loss as well as use of a said conjugate for the manufacture of a pharmaceutical composition for use in treating or preventing osteoporosis; a method for reducing blood glucose levels comprising administering to a subject in need thereof a conjugate comprising glucagon-like peptide-1 and Z in an amount effective to reduce blood sugar levels, as well as use of said conjugate in the treatment of diabetes; a conjugate comprising delta sleep inducing peptide and Z in an amount effective to prevent convulsions, act as a neuroprotectant during ischemia and act as a detoxification agent of an opioid as well as a use of said conjugate for the manufacture of a pharmaceutical composition for use in treating sleep disorders; a method for regulating production of sex hormones comprising administering to a subject in need thereof a conjugate comprising gonadotropin releasing hormone and Z in an amount effective to regulate production of sex hormones as well as use of said conjugate for the manufacture of a pharmaceutical composition for use in regulating the level of sex hormones.

15

In another aspect the present invention relates to the use of a peptide conjugate, as defined herein, for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of a condition or disorder, where the peptide sequence X, when not bound to Z, is able to interact with a receptor (or a receptor system) involved with the condition or disorder in question, and where the interaction between X, when not bound to Z, and the receptor (or receptor system) has a therapeutic or prophylactic effect on the condition or disorder.

The present invention also relates to methods for the preparation of said pharmacologically active peptide conjugate, by means of recombinant DNA-technology comprising the steps of (a) introducing a nucleic acid sequence encoding said conjugate into a host cell and (b) culturing said host cell and (c) isolating said conjugate from the culture or (a) culturing a recombinant host cell comprising a nucleic acid sequence encoding said conjugate under conditions permitting the production of said conjugate and (b) isolating said conjugate from the culture.

The method also relates to methods for the preparation of said pharmacologically active peptide conjugate in which the pharmacologically active peptide X is obtained via recombinant DNA methods by isolating said peptide or from commercial sources. X is then conjugated to Z which is attached to a solid support or has been prepared by solid phase
5 synthetic methods.

Furthermore, the invention relates to the use of a stabilising peptide sequence (Z) for the preparation of a pharmacologically active peptide conjugate.

10 DETAILED DESCRIPTION OF THE INVENTION

Peptide Conjugates

In the present context, the term "amino acid residue" as used in connection with X means any naturally occurring or synthetic α , β , or γ -amino acid (whether in the L-form or the D-
15 form) as well as side-chain modified amino acids such as modified tyrosines wherein the aromatic ring is further substituted with e.g., one or more halogens, sulfono groups, nitro groups etc., and/or the phenol group is converted into an ester group, etc, including side-chain protected amino acids, wherein the amino acid side-chains are protected in accordance with methods known to the person skilled in peptide chemistry, such as described in, e.g.,
20 M. Bodanszky and A. Bodanszky, "The Practice of Peptide Synthesis", 2. Ed, Springer-Verlag, 1994, and J. Jones, "The Chemical Synthesis of Peptides", Clarendon Press, 1991.

In the present context, the term "pharmacologically active peptide sequence" or "free peptide" as applied to X is intended to mean any peptide or peptide-containing structure,
25 either naturally occurring or synthetic which is therapeutically or prophylactically active without the stabilising sequence Z covalently bound thereto. As defined herein, a peptide sequence is "therapeutically active" if it can be used for the treatment, remission, or attenuation of a disease state, physiological condition, symptoms or etiological indication(s) or evaluation or diagnosis thereof. A peptide sequence is "prophylactically active" if it can
30 be used to prevent a disease state, physiological condition, symptoms or etiological indications. A pharmacologically active agent is also physiologically or biologically active. Pharmacological activity measures the effect of a substance (peptide) on physiological or

6645479PC1

biological systems *in vitro*, *in vivo* or *ex vivo* and may be assayed using standard *in vitro*, *in vivo* or *ex vivo* assays known in the art for a particular peptide or a peptide with a similar physiological function

- 5 Peptides are utilised in a number of processes, e.g., cell-to-cell communication, some being present in the autonomic and central nervous system. Some of the latter peptides, and a number of other peptides, exert important effects on vascular and other smooth muscles. In a preferred embodiment, X has at the most 75 amino acid residues (or a structure corresponding to at the most 75 amino acid residues). Alternatively, X consists of at most
10 65, 60, 55, 53, 50, 45, 40, 35, 30, 25, 20, 15, or at the most 10 amino acid residues and consists of at least 2, preferably 5 and more preferably 10 amino acid residues.

In the present context, the pharmacologically active peptide sequence X can be any peptide which in its native form is present as the C-terminal free carboxylic acid, such as Leu-
15 enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH), or is present in its native form as a C-terminal amide, such as oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂), or is present in its native form as a C-terminal ester. Furthermore, the pharmacologically active peptide may also contain other special structural features such as disulfide bridges as in the case insulin.

- 20 The pharmacologically active peptide may be selected from the group consisting of enkephalin, Leu-enkephalin, Met-enkephalin, angiotensin I, angiotensin II, vasopressin, endothelin, vasoactive intestinal peptide, neurotensin, endorphins, insulin, gramicidin, paracelsin, delta-sleep inducing peptide, gonadotropin-releasing hormone, human parathyroid hormone (1-34), truncated erythropoietin analogues described in Wrighton et al., 1996,
25 Science 273:458-463), specifically EMP-1, Atrial natriuretic peptide (ANP, ANF), human brain natriuretic peptide (hBNP), cecropin, kinetensin, neurophysins, elafin, guamerin, atriopeptin I, atriopeptin II, atriopeptin III, deltorphin I, deltorphin II, vasotocin, bradykinin, dynorphin, dynorphin A, dynorphin B, growth hormone release factor, growth hormone, growth hormone releasing peptide, oxytocin, calcitonin, calcitonin gene-related peptide,
30 calcitonin gene-related peptide II, growth hormone releasing peptide, tachykinin, adrenocorticotrophic hormone (ACTH), brain natriuretic polypeptide, cholecystokinin, corticotropin releasing factor, diazepam binding inhibitor fragment, FMRF-amide, galanin,

gastric releasing polypeptide, gastric inhibitory polypeptide, gastrin, gastrin releasing peptide, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, LHRH, melanin concentrating hormone, melanocyte stimulating hormone (MSH), alpha-MSH, morphine modulating peptides, motilin, neurokinin A, neurokinin B, neuromedin B, neuromedin C, 5 neuromedin K, neuromedin N, neuromedin U, neuropeptide K, neuropeptide Y, pituitary adenylate cyclase activating polypeptide (PACAP), pancreatic polypeptide, peptide YY, peptide histidine-methionine amide (PHM), secretin, somatostatin, substance K, thyrotropin-releasing hormone (TRH), kyotorphin, melanostatin (MIF-1), thrombopoietin analogs, in particular AF 12505 (Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg- 10 Ala), insulin-like growth factor I (57-70) (Ala-Leu-Leu-Glu-Thr-Tyr-Cys-Ala-Thr-Pro-Ala-Lys-Ser-Glu), insulin-like growth factor I(30-41) (Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr), insulin-like growth factor I(24-41)(Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr) , insulin-like growth factor II (33-40) (Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg), insulin-like growth [tyro] factor II (33-40) (Tyr-Ser-Arg-Val- 15 Ser-Arg-Arg-Ser-Arg), insulin-like growth factor II (69-84) (Asp-Val-Ser-Thr-Pro-Pro-Thr-Val-Leu-Pro-Asp-Asn-Phe-Pro- Arg-Tyr), growth hormone (GH)-releasing peptide-6 (GHRP-6) (His-DTrp-Ala-Trp-DPhe-Lys-NH₂), beta-Interleukin I (163-171) (Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys), beta-Interleukin II (44-56) (Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu), Interleukin II (60-70) (Leu-Thr-Phe-Lys-Phe-Tyr-Met-Pro-Lys- 20 Lys-Ala), exendin-4 (GLP-1 analog) (His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-NH₂), exendin-3 (GLP-1 analog) (His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser), [Cys(Acm)_{20,31}] epidermal 25 growth factor (20-31) Cys(Acm)-Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys(Acm), bivalirudin (Hirulog) (D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu), hirulog-1 D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Tyr-Leu, C-type natriuretic peptide (1-53) (CNP) (Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala- 30 Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys; Disulfide bridge: Cys37-Cys53), "Mini ANP" (Met-Cys-His-cyclohexylAla-Gly-Gly-Arg-Met-Asp-Arg-Ile-Ser-Cys-Tyr-Arg, disulfide bridge cys2-

0045907130
06574660

- cys13), Melanotan-II (also known as MT-II, alpha-MSH4-10-NH₂, or Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰), thymosin alpha1 (TA1) (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn), ornipressin (also known as 8-ornithine-vasopressin, (POR-8),
- 5 [Phe²,Ile³,Orn⁸]vasopressin), Cys-Phe-Ile-Gln-Asn-Cys-Pro-Orn-Gly-NH₂, Disulfide bridge: Cys1-Cys6), octreotide (201-995) (DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr-ol; disulfide bridge: Cys2-Cys7), eptifibatide (INTEGRILIN), calcitonin gene-related peptide (CGRP) (Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH₂;
- 10 Disulfide bridge: Cys2-Cys7), endomorphin-1 Tyr-Pro-Trp-Phe-NH₂; endomorphin-2 Tyr-Pro-Phe-Phe-NH₂, nociceptin (also known as Orphanin FQ, Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln), angiotensinogen (1-13) (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His), adrenomodullin (1-12) (Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg), antiarrhythmic peptide (AAP) (Gly-Pro-Hyp-Gly-Ala-
- 15 Gly), Antagonist G (Arg-DTrp-(nMe)Phe-DTrp-Leu-Met-NH₂), indolicidin (Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH₂), osteocalcin (37-49) (Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val), cortistatin 29 (1-13) (Glp)-Glu-Arg-Pro-Pro-Leu-Gln-Gln-Pro-Pro-His-Arg-Asp), cortistatin 14 Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys; Disulfide bridge: Cys2-Cys13, PD-145065 (Ac-D-Bhg-Leu-Asp-Ile-
- 20 Ile-Trp), PD-142893 (Ac-D-Dip-Leu-Asp-Ile-Ile-Trp), fibrinogen binding inhibitor peptide (His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val), leptin (93-105) (Asn-Val-Ile-Gln-Ile-Ser-Asn-Asp-Leu-Glu-Asn-Leu-Arg), GR 83074 (Boc-Arg-Ala-DTrp-Phe-DPro-Pro-Nle-NH₂), Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH₂), parathyroid hormone related peptide (107-111) (Thr-Arg-Ser-Ala-Trp), angiotensinogen (1-14) Asp-Arg-Val-Tyr-Ile-His-Pro-
- 25 Phe-His-Leu-Val-Ile-His-Asn, Leupeptin (Ac-Leu-Leu-Arg-CHO), and any modified or truncated analogue thereof.

It is well known that many pharmacologically active peptides also exert their desired pharmaceutical effect when present in a modified or truncated form. In the case of, for

30 example, insulin, porcine insulin differ from human insulin by only one amino acid residue, the B30 amino acid in porcine insulin being Ala and the B30 amino acid in human insulin being Thr. Despite this difference, porcine insulin has been used as an effective diabetes

drug for many years. In a similar way it has been found that the essential features for activity in the heptadecapeptide Porcine gastrin I are all contained in the C-terminal tetrapeptide and that essentially all pharmaceutical effects of neurotensin are associated with the C-terminal hexapeptide. Furthermore, pharmacologically active peptides, wherein one or more amide bonds have been modified, e.g., reduced, often exhibit a similar or even enhanced pharmaceutical activity; for example the $\text{Cys}^2\psi[\text{CH}_2\text{NH}]\text{Tyr}^3$ analogue of somatostatin was found to be an even more potent growth hormone releasing agent than somatostatin itself, and also the transition state analogue $\text{Leu}^{10}\psi[\text{CH}(\text{OH})\text{CH}_2]\text{Val}^{11}$ of angiotensin has been found to show strong inhibitory effect against the aspartic acid protease Renin. Thus, the term "modified or truncated analogue thereof" is intended to mean such peptides are modified by changing and/or deleting one or more amino acid residues in the sequence of the native peptide, including modification of the side-chain, stereochemistry, and backbone in the individual amino acid residues, such as changing one or more peptide bonds ($-\text{C}(=\text{O})-\text{NH}-$) into e.g., reduced forms such as ($-\text{CH}(\text{OH})-\text{N}-$), ($-\text{CH}_2-\text{N}-$), and other peptide bond mimetics such as ($-\text{C}(=\text{O})-\text{N}(\text{CH}_3)-$), ($-\text{C}(=\text{O})-\text{O}-$), ($-\text{C}(=\text{O})-\text{CH}_2-$), ($-\text{CH}=\text{CH}-$), ($-\text{PO}_2-\text{NH}-$), ($\text{SO}-\text{CH}_2-$), ($\text{SO}_2-\text{N}-$), etc.

This being said, it should be understood that the peptide sequence X in question should preferably comprise at least one peptide bond (preferably at least two peptide bonds (this naturally does not apply for a dipeptide)) susceptible to enzymatic degradation in order to fully take advantage of the present invention.

In the present context, the term " C_{1-6} -alkyl" used alone or as part of another group designates a straight, branched or cyclic saturated hydrocarbon group having from one to six carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.butyl, tert.butyl, n-pentyl, n-hexyl, cyclohexyl, etc.

In the present context, the term " C_{2-6} -alkenyl" designates a hydrocarbon group having from two to six carbon atoms, which may be straight, branched, or cyclic and may contain one or more double bonds, such as vinyl, allyl, 1-butenyl, 2-butenyl, isobutenyl, 1-pentenyl, 2-pentenyl, 4-pentenyl, 3-methyl-1-butenyl, 2-hexenyl, 5-hexenyl, cyclohexenyl, 2,3-dimethyl-2-butenyl etc., which may have *cis* and/or *trans* configuration.

The term "aryl" is intended to mean an aromatic, carbocyclic group such as phenyl or naphthyl.

- 5 The term "heteroaryl" includes 5- or 6-membered aromatic monocyclic heterocyclic groups containing 1-4 heteroatoms selected from nitrogen, oxygen and sulphur, such as pyrrolyl, furyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadizolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, and aromatic bicyclic heterocyclic groups containing 1-6 heteroatoms selected from nitrogen,
10 oxygen and sulphur, such as quinoliny.

The term "halogen" includes fluorine, chlorine, bromine, and iodine.

- The peptide sequence Z is the part of the peptide conjugate responsible for introduction
15 and/or stabilisation of a certain secondary structure into the molecule which will render the compound more stable towards degradation by proteases. It is believed that Z needs to include at least 4 amino acid residues in order to introduce such a stabilising structural element. On the other hand it is also believed that a sequence of more than around 20 amino acid residues will not improved the stability further. Thus, Z is typically a peptide sequence
20 of 4-20 amino acid residues, e.g., in the range of 4-15, more preferably in the range of 4-10 in particular in the range of 4-7 amino acid residues, e.g., of 4, 5, 6 or 7 amino acid residues. When Z is conjugated to X, the half-life of said peptide conjugate when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in plasma or serum is at least about 2, preferably at least
25 about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g., at least about 10 more than the half-life of X when not conjugated to Z. Furthermore, when the pharmacologically active peptide X is not orally absorbed, the conjugate is orally absorbed.
- 30 Each of the amino acid residues in the peptide sequence Z are independently selected from Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acids of the formula I as defined herein such as diaminobutanoic acid or diaminopropanoic acid.

Preferably, the amino acid residues are selected from Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Orn, and Met, more preferably from Glu, Lys, and Met, especially Lys. The above-mentioned amino acids may have either D- or L-configuration, but preferably the above-mentioned amino acids have an L-configuration. As the pharmacologically active peptide sequence X usually consists exclusively of L-amino acids, it must be expected, in order to preserve a possible stabilising helix structure of the entire peptide conjugate, that a peptide sequence Z consisting only or principally of L-amino acids will be advantageous compared to a peptide sequence Z consisting only or principally of D-amino acids. Furthermore, it is envisaged that a peptide sequence Z consisting only or principally of D-amino acids may exert toxicological effects due to the resistance of D-peptides and D-amino acids towards biodegradation.

Thus, illustrative examples of the peptide sequence Z are:

Lys-Lys-Lys-Lys, Xaa-Lys-Lys-Lys, Lys-Xaa-Lys-Lys, Lys-Lys-Xaa-Lys, Lys-Lys-Lys-Xaa, Xaa-Xaa-Lys-Lys, Xaa-Lys-Xaa-Lys, Xaa-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys, Lys-Xaa-Lys-Xaa, Lys-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Xaa, Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Xaa-Xaa, Lys-Lys-Lys-Lys-Lys, Xaa-Lys-Lys-Lys-Lys, Lys-Xaa-Lys-Lys-Lys, Lys-Lys-Xaa-Lys-Lys, Lys-Lys-Lys-Xaa-Lys, Lys-Lys-Lys-Lys-Xaa, Xaa-Xaa-Lys-Lys-Lys, Xaa-Lys-Xaa-Lys-Lys, Xaa-Lys-Lys-Xaa-Lys, Xaa-Lys-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys-Lys, Lys-Xaa-Lys-Lys-Xaa, Lys-Lys-Xaa-Xaa-Lys, Lys-Lys-Xaa-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Lys-Xaa, Lys-Xaa-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Lys-Xaa, Xaa-Xaa-Xaa-Lys-Lys, Lys-Xaa-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Xaa, Xaa-Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Xaa-Xaa-Xaa, Lys-Lys-Lys-Lys-Lys-Lys, Xaa-Lys-Lys-Lys-Lys-Lys, Lys-Xaa-Lys-Lys-Lys-Lys, Lys-Lys-Lys-Xaa-Lys-Lys, Lys-Lys-Lys-Lys-Xaa-Lys, Lys-Lys-Lys-Lys-Lys-Xaa, Xaa-Xaa-Lys-Lys-Lys-Lys, Xaa-Lys-Xaa-Lys-Lys-Lys, Xaa-Lys-Lys-Xaa-Lys-Lys, Xaa-Lys-Lys-Lys-Xaa-Lys, Xaa-Lys-Lys-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys-Lys-Lys, Lys-Xaa-Lys-Xaa-Lys-Lys, Lys-Xaa-Lys-Lys-Lys-Lys-Xaa, Lys-Lys-Xaa-Xaa-Lys-Lys, Lys-Lys-Lys-Xaa-Xaa-Lys, Lys-Lys-Lys-Xaa-Lys-Xaa, Lys-Lys-Lys-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Lys-Lys, Xaa-Xaa-Lys-Xaa-

5 Lys-Lys-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Lys-Xaa, Lys-Xaa-Lys-Xaa-Xaa-Lys, Lys-Xaa-Xaa-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys-Xaa-Lys, Lys-Xaa-Xaa-Xaa-Lys-Lys, Lys-Lys-Xaa-Xaa-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Xaa-Xaa, Lys-Xaa-Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Xaa-Lys-Xaa, Lys-Xaa-Xaa-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Lys-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Lys-Xaa, Xaa-Lys-Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Lys-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Lys-Xaa, Xaa-Lys-Xaa-Lys-Xaa, Xaa-Xaa-Lys-Xaa-Lys-Xaa, Xaa-Xaa-Lys-Lys-Xaa, Xaa-Xaa-Lys-Xaa-Lys, Xaa-Xaa-Xaa-Lys-Lys, Lys-Xaa-Xaa-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Xaa-Lys-Xaa, Xaa-Xaa-Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Xaa-Xaa-Xaa-Xaa, wherein each Xaa is independently selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Met, Orn, and amino acids of the formula I as defined herein, e.g., Dbu or Dpr.

20 particular from about 0 to +6, such as from about 0 to +4, e.g., from 0 to +3, at pH 7. Without being bound by any specific theory, it is envisaged that the non-negative charge at the stabilising peptide sequence Z may also to some extent facilitate transportation to and over cell membranes which possess a negative potential at the extracellular site. Thus, in order to secure a non-negative overall charge on the stabilising peptide sequence Z, the

25 peptide sequence Z preferably comprises at least one Lys amino acid residue, more preferably at least two Lys amino acid residues, such as at least three Lys amino acid residues, e.g., at least four Lys amino acid residues, even more preferably at least five Lys amino acid residues, such as at least six Lys amino acid residues.

30 As indicated above, the amino acid residues of Z may of course all be different or all be identical. However, in interesting embodiments of the present invention, the amino acid residues in Z are selected from two or three different amino acids, or are identical amino

- acids. Examples of suitable peptide sequences, wherein the amino acid residues in Z are identical are e.g., $(\text{Lys})_n$, wherein n is an integer in the range from 4 to 15, preferably in the range from 4 to 10, such as in the range from 4 to 8, e.g., in the range from about 4 to 6, e.g., Lys_4 , Lys_5 or Lys_6 . Examples of suitable peptide sequences, wherein the amino acid residues in Z are selected from about two different amino acids are e.g., $(\text{Lys-Xaa})_m$ or $(\text{Xaa-Lys})_m$, wherein m is an integer in the range from about 2 to 7, preferably in the range from 2 to 5, such as in the range from 2 to 4, e.g., 3, and Xaa is independently selected from the group consisting of Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Orn, 2,4-diaminobutanoic acid, 2,3-diaminopropanoic acid and Met. More preferably such peptide sequences are e.g., $(\text{Lys-Xaa})_3$ or $(\text{Xaa-Lys})_3$, wherein Xaa is as defined above, such as $(\text{Lys-Glu})_3$ or $(\text{Glu-Lys})_3$. Other examples of suitable peptide sequences, wherein the amino acid residues in Z are selected from about two amino acid residues are e.g., $\text{Lys}_p\text{-Xaa}_q$ or $\text{Xaa}_p\text{-Lys}_q$, wherein p and q are integers in the range from 1 to 14, with the proviso that p+q is in the range from 4 to 15, preferably in the range from 4 to 10, such as in the range from 4 to 8, e.g., in the range from 4 to 6, e.g., 4, 5 or 6, and Xaa is independently selected from the group consisting of Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His and Met. More preferably such peptide sequences are e.g., $\text{Lys}_3\text{-Xaa}_3$ or $\text{Xaa}_3\text{-Lys}_3$, wherein Xaa is as defined above, such as $\text{Lys}_3\text{-Glu}_3$ or $\text{Glu}_3\text{-Lys}_3$.
- Examples of suitable peptide sequences, wherein the amino acid residues in Z are selected from three different amino acids are e.g., $\text{Xaa}^1\text{-(Lys)}_x\text{-(Xaa}^2\text{)}_y$, $\text{Xaa}^1\text{-(Xaa}^2\text{)}_x\text{-(Lys)}_y$, $(\text{Lys})_x\text{-(Xaa}^2\text{)}_y\text{-Xaa}^1$, $(\text{Xaa}^1\text{)}_x\text{-(Lys)}_y\text{-Xaa}^2$, $(\text{Lys})_x\text{-Xaa}^1\text{-(Xaa}^2\text{)}_y$, $(\text{Xaa}^1\text{)}_x\text{-Xaa}^2\text{-(Lys)}_y$, $\text{Xaa}^1\text{-Lys-Xaa}^2$, $\text{Xaa}^1\text{-Lys-Xaa}^2\text{-Lys-Xaa}^2$, $\text{Xaa}^1\text{-Lys-Xaa}^2\text{-Lys-Xaa}^2\text{-Lys}$, $\text{Xaa}^1\text{-Xaa}^2\text{-Lys-Xaa}^2$, $\text{Xaa}^1\text{-Xaa}^2\text{-Lys-Xaa}^2\text{-Lys}$, $\text{Xaa}^1\text{-Xaa}^1\text{-Lys-Xaa}^2\text{-Lys-Xaa}^2$, $\text{Lys-Xaa}^2\text{-Lys-Xaa}^1$, $\text{Lys-Xaa}^2\text{-Lys-Xaa}^2\text{-Xaa}^1$, $\text{Lys-Xaa}^2\text{-Lys-Xaa}^2\text{-Lys-Xaa}^1$, $\text{Xaa}^2\text{-Lys-Xaa}^2\text{-Xaa}^1$, $\text{Xaa}^2\text{-Lys-Xaa}^1\text{-Lys-Xaa}^2\text{-Xaa}^1$, etc., wherein x and y are integers in the range from about 1 to 4 with the proviso that x+y is at the most 5, and Xaa^1 and Xaa^2 is independently selected from about the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Met, Orn, 2,3-diaminopropanoic acid, 2,4-diaminobutanoic acid and amino acids of the formula I as defined herein.

With respect to the peptide sequence Z, it is envisaged that the specific amino acid residues mentioned as constituents of the peptide sequence Z, i.e. Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, 2,3-diaminopropanoic acid (Dpr), 2,4-diaminobutanoic acid (Dbu) and amino acid residues of the formula I as defined herein, are amino acid
 5 residues which, due to their sterical arrangement around the α -carbon atom, and probably also due to a specific electronic configuration, have certain preferences for participating in, or even stabilising or initiating, helix-like structures. The Chou-Fasman approach (Chou, P.Y. & Fasman, G.D. *Ann. Rev. Biochem.* 47, 251-276 (1978)) is one attempt to quantify (empirically) the likelihood for a specific amino acid residue to be involved in an α -helix
 10 structure (expressed as the "Conformational parameter P_{α} "). Chou and Fasman's studies and related studies have, however, shown that amino acid residues which have a low parameter P_{α} , may be found in α -helices, but of course not as often as amino acid residues having a higher P_{α} . Thus, in the peptide sequence Z, it is considered possible to include a small proportion of amino acid residues which are not among the amino acid residues selected
 15 above as constituents of Z, and still obtain the desired effect from the peptide sequence Z, in that the selected amino acid residues are believed to compensate for any negative or neutral effect of such an alternative amino acid residue.

In a specific embodiment, Z is $(\text{Dbu})_n$ or $(\text{Dpr})_n$, wherein n is an integer in the range from
 20 about 4 to 15, preferably in the range from about 4 to 10, such as in the range from about 4 to 8, e.g., in the range from about 4 to 6. In a most specific embodiment, Z is Dpr_6 .

Thus, in embodiments which are within the scope of the present invention, it may be realistic to include up to 25% of amino acid residues which are not among the amino acids
 25 preferred as constituents of Z. (By "25% percent" is referred to the number of amino acid residues, i.e. no alternative amino acid residues are allowed in di- and tripeptides, up to one alternative amino acid residue is allowed in tetra-, penta-, hexa-, and heptapeptides, up to two alternative amino acid residues are allowed in octapeptides, etc.). Such alternative amino acid residues may be selected from Val, Ile, Pro, Phe, Gly, Trp, as well as N-methyl
 30 amino acid residues, however, preferably not Pro, Gly and N-methyl amino acid residues. Moreover, the C-terminal of Z may be in the form of the free acid, the amide, or an ester, e.g., methyl ester, ethyl ester, benzyl ester, etc., depending on the type of solid support

material and cleavage conditions used in connection with the syntheses of the peptide conjugates as will be clear to the person skilled in the art. The N-terminal may be in the form of the free amine or a lactam.

- 5 The stabilising peptide sequence Z may be bound to the C-terminal or the N-terminal of the pharmacologically active peptide sequence, X, or two peptide sequences may be bound individually to both the C- and N-terminal of X. In case the native pharmacologically active peptide X possesses a free C-terminal carboxylic acid (as in the case of Leu-enkephalin), the peptide sequence Z may be attached to either the C-terminal of the peptide
- 10 X or to the N-terminal of the peptide X, or the C- and N-terminal of X may both be bound to each individual peptide sequence Z. Alternatively, Z may be bound to the nitrogen atom on the side chain of lysine, histidine or arginine or a carbonyl function on the side chain of glutamic acid or aspartic acid anywhere within the peptide sequence X. In one embodiment, Z may be attached to X within the sequence and to the N- an/or C-terminal of
- 15 X. Whether the sequence should be attached to the peptide sequence X at its C-terminal, at its N-terminal, or both, or within the peptide sequence X depends on the specific peptide X and the pharmaceutical function that said peptide X exerts and can be easily determined by the person skilled in the art. In some cases, the biological or physiological activity may depend crucially on the negative charge at the C-terminal of the pharmacologically active
- 20 peptide X. Accordingly, in such cases, the activities and consequently pharmacological effect of X may be obstructed by blocking the negative charge on the C-terminal of the pharmacologically active peptide X and it may therefore be advantageous to attach the peptide sequence Z to the N-terminal of the peptide X. In a similar way, in cases where the pharmacologically active peptide X is present in its native form as a C-terminal amide (such
- 25 as oxytocin) it may be advantageous to attach the stabilising peptide sequence Z to the N-terminus of the peptide X if it is believed that the amide group has an important pharmacological function. Thus, it should be understood that any peptide sequences corresponding to pharmacologically active peptides X having a free C-terminal carboxyl group as well as peptides corresponding to pharmacologically active peptides X having a C-
- 30 terminal amide or ester group may be used in the peptide conjugates of the invention. However, in an interesting embodiment of the invention the peptide sequence Z is attached

0654590-0654590

to the C-terminal of the pharmacologically active peptide X (whether X in its native form is a free carboxylic acid, an amide or an ester).

It should be understood that the peptide conjugates of the invention might also be in the form of a salt thereof. Salts include pharmaceutically acceptable salts, such as acid addition salts and basic salts. Examples of acid addition salts are hydrochloride salts, sodium salts, calcium salts, potassium salts, etc. Examples of basic salts are salts where the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and ammonium ions $^+N(R^3)_3(R^4)$, where R^3 and R^4 independently designates optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, optionally substituted aryl, or optionally substituted heteroaryl. Other examples of pharmaceutically acceptable salts are; e.g., those described in "Remington's Pharmaceutical Sciences" 17. Ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, PA, U.S.A., 1985 and more recent editions, and in Encyclopedia of Pharmaceutical Technology.

15

In a most specific embodiment, the peptide conjugate is selected from the group consisting of

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Lys₆-NH₂ (GHRH(1-44)(Human)-Lys₆-NH₂);

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Glu₆-NH₂ (GHRH (1-44)(Human)-Glu₆-NH₂);

H- Lys₆-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Lys₆-PTH(1-34)(Human)-OH);

30

66ET/0"06514E60

20

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Lys₆-OH (PTH(1-34)(Human)-Lys₆-OH);

- 5 H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys₆-OH (GLP-1-(7-36)(Human)-Lys₆-OH);

H-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly-Lys₆-OH (EMP-1-Lys₆-OH);

10

H- Lys₆-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly-OH (Lys₆-EMP-1-OH);

- H- Lys₆-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly- Lys₆-OH (Lys₆-EMP-1- Lys₆-OH);

15

H-Aib-His-2-D-Nal-D-Phe-Lys-(Lys)₆-NH₂ (GHRP-(Lys)₆-NH₂);

- 20 H-Tyr-Gly-Gly-Phe-Leu-Lys-Lys-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Lys-Glu-Glu-Glu-Lys-OH);

H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Glu-Glu-Glu-Glu-Lys-OH);

25

H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-(Lys-Glu)₃);

H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH (Leu-enkephalin-(Dpr)₆-OH);

- 30 H-Lys₆-Tyr-Gly-Gly-Phe-Leu-OH (H-Lys₆-Leu-enkephalin);

666720"06574660

H-Tyr-Gly-Gly-Phe-Leu- Lys₆-OH (H-Leu-enkephalin-Lys₆);

H-Lys₆-Tyr-Gly-Gly-Phe-Leu-Lys₆-OH (H-Lys₆-Leu-enkephalin-Lys₆-OH);

5 Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys)₆-OH (GnRH-Lys₆-OH);

Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys-Glu)₃-OH (GnRH-(Lys-Glu)₃-OH); and

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-
 10 Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys-Glu)₃-OH (PTH
 1-34 human-(Lys-Glu)₃-OH).

As explained above, the peptide sequence Z is the part of the peptide conjugate responsible for introducing of a certain structure into the molecule which will render the compound
 15 more stable towards protease-catalysed degradation. Therefore, the present invention also relates to the use of a stabilising peptide sequence (Z) as defined above for the preparation of a pharmacologically active peptide conjugate as defined above.

As mentioned previously, the routes of administration of pharmacologically active peptides
 20 have thus far been rather limited due to the fast biodegradation by proteases such as chymotrypsin, trypsin, carboxypeptidase A, pepsin, leucine aminopeptidase, etc. Thus, the requirements to the pharmacologically active peptide conjugates suitable for the demanding purpose is that on the one hand, the peptide conjugate should, at least to some extent, be able to resist protease-catalysed hydrolysis, and on the other hand, the peptide conjugate
 25 should still, at least to some extent, be able to exert the desired pharmaceutical effect normally provided by the free peptide X.

On this basis, *in vitro* assays have been developed which give an assessment of the capacity of a peptide conjugate to exert the desired properties. Such assays, as well as the results
 30 thereof, are illustrated in the examples. These types of assays are excellent preliminary tests which can be easily performed by the person skilled in the art to assess the suitability of any given peptide conjugate prepared according to the principles disclosed herein.

Thus, the tendency of the pharmacologically active peptide conjugates of the invention to resist protease-catalysed hydrolysis can be measured directly by the *in vitro* enzyme assays shown in the examples. The tendency of the peptide conjugate to resist degradation can for
5 example be expressed as a pseudo-first-order rate constant and/or as the half-life of said peptide conjugates, which can then be compared to the corresponding values of the free peptide X.

As will be apparent from the examples provided herein, it has been found that it is possible
10 to obtain a remarkable increase in the half-life ($t_{1/2}$) of a pharmacologically active peptide sequence by conjugating the peptide (X) in question with a stabilising peptide sequence (Z) according to the invention.

Thus, in a preferred embodiment of the invention, the ratio between the half-life of the
15 peptide conjugate in question in the "Hydrolysis in enzyme solution test", as defined herein, and the half-life of the corresponding free peptide (X), in the "Hydrolysis in enzyme solution test", is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 10, especially at least about 20, such as at least about 50, e.g., at least about 100, when using carboxypeptidase A or leucine aminopeptidase.

20 Although the proteases carboxypeptidase A and leucine aminopeptidase have been used in the tests described herein, it is envisaged that the ability of the peptide conjugates to resist protease degradation may also be tested in identical or similar test systems using other endo- or exopeptidases, such as trypsin, or mixtures of such peptidases, e.g., artificial
25 gastric juice.

Furthermore, the ability of the peptide conjugates of the invention to exert the desired pharmaceutical effect was tested in various *in vitro* and *in vivo* assay procedures disclosed herein. Thus, preferred peptide conjugates are such conjugates which exert some
30 pharmaceutical effect, preferably a similar and in some cases even an enhanced pharmaceutical effect compared to the pharmacologically active free peptide (X).

As will be understood from examples provided herein, the peptide conjugates of the invention are able to "survive" various proteolytic barriers present in the gastrointestinal environment. Thus, as demonstrated in the examples herein, it is possible to administer a pharmacologically active peptide conjugate (e.g., orally) as some fraction of the administered peptide conjugate (e.g., at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or even at least 99% of the total amount peptide conjugate administered) is able to enter the blood stream. Therefore, especially interesting peptide conjugates of the invention are such compounds which when administered orally in a pharmacologically effective dose (which of course depends on the actual illness or disorder to be treated and the actual peptide or peptide conjugate selected for said treatment) is present in the blood stream in a therapeutically or prophylactically effective concentration after a period of from about 0.1 min to 24 hrs., 0.1 min to 5 hours, e.g., after a period of from about 0.5 min to 3 hours, such as from about 1 min to 2 hours, preferably after a period from about 3 min to 1 hour, such as from about 5 min to 1 hour, e.g., from about 10 min to 1 hour, 1 min.-16 hrs, 0.1 min-12 hrs. Therapeutically relevant concentrations of said peptide conjugates will, of course, depend on the actual illness or disorder to be treated, and such therapeutically relevant concentrations will be known to the person skilled in the art.

Moreover, the peptide conjugates of the invention are surprisingly stable in e.g., blood serum and plasma. Thus, preferred peptide conjugates of the invention are such compounds which have a half-life in human or mice serum or plasma (optionally containing a buffer to secure a certain pH, e.g., a pH at 7.4) at 37°C of at least about 10 minutes, such as at least about 15 min, e.g., at least about 0.5 h, preferably at least about 1 h, such as at least about 2 h, e.g., at least about 3 h, more preferably at least about 4 h, such as at least about 5 h, e.g., at least about 6 h, in particular at least about 12 h, such as at least about 24 h, e.g., at least about 36 h. Especially preferred is where the ratio of half-life of said peptide conjugate and the half-life of the corresponding pharmacologically active peptide sequence, X, in plasma or serum is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g., at least about 10.

Compositions

The invention also concerns a composition comprising a pharmacologically active peptide conjugate as defined above in combination with a pharmaceutically acceptable carrier.

- 5 Such compositions may be in a form adapted to oral, subcutaneous, parenteral (intravenous, intraperitoneal), intramuscular, rectal, epidural, intratracheal, intranasal, dermal, vaginal, buccal, ocularly, direct brain or pulmonary administration, preferably in a form adapted to oral administration, and such compositions may be prepared in a manner well-known to the person skilled in the art, e.g., as generally described in "Remington's Pharmaceutical
10 Sciences", 17. Ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, PA, U.S.A., 1985 and more recent editions and in the monographs in the "Drugs and the Pharmaceutical Sciences" series, Marcel Dekker. The compositions may appear in conventional forms, for example, capsules, tablets, aerosols, solutions, suspensions or topical applications.

15

- The pharmaceutical carrier or diluent employed may be a conventional solid or liquid carrier. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty
20 acid amines, polyoxyethylene and water.

Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

- 25 If a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about about 25 mg to about 1 g.

- 30 A typical tablet which may be prepared by conventional tableting techniques may contain:

Core: active compound (as free compound or salt thereof) 100 mg; colloidal silicon dioxide (Aerosil) 1.5 mg; cellulose, microcryst. (Avicel) 70 mg; modified cellulose gum (Ac-Di-Sol) 7.5 mg; magnesium stearate.

- 5 Coating: HPMC approx. 9 mg; *Mywacett 9-40T approx. 0.9 mg; *acylated monoglyceride used as plasticizer for film coating.

If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid

- 10 suspension or solution.

For nasal administration, the preparation may contain a conjugate of the present invention dissolved or suspended in a liquid carrier, in particular, an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g., propylene
15 glycol, surfactants such as bile acid salts or polyoxyethylene higher alcohol ethers, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabines.

The composition may also be in a form suited for local or systemic injection or infusion and
20 may, as such, be formulated with sterile water or an isotonic saline or glucose solution. The compositions may be sterilized by conventional sterilization techniques which are well known in the art. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with the sterile aqueous solution prior to administration. The composition may contain
25 pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents and the like, for instance sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.

The invention also concerns a pharmacologically active peptide conjugate as defined above
30 for use in therapy, and the use of a pharmacologically active peptide conjugate as defined above for the manufacture of a pharmaceutical composition for use in therapy, e.g., in the treatment of disorders in the central nervous system, in vaccine therapy, and in the treatment

20479PC1 05/14/60

of HIV, cancer, diabetes, incontinence, hypertension, amnesia, Alzheimer's disease, fever, depression, sex hormone regulation, eating, schizophrenia, osteoporosis and insomnia., and as analgesics and contraceptives, and such indications known to be treated by therapy comprising administration of pharmacologically active peptides.

5

In specific embodiments, a conjugate comprising enkephalin and Z may be used to inhibit neurons from transmitting pain impulses, a conjugate comprising growth hormone releasing hormone or growth hormone releasing peptide and Z may be used to stimulate the release of growth hormone, for use in stimulating the release of growth hormone, a conjugate
10 comprising EMP-1 and Z may be used to increase hemoglobin levels a conjugate comprising parathyroid hormone and Z may be used to treat or prevent bone loss, a conjugate comprising glucagon-like peptide-1 and Z may be used in the treatment of diabetes, a conjugate comprising delta sleep inducing peptide and Z may be used for treating sleep disorders and a conjugate comprising gonadotropin releasing hormone and Z
15 may be used to regulate sex hormones.

As mentioned above, a major obstacle to the application of peptides as clinically useful drugs is their poor delivery characteristics since most peptides are rapidly metabolised by proteolysis at most routes of administration. Consequently, a very interesting prospect of the
20 present invention is that it is possible to prepare pharmacologically active peptide conjugates for the treatment of mammals, such as humans, which are stabilised towards degradation by proteases and, at the same time, are able to exert a pharmaceutical effect in the environment in which the free peptide (X) will exhibit a pharmaceutical action. Accordingly, the present invention also relates to the use of a pharmacologically active
25 peptide conjugate as defined above for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of a condition or disorder, where the peptide sequence X, when not bound to Z, is able to interact with a receptor (or a receptor system) involved with the condition or disorder in question, and where the interaction between X, when not bound to Z, and the receptor (or receptor system) has a therapeutic or prophylactic effect on the
30 condition or disorder. Thus, it should be understood that a peptide conjugate of the present invention may substitute the corresponding free peptide (X) in e.g., therapies where the free peptide X is administrated intravenous since the peptide conjugates of the invention may be

administered in a more convenient way, e.g., orally, as said peptide conjugates are able to overcome proteolytic barriers prevailing in the body. In a similar way, the peptide conjugates of the invention may be used in therapies where it has not previously been possible to use the corresponding free peptide (X) as X has been readily degraded in or
 5 secreted from the body.

Preparation of Conjugates

The peptide conjugates of the invention may be prepared by methods known per se in the
 10 art. Thus, the peptide sequences X and Z may be prepared by standard peptide-preparation techniques such as solution synthesis or Merrifield-type solid phase synthesis.

In one possible synthesis strategy, the peptide conjugates of the invention may be prepared by solid phase synthesis by first constructing the peptide sequence Z using well-known
 15 standard protection, coupling and deprotection procedures, thereafter sequentially coupling the pharmacologically active sequence X on Z in a manner similar to the construction of Z, and finally cleaving off the entire peptide conjugate from the carrier. This strategy yields a peptide conjugate, wherein the stabilising peptide sequence Z is covalently bound to the pharmacologically active peptide X at the C-terminal carbonyl function of X. If the desired
 20 peptide conjugate, however, is a peptide conjugate, wherein two stabilising sequences Z are covalently and independently bound to both the C- and the N-terminal of the pharmacologically active peptide X, the above strategy is also applicable but, as will be understood by the person skilled in the art, before cleaving the off the C-terminal bound peptide conjugate from the solid support, it is necessary to sequentially couple the second
 25 stabilising peptide sequence Z to the N-terminal of X in a manner similar to the procedure described above. This strategy may also be used to attach Z to the carbonyl function on the side chain of Glu or Asp.

A possible strategy for the preparation of peptide conjugates, wherein the stabilising peptide
 30 sequence Z is covalently bound to the N-terminal nitrogen atom or covalently bound to the nitrogen atom on the side chain of Lys, Arg or His of X is analogous with the method described above, i.e. said peptide conjugates may be prepared by solid phase synthesis by

first constructing the pharmacologically active peptide sequence X using well-known standard protection, coupling and deprotection procedures, thereafter sequentially coupling the stabilising peptide sequence Z on X in a manner similar to the construction of X, and finally cleaving off the entire peptide conjugate from the carrier.

5

Another possible strategy is to prepare one or both of the two sequences X and Z (or parts thereof) separately by solution synthesis, solid phase synthesis, recombinant techniques, or enzymatic synthesis, followed by coupling of the two sequences by well-known segment condensation procedures, either in solution or using solid phase techniques or a combination thereof. In one embodiment, X may be prepared by recombinant DNA methods and Z may be prepared by solid phase synthesis. The conjugation of X and Z may be carried out by using chemical ligation. This technique allows for the assembling of totally unprotected peptide segments in a highly specific manner (Liu et al., 1996, J. Am. Chem. Soc. 118:307-312 and Dawson et al., 1996, 226:776). The conjugation can also be performed by protease-catalysed peptide bond formation, which offers a highly specific technique to combine totally unprotected peptide segments via a peptide bond (W. Kullmann, 1987, Enzymatic Peptide Synthesis, CRC Press, Boca Raton, Florida, pp. 41-59).

Side chain derivatization of Lys, Arg, His, Trp, Ser, thr, Cys, Tyr, Asp and Glu with the stabilising peptide sequence, Z can be carried out by traditional convergent peptide synthesis using suitable orthogonal protecting schemes as known in the art, or by using the equally well known general solid phase method with suitable orthogonal removable side chain protection.

Furthermore, it is envisaged that a combination of the above-mentioned strategies may be especially applicable where a modified peptide sequence, e.g., from a pharmacologically active peptide comprising isosteric bonds such as reduced peptide bonds or N-alkylated peptide bonds, is to be coupled to a peptide sequence Z. In this case, it may be advantageous to prepare the immobilised fragment of Z by successive coupling of amino acids, and then couple a complete pharmacologically active peptide sequence X (prepared in solution or fully or partially using solid phase techniques or by means of recombinant techniques) to the fragment.

Examples of suitable solid support materials (SSM) are e.g., functionalised resins such as polystyrene, polyacrylamide, polydimethylacrylamide, polyethyleneglycol, cellulose, polyethylene, polyethyleneglycol grafted on polystyrene, latex, dynabeads, etc.

5

It should be understood that it may be necessary or desirable that the C-terminal amino acid of the peptide sequence Z or the C-terminal amino acid of the pharmacologically active peptide X is attached to the solid support material by means of a common linker such as 2,4-dimethoxy-4'-hydroxy-benzophenone, 4-(4-hydroxy-methyl-3-methoxyphenoxy)-
10 butyric acid, 4-hydroxy-methylbenzoic acid, 4-hydroxymethyl-phenoxyacetic acid, 3-(4-hydroxymethylphenoxy)propionic acid, and p-[(R,S)-a[1-(9H-fluoren-9-yl)methoxyformamido]-2,4-dimethoxybenzyl]-phenoxy-acetic acid.

The peptide conjugates of the invention may be cleaved from the solid support material by
15 means of an acid such as trifluoroacetic acid, trifluoromethanesulfonic acid, hydrogen bromide, hydrogen chloride, hydrogen fluoride, etc. optionally in combination with one or more "scavengers" suitable for the purpose, e.g., ethanedithiol, triisopropylsilane, phenol, thioanisole, etc., or the peptide conjugate of the invention may be cleaved from the solid support by means of a base such as ammonia, hydrazine, an alkoxide, such as sodium
20 ethoxide, an hydroxide, such as sodium hydroxide, etc.

Thus, the present invention also relates to a method for the preparation of a pharmacologically active peptide conjugate, wherein Z is covalently bound to X at the C-terminal function of X (X-Z), comprising the steps of:

25

- a) coupling an N- α -protected amino acid in the carboxyl activated form, or an N- α -protected dipeptide in the C-terminal activated form to an immobilised peptide sequence H-Z-SSM, thereby forming an immobilised N- α -protected peptide fragment,
- 30 b) removing the N- α -protecting group, thereby forming an immobilised peptide fragment having an unprotected N-terminal end,

c) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of the immobilised peptide fragment, and repeating the removal/coupling step procedure in step b) and c) until the desired peptide sequence X is obtained, and then

5

d) cleaving off the peptide conjugate from the solid support material.

In a further aspect the present invention also relates to a method for the preparation of a pharmacologically active peptide conjugate, wherein Z is covalently bound to the N-
10 terminal nitrogen atom of X (Z-X), comprising the steps of:

a) coupling an N- α -protected amino acid, or an N- α -protected dipeptide to a solid support material (SSM), thereby forming an immobilised N- α -protected amino acid, or an immobilised N- α -protected dipeptide fragment,

15

b) removing the N- α -protecting group, thereby forming an immobilised amino acid or peptide fragment having an unprotected N-terminal end,

c) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an
20 additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of the immobilised amino acid or peptide fragment, and repeating the removal/coupling step procedure in step b) and c) until the desired peptide sequence X is obtained,

d) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an
25 additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of the immobilised peptide fragment, and

repeating the removal/coupling step procedure in step b) and d) until the desired peptide sequence Z is obtained, and then

30

e) cleaving off the peptide conjugate from the solid support material.

In a still further aspect the present invention relates to a method for the preparation of a pharmacologically active peptide conjugate, wherein a first sequence (Z) is covalently bound to X at the C-terminal function of X and a second sequence (Z) is covalently bound to the N-terminal nitrogen atom of X (Z-X-Z), comprising the steps of:

- 5 a) coupling an N- α -protected amino acid in the carboxyl activated form, or an N- α -protected dipeptide in the C-terminal activated form to an immobilised peptide sequence H-Z-SSM, thereby forming an immobilised N- α -protected peptide fragment,
 - 10 b) removing the N- α -protecting group, thereby forming an immobilised peptide fragment having an unprotected N-terminal end,
 - c) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of
 - 15 the immobilised peptide fragment, and repeating the removal/coupling step procedure in step b) and c) until the desired peptide sequence X is obtained, and then
 - d) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of
 - 20 the immobilised peptide fragment, and repeating the removal/coupling step procedure in step b) and d) until the desired peptide sequence Z is obtained, and then
 - e) cleaving off the peptide conjugate from the solid support material.
- 25 The coupling, removal and cleavage steps are performed by methods known to the person skilled in the art taking into consideration the protection strategy and the selected solid phase material. In general, however, it is believed that the Boc (tert.butyloxycarbonyl) as well as the Fmoc (9-fluorenylmethyloxycarbonyl) protection strategies are applicable and that peptide bonds may be formed using the various activation procedures known to the
- 30 person skilled in the art, e.g., by reacting a C-terminal activated derivative (acid halide, acid anhydride, activated ester e.g., HOBT-ester, etc.) of the appropriate amino acid or peptide

65450 06544650

with the amino group of the relevant amino acid or peptide as known to a person skilled in peptide chemistry.

Furthermore, it may be necessary or desirable to include side-chain protection groups when
5 using amino acid residues carrying functional groups which are reactive under the prevailing conditions. The necessary protection scheme will be known to the person skilled in the art (see e.g., M. Bodanszky and A. Bodanszky, "The Practice of Peptide Synthesis", 2. Ed, Springer-Verlag, 1994, J. Jones, "The Chemical Synthesis of Peptides", Clarendon Press, 1991, and Dryland et al., 1986, J. Chem. Soc., Perkin Trans. 1:125-137).

10

The peptide conjugates may also be prepared by means of recombinant DNA-technology using general methods and principles known to the person skilled in the art. A nucleic acid sequence encoding the conjugate may be prepared synthetically by established standard methods, e.g., the phosphoamidite method described by S.L. Beaucage and M.H. Caruthers,
15 Tetrahedron Letters 22, 1981, pp. 1859-1869, or the method described by Matthes et al., EMBO Journal 3, 1984, pp. 801-805. According to the phosphoamidite method, oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

20 The techniques used to isolate or clone a nucleic acid sequence encoding the pharmacologically active peptide X are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression
25 libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, A Guide to Methods and Application, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used. It can then be ligated to a nucleic acid sequence encoding Z.

30

The nucleic acid sequence encoding the conjugate is then inserted into a recombinant expression vector which may be any vector which may conveniently be subjected to

recombinant DNA procedures. The choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid. Alternatively, the vector may be
5 one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the nucleic acid sequence encoding the conjugate of the present invention should be operably connected to a suitable promoter sequence. The promoter may be any
10 nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the nucleic acid sequence encoding said conjugate in mammalian cells are the SV 40 promoter (Subramani et al., Mol. Cell Biol. 1, 1981, pp. 854-864), the MT-1 (metallothionein gene) promoter
15 (Palmiter et al., Science 222, 1983, pp. 809-814) or the adenovirus 2 major late promoter, a Rous sarcoma virus (RSV) promoter, cytomegalovirus (CMV) promoter (Boshart et al., 1981, Cell 41:521-530) and a bovine papilloma virus promoter (BPV). A suitable promoter for use in insect cells is the polyhedrin promoter (Vasuvedan et al., FEBS Lett. 311, 1992, pp. 7-11).

20

Examples of suitable promoters for directing the transcription of the nucleic acid sequence encoding the conjugate, especially in a bacterial host cell, are the promoters obtained from the E. coli lac operon, the Streptomyces coelicolor agarase gene (dagA), the Bacillus subtilis levansucrase gene (sacB), the Bacillus licheniformis alpha-amylase gene (amyL),
25 the Bacillus stearothermophilus maltogenic amylase gene (amyM), the Bacillus amyloliquefaciens alpha amylase gene (amyQ), the Bacillus licheniformis penicillinase gene (penP), the Bacillus subtilis xylA and xylB genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the tac promoter (DeBoer et al., 1983, Proceedings of the
30 National Academy of Sciences USA 80:21 25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.

060720 065746G

- Examples of suitable promoters for directing the transcription of the nucleic acid sequence encoding the conjugate in a filamentous fungal host cell are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (glaA), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium oxysporum* trypsin-like protease (as described in U.S. Patent No. 4,288,627, which is incorporated herein by reference), and hybrids thereof. Particularly preferred promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral a amylase and *Aspergillus oryzae* triose phosphate isomerase), and glaA promoters.
- 15 In a yeast host, useful promoters are obtained from the *Saccharomyces cerevisiae* enolase (ENO-1) gene, the *Saccharomyces cerevisiae* galactokinase gene (GAL1), the *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the *Saccharomyces cerevisiae* 3-phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by Romanos et al., 1992, *Yeast* 8:423-488.

The nucleic acid sequence encoding said conjugate may also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) Preferred terminators for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes encoding *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), or *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, *supra*.

The vector may further comprise elements such as polyadenylation signals (e.g., from SV 40 or the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g., the SV 40 enhancer) and translational enhancer sequences (e.g., the ones encoding adenovirus VA
5 RNAs). Furthermore, preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, and *Aspergillus niger* alpha-glucosidase. Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Molecular Cellular Biology* 15:5983-5990.

10

The recombinant expression vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such a sequence (when the host cell is a mammalian cell) is the SV 40 or polyoma origin of replication. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19,
15 pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAM β 1. Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1. The origin of replication may be one having a mutation to make its function temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, *Proc. Natl. Acad. Sci. USA* 75:1433).

20

The vector may also comprise a selectable marker, e.g., a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g., neomycin, geneticin, ampicillin, or hygromycin. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3,
25 TRP1, and URA3. A selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenylyltransferase), trpC (anthranilate synthase), and glufosinate resistance
30 markers, as well as equivalents from other species. Preferred for use in an *Aspergillus* cell are the amdS and pyrG markers of *Aspergillus nidulans* or *Aspergillus oryzae* and the bar marker of *Streptomyces hygrosopicus*. Furthermore, selection may be accomplished by

cotransformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.

The procedures used to ligate the nucleic acid sequences coding for the conjugate, the
5 promoter and the terminator, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

The host cell into which the expression vector is introduced may be any cell which is
10 capable of producing the conjugate and is may be a eukaryotic cell, such as invertebrate (insect) cells or vertebrate cells, e.g., *Xenopus laevis* oocytes or mammalian cells, in particular insect and mammalian cells. Examples of suitable mammalian cell lines are the COS (e.g., ATCC CRL 1650), BHK (e.g., ATCC CRL 1632, ATCC CCL 10) or CHO (e.g., ATCC CCL 61) cell lines.

15 Methods for transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g., Kaufman and Sharp, 1982, J. Mol. Biol. 159:601-621; Southern and Berg, 1982, J. Mol. Appl. Genet. 1:327-341; Loyter et al., 1982, Proc. Natl. Acad. Sci. USA 79:422-426; Wigler et al., 1978, Cell 14:725; Corsaro and Pearson, 1981, Somatic
20 Cell Genetics 7:603, Graham and van der Eb, 1973, Virology 52:456; Fraley et al., 1980, JBC 225:10431; Capecchi, 1980, Cell 22:479; Wiberg et al., 1983, NAR 11:7287; and Neumann et al., 1982, EMBO J. 1:841-845.

The host cell may also be a unicellular pathogen, e.g., a prokaryote, or a non-unicellular
25 pathogen, e.g., a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, e.g., *Streptomyces*
30 *lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas* sp. The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General

Genetics 168:111-115), by using competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnar and Davidoff Abelson, 1971, Journal of Molecular Biology 56:209-221), by electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:742-751), or by conjugation (see, e.g., Koehler and Thorne, 1987, Journal of Bacteriology 169:5771-5278).

The host cell may be a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra). Representative groups of Ascomycota include, e.g., Neurospora, Eupenicillium (=Penicillium), Emericella (=Aspergillus), Eurotium (=Aspergillus), and the true yeasts listed above. The fungal host cell may also be a yeast cell. "Yeast" as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). The medium used to culture the cells may be any conventional medium suitable for growing mammalian cells, such as a serum-containing or serum-free medium containing appropriate supplements, or a suitable medium for growing insect, yeast or fungal cells. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g., in catalogues of the American Type Culture Collection).

The conjugate produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g., ammonium sulphate, purification by a variety of chromatographic procedures, e.g., ion exchange chromatography, affinity chromatography, or the like.

The invention is further illustrated by the following examples.

EXAMPLES

Peptide Synthesis

5

General Procedures

Apparatus and synthetic strategy

Peptides were synthesized batchwise in a polyethylene vessel equipped with a polypropylene filter for filtration using 9-fluorenylmethyloxycarbonyl (Fmoc) as the N- α -amino protecting group and suitable common protection groups for side-chain functionalities (Dryland et al., 1986, J. Chem. Soc., Perkin Trans. 1:125-137).

Solvents

15 Solvent DMF (*N,N*-dimethylformamide, Riedel de-Häen, Germany) was purified by passing it through a column packed with a strong cation exchange resin (Lewatit S 100 MB/H strong acid, Bayer AG Leverkusen, Germany) and analysed for free amines prior to use by addition of 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (Dhbt-OH) giving rise to a yellow colour (Dhbt-O-anion) if free amines are present. Solvent DCM (dichloromethane, 20 analytical grade, Riedel de-Häen, Germany) was used directly without purification.

Amino acids

Fmoc-protected amino acids were purchased from MilliGen (UK) and from PerSeptive Biosystems GmbH Hamburg, Germany in suitable side-chain protected forms. Non-protein 25 amino acids FmocOrn(Boc)-OH, Fmoc-2-D-Nal-OH, Fmoc-D-Phe-OH, Fmoc-Aib-OH were purchased from Bachem (Switzerland) and FmocDbu(Boc)-OH, FmocDpr(Boc)-OH from Neosystem, France.

Linker

30 (4-hydroxymethylphenoxy)acetic acid (HMPA), Novabiochem, Switzerland was coupled to the resin either as a preformed or *in situ* generated 1-hydroxybenzotriazole (HObt) ester by means of DIC.

0944590.071390

Coupling reagents

Coupling reagent diisopropylcarbodiimide (DIC) was purchased from (Riedel de-Häen, Germany) and distilled prior to use, dicyclohexylcarbodiimide (DCC) was purchased from 5 Merck-Schuchardt, München, Germany, and purified by distillation.

Solid supports

Peptides synthesized according to the Fmoc-strategy were synthesized on the following types of solid support using 0.05 M or higher concentrations of Fmoc-protected activated amino acid in DMF. 1) PEG-PS (polyethyleneglycol grafted on polystyrene; 2) NovaSyn TG resin, 0.29 mmol/g, Novabiochem, Switzerland); 3) TentaGel S resins 0.22-0.31 mmol/g (TentaGel-S-NH₂; TentaGel S-Ram, TentaGel S PHB-Lys(Boc)Fmoc, TentaGel S RAM-Lys(Boc)Fmoc; Rapp polymere, Germany).

15 Catalysts and other reagents

Diisopropylethylamine (DIEA) was purchased from Aldrich, Germany, and ethylenediamine from Fluka, piperidine and pyridine from Riedel-de H  en, Frankfurt, Germany. 4-(N,N-dimethylamino)pyridine (DMAP) was purchased from Fluka, Switzerland and used as a catalyst in coupling reactions involving symmetrical anhydrides. Ethanedithiol was purchased from Riedel-de H  en, Frankfurt, Germany. 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (Dhbt-OH) and 1-hydroxybenzotriazole (HObt) were obtained from Fluka, Switzerland.

Enzymes

25 Carboxypeptidase A (EC 3.4.17.1) type I from bovine pancreas, leucine aminopeptidase (EC 3.4.11.1) type III-CP from porcine kidney, α -chymotrypsin (EC 4.4.21.1) from bovine pancreas, and pepsin A (EC 3.4.23.1) from porcine stomach mucosa bovine pancreas were obtained from Sigma, UK.

30 Coupling procedures

The first amino acid was coupled as a symmetrical anhydride in DMF generated from the appropriate N- α -protected amino acid by means of DIC or DCC. The following amino acids

were coupled as preformed HOBT esters made from appropriate N- α -protected amino acids and HOBT by means of DIC in DMF. Acylations were checked by the ninhydrin test performed at 80°C in order to prevent Fmoc deprotection during the test (Larsen, B. D. and Holm, A., 1994, Int. J. Peptide Protein Res. 43:1-9).

5

Coupling as HOBT-ester

Method a. 3 eq. N- α -amino protected amino acid was dissolved in DMF together with 3 eq. HOBT and 3 eq DIC. The solution was left at r.t. for 10 minutes and then added to the resin, which had been washed with a solution of 0.2% Dhbt-OH in DMF prior to the addition of
10 the preactivated amino acid.

Method b. 3 eq. N- α -amino protected amino acid was dissolved in DMF together with 3 eq. HOBT. 3 eq DIC were added just prior to use. The final solution was added to the resin.

15 Preformed symmetrical anhydride

6 eq. N- α -amino protected amino acid was dissolved in DCM and cooled to 0°C. DCC or DIC (3 eq.) was added and the reaction continued for 10 min. The solvent was removed *in vacuo* and the residue dissolved in DMF. The DMF-solution was filtered in case of using DCC and immediately added to the resin followed by 0.1 eq. of DMAP.

20

Estimation of the coupling yield of the first N- α -amino protected amino acid

3-5 mg dry Fmoc-protected peptide-resin was treated with 5 ml 20% piperidine in DMF for 10 min at r.t. and the UV absorption for the dibenzofulvene-piperidine adduct was estimated at 301 nm. The yield was determined using a calculated extinction coefficient ϵ_{301} based on a
25 Fmoc-Ala-OH standard.

Deprotection of the N- α -amino Fmoc protecting group

Deprotection of the Fmoc group was performed by treatment with 20% piperidine in DMF (1 x 5 and 1 x 10 min.), followed by wash with DMF until no yellow colour (Dhbt-O-) could be detected after addition of Dhbt-OH to the drained DMF.
30

0944590.071390

Cleavage of peptide from resin with acid

Method a. Peptides were cleaved from the resins by treatment with 95% trifluoroacetic acid (TFA, Riedel-de Häen, Frankfurt, Germany)-water v/v or with 95% TFA and 5% ethanedithiol v/v at r.t. for 2 h. The filtered resins were washed with 95% TFA-water and
5 filtrates and washings evaporated under reduced pressure. The residue was washed with ether and freeze dried from acetic acid-water. The crude freeze dried product was analysed by high-performance liquid chromatography (HPLC) and identified by mass spectrometry (MS).

10 *Method b.* Peptides were cleaved from the resins by treatment with 95% trifluoroacetic acid (TFA, Riedel-de Häen, Frankfurt, Germany)-water v/v or with 95% TFA and 5% ethanedithiol v/v at r.t. for 2 h. The filtered resins were washed with 95% TFA-water and filtrates and washings were diluted by adding 10% acetic acid. The resulting mixture was extracted 3 times with ether and finally freeze dried. The crude freeze dried product was
15 analysed by high-performance liquid chromatography (HPLC) and identified by mass spectrometry (MS).

Method c. Peptides were cleaved from the resins by treatment with 95% trifluoroacetic acid and 5% triisopropylsilane (Sigma) v/v at r.t. for 2 h. The filtered resins were washed with
20 95% TFA-water and filtrates and washings evaporated under reduced pressure. The residue was washed with ether and freeze dried from acetic acid-water. The crude freeze dried product was analysed by high-performance liquid chromatography (HPLC) and identified by mass spectrometry (MS).

25 Disulfide bond formation

The crude Acn protected peptide was dissolved in methanol/water 4:1 and pH adjusted to 3.33 (by adding conc. Acetic acid) and the concentration of the peptide was approximately 10^{-3} M. 10-eq iodine dissolved in methanol (20 mg/ml) was added to the peptide solution in one portion. The reaction proceeded for 4-5 days at -18 to -20°C and was followed by
30 HPLC. The reaction mixture was then diluted by adding one extra volume water, and extracted 3 times with chloroform or tetrachlormethane. The clear water solution was then freeze-dried and the product was purified by preparative HPLC as described above.

Batchwise peptide synthesis on PEG-PS

NovaSyn TG resin (250 mg, 0.27-0.29 mmol/g) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration. The resin was swelled in DMF (5 ml),
5 and treated with 20% piperidine in DMF to secure the presence of non-protonated amino groups on the resin. The resin was drained and washed with DMF until no yellow colour could be detected after addition of Dhbt-OH to the drained DMF. HMPA (3 eq.) was coupled as a preformed HOBT-ester as described above and the coupling was continued for 24 h. The resin was drained and washed with DMF (5 x 5 ml, 5 min each) and the acylation
10 checked by the ninhydrin test. The first amino acid was coupled as a preformed symmetrical anhydride as described above. The coupling yields of the first Fmoc-protected amino acids were estimated as described above. It was in all cases better than 60%. The following amino acids according to the sequence were coupled as preformed Fmoc-protected, and if necessary side-chain protected, HOBT esters (3 eq.) as described above. The couplings were
15 continued for 3 h, unless otherwise specified. The resin was drained and washed with DMF (5 x 5 ml, 5 min each) in order to remove excess reagent. All acylations were checked by the ninhydrin test performed at 80°C. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 5 min each), DCM (3x5 ml, 1 min each) and finally diethyl ether (3x5 ml, 1 min each) and dried *in vacuo* over night.

20

Batchwise peptide synthesis on TentaGel S-NH₂

TentaGel S-NH₂ resin (100-500 mg, 0.22-0.31 mmol/g) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration. The resin was swelled in DMF (5-10 ml), and treated with 20% piperidine in DMF to secure the presence of non-protonated amino
25 groups on the resin. The resin was drained and washed with DMF until no yellow colour could be detected after addition of Dhbt-OH to the drained DMF. HMPA (3 eq.) was coupled as an HOBT-ester generated *in situ* by means of DIC as described above and the coupling was continued for 24 h. The resin was drained and washed with DMF (4 x 5-10 ml, 2 min each) and the acylation checked by the ninhydrin test. The first amino acid was
30 coupled as a preformed symmetrical anhydride as described above. The coupling yields of the first Fmoc-protected amino acids were estimated as described above. It was in all cases better than 60%. The following amino acids according to the sequence were coupled as

Fmoc-protected HOBT esters (3 eq.) generated *in situ* by means of DIC as described above. The couplings were continued for 3 h, unless otherwise specified. The resin was drained and washed with DMF (4 x 5-10 ml, 2 min each) in order to remove excess reagent. All acylations were checked by the ninhydrin test performed at 80 °C. After completion of the
5 synthesis, the peptide-resin was washed with DMF (3 x 5-10 ml, 5 min each), DCM (3 x 5-10 ml, 1 min each) and finally diethyl ether (3 x 5-10 ml, 1 min each) and dried *in vacuo*.

Batchwise peptide synthesis on TentaGel S-RAM

TentaGel S-RAM resin (100-1000 mg, 0.22-0.31 mmol/g) was placed in a polyethylene
10 vessel equipped with a polypropylene filter for filtration. The resin was swelled in DMF (5-10 ml), and the Fmoc group was removed according to the procedure described above. The following amino acids according to the sequence were coupled as Fmoc-protected HOBT esters (3 eq.) generated *in situ* by means of DIC as described above. The couplings were continued for 3 h, unless otherwise specified. The resin was drained and washed with DMF
15 (4 x 5-10 ml, 2 min each) in order to remove excess reagent. All acylations were checked by the ninhydrin test performed at 80°C. After completion of the synthesis, the peptide-resin was washed with DMF (3 x 5-10 ml, 5 min each), DCM (3 x 5-10 ml, 1 min each) and finally diethyl ether (3 x 5-10 ml, 1 min each) and dried *in vacuo*.

20 HPLC conditions

Isocratic HPLC analysis was performed on a Shimadzu system consisting of an LC-6A pump, an MERCK HITACHI L-4000 UV detector operated at 215 nm and a Rheodyne 7125 injection valve with a 20 µl loop. The column used for isocratic analysis was a Spherisorb ODS-2 (100 x 3 mm; 5-µm particles) (MicroLab, Aarhus, Denmark).

25

HPLC analysis using gradients was performed on a MERCK-HITACHI L-6200 Intelligent pump, an MERCK HITACHI L-4000 UV detector operated at 215 nm and a Rheodyne 7125 injection valve with a 20 µl loop, or on a Waters 600 E instrument equipped with a Waters 996 photodiode array detector. The columns used were a Rescorce™ RPC 1 ml
30 (Waters) or a LiChroCART 125-4, LiChrospher 100 RP-18 (5 µm) (Merck).

Buffer A was 0.1 vol % TFA in water and buffer B 90 vol% acetonitrile, 9.9 vol% water and 0.1 vol% TFA. The buffers were pumped through the columns at a flow rate of 1.3-1.5 ml/min using either of the following gradients for peptide analysis 1) Linear gradient from 0% - 100% B (30 min) or 2) 0% B (2 min) linear gradient from 0-50% B (23 min) 50-100% B (5 min).

For Preparative HPLC, purification was performed on a Waters 600 E instrument equipped with a Waters 996 photodiode array detector. The column used was a Waters Delta-Pak C-18 15 μ m, 100 Å, 25 x 100 mm. Gradient "2" was used with a flow rate of 9 ml/min.

10

Mass spectroscopy

Mass spectra were obtained on a Finnigan Mat LCQ instrument equipped with an electrospray (ESI) probe (ES-MS) and on a ToFSpec E, Fisons Instrument (MALDI-TOF) using β -cyano-*p*-hydroxycinnamic acid as matrix.

15

Peptide synthesis of individual peptides

1. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-Glu₆-OH (Leu-enkephalin-Glu₆-OH) on NovaSyn TentaGel

- 20 Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe Glu₆. The following amino acids forming the Leu-enkephalin sequence were coupled as preformed Fmoc-protected, if necessary side-chain protected, HOBT esters (3 eq.) in DMF (5 ml) generated by means of
- 25 DIC. Before each of the last five couplings, the resin was washed with a solution of Dhbt-OH (80 mg in 25 ml), in order to follow the disappearance of the yellow colour as the coupling reaction proceeded. When the yellow colour was no longer visible, the couplings were interrupted by washing the resin with DMF (5 x 5 ml, 5 min each). The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After
- 30 completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method a*. The crude freeze dried product was analysed by HPLC and the purity was found to be better than 90%. The identity of the peptide was confirmed by ES-MS. Yield 76%.

5 2. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-Lys₆-OH (Leu-enkephalin-Lys₆-OH) on NovaSyn TentaGel

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe Lys₆. The following amino
10 acids forming the Leu-enkephalin sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC. Before each of the last five couplings, the resin was washed with a solution of Dhbt-OH (80 mg in 25 ml), in order to follow the disappearance of the yellow colour as the coupling reaction proceed. When the yellow colour was no longer visible, the couplings were interrupted by washing the resin
15 with DMF (5 x 5 ml, 5 min each). The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

20 The peptide was cleaved from the resin according to *method a*. The crude freeze dried product was analysed by HPLC and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 84%.

3. Peptide synthesis of H-Lys₆-Tyr-Gly-Gly-Phe-Leu-OH (H-Lys₆-Leu-enkephalin) on

25 NovaSyn TentaGel

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" and the first amino acid leucine was coupled as described under coupling procedures. The following amino acids forming the H-Lys₆-enkephalin
30 sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC and the couplings were continued for at least 2 hours. The acylations were then checked by the ninhydrin test performed at 80°C as earlier described.

After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin as described above using 95% TFA and 5% water (v/v) as cleavage reagent and freeze dried from acetic acid. The crude freeze dried product was analysed by HPLC and found to be homogeneous without deletion and Fmoc-protected sequences. The purity was found to be better than 98% and the identity of the peptide conjugate was confirmed by ES-MS. Yield 89%.

10 4. Peptide synthesis of H-Lys₆-Tyr-Gly-Gly-Phe-Leu-Lys₆-OH (H-Lys₆-Leu-enkephalin-Lys₆-OH) on NovaSyn TentaGel

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe Lys₆. The following amino acids forming the H-Lys₆-enkephalin sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC and the couplings were continued for at least 2 hours. The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method a*. The crude freeze dried product was analysed by HPLC and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 90%.

25

5. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-Lys-Lys-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Lys-Glu-Glu-Glu-Lys-OH) on TentaGel S-PHB-Lys(Boc)Fmoc

Dry TentaGel S-PHB-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above and the synthesis was continued until finishing the peptide sequence as described under "Batchwise peptide synthesis on TentaGel S-PHB-Lys(Boc)Fmoc". After completion of the

synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and
 5 freeze dried from acetic acid. The crude freeze dried peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 90%. The identity of the peptide was confirmed by ES-MS. Yield 60 %.

10 6. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Glu-Glu-Glu-Glu-Lys-OH) on TentaGel S-PHB-Lys(Boc)Fmoc

Dry TentaGel S-PHB-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above.

15 And the synthesis was continued until finishing the peptide sequence as described under "Batchwise peptide synthesis on TentaGel S-PHB-Lys(Boc)Fmoc". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

20 The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 65%.

25

7. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-(Orn)₆-OH (Leu-enkephalin-(Orn)₆-OH) on TentaGel S-NH₂

Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml).

30 The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-

06514660
 070
 06514660

resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

- The peptide was cleaved from the resin according to *method b* as described above and
- 5 freeze dried from acetic acid. The crude freeze dried product was oxidized in order to make the disulfide bond according to the procedure described above. The crude cyclized peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 90%. The identity of the peptide was confirmed by ES-MS. Yield 20%.

10

8. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-(Dbu)₆-OH (Leu-enkephalin-(Dbu)₆-OH) on TentaGel S-NH₂

Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml).

- 15 The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.
- 20 The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was oxidized in order to make the disulfide bond according to the procedure described above. The crude cyclized peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 90%. The
- 25 identity of the peptide was confirmed by ES-MS. Yield 22%.

9. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH (Leu-enkephalin-(Dpr)₆-OH) on TentaGel S-NH₂

Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel

30 equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml).

The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-

resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 22%.

10 10. Peptide synthesis of H-Tyr-Gly-Gly-Phe-Leu-Lys₁₀-OH (Leu-enkephalin-Lys₁₀-OH) on TentaGel S-PHB-Lys(Boc)Fmoc

Dry TentaGel S-PHB-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above and the synthesis was continued until finishing the peptide sequence as described under "Batchwise peptide synthesis on TentaGel S-PHB-Lys(Boc)Fmoc". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

20 The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 7.1%.

25

11. Peptide synthesis of H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-Glu₆-OH (DSIP-Glu₆-OH) on NovaSyn TentaGel

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe Glu₆. The following amino acids forming the DSIP sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC. Before each of the last nine couplings,

the resin was washed with a solution of Dhbt-OH (80 mg in 25 ml), in order to follow the disappearance of the yellow colour as the coupling reaction proceeds. When the yellow colour was no longer visible, the couplings were interrupted by washing the resin with DMF (5 x 5 ml, 5 min each). The acylations were then checked by the ninhydrin test performed at 5 80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each), and dried *in vacuo*.

The peptide was cleaved from the resin according to *method a*. The crude freeze dried 10 product was analysed by HPLC and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 80%.

12. Peptide synthesis of H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH (DSIP-(Lys-Glu)₃-OH) on NovaSyn TentaGel

15 Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe (LysGlu)₃. The following amino acids forming the DSIP sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC. Before each of the last nine 20 couplings, the resin was washed with a solution of Dhbt-OH (80 mg in 25 ml), in order to follow the disappearance of the yellow colour as the coupling reaction proceeds. When the yellow colour was no longer visible, the couplings were interrupted by washing the resin with DMF (5 x 5 ml, 5 min each). The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After completion of the synthesis, the peptide-resin 25 was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each), and dried *in vacuo*.

The peptide was cleaved from the resin according to *method a*. The crude freeze dried product was analysed by HPLC and the purity was found to be better than 98%. The the 30 identity of the peptide was confirmed by ES-MS. Yield 91%.

13. Peptide synthesis of H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH (DSIP) on NovaSyn TentaGel (Reference)

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS". The first amino acid was coupled as a preformed symmetrical anhydride as described above. The coupling yields of the first Fmoc-protected amino acids were estimated as described above. The yields were in all cases better than 60%. The following amino acids forming the DSIP sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC. Before each of the last eight couplings, the resin was washed with a solution of Dhbt-OH (80 mg in 25 ml), in order to follow the disappearance of the yellow colour as the coupling reaction proceeds. When the yellow colour was no longer visible, the couplings were interrupted by washing the resin with DMF (5 x 5 ml, 5 min each). The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each), and dried *in vacuo*.

The peptide was cleaved from the resin according to *method a*. The crude freeze dried product was analysed by HPLC and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 78%.

14. Peptide synthesis of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-Lys₆-OH (Substance P-Lys₆-OH) on NovaSyn TentaGel

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe Lys₆. The following amino acids forming the Substance P sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC and the couplings were continued for at least 2 hours. The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method a*. The crude freeze dried product was analysed by HPLC and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 80%.

5

15. Peptide synthesis of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂
(Substance-P-NH₂) on TentaGel S-RAM

Dry TentaGel S-RAM resin (0.25 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml).

- 10 The Fmoc group was removed according to the procedure described above, and the peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S-RAM resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

15

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-

- 20 MS. Yield 12.3%.

16. Peptide synthesis of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-Lys₆-NH₂
(Substance-P-Lys₆-NH₂) on TentaGel S-RAM-Lys(Boc)Fmoc

Dry TentaGel S-RAM-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above and the synthesis was continued until finishing the peptide sequence as described under "Batchwise peptide synthesis on TentaGel S-Ram-Lys(Boc)Fmoc". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1

- 30 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 17.2%.

17. Peptide synthesis of H-(Lys)₆-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ (K₆-Substance-P-NH₂) on TentaGel S-RAM

Dry TentaGel S-RAM resin (0.25 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group was removed according to the procedure described above, and the peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S-RAM resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 10.3%.

18. Peptide synthesis of H-Aib-His-2-D-Nal-D-Phe-Lys-(Lys)₆-NH₂ (GHRP-(Lys)₆-NH₂) on TentaGel S-RAM-Lys(Boc)Fmoc

Dry TentaGel S-RAM-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above and the synthesis was continued until finishing the peptide sequence as described under "Batchwise peptide synthesis on TentaGel S-Ram-Lys(Boc)Fmoc". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 90%. The identity of the peptide was confirmed by ES-MS. Yield 35%.

19. Peptide synthesis of H-Aib-His-2-D-Nal-D-Phe-Lys-NH₂ (GHRP-NH₂) on TentaGel S-RAM

Dry TentaGel S-RAM resin (0.25 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group was removed according to the procedure described above, and the peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S-RAM resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was found to be homogeneous and the purity was found to be better than 95%. The identity of the peptide was confirmed by ES-MS. Yield 21%.

20. Peptide synthesis of H-(Lys)₆-Aib-His-2-D-Nal-D-Phe-Lys-NH₂ (K₆-GHRP-NH₂) on TentaGel S-RAM

Dry TentaGel S-RAM resin (0.25 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group was removed according to the procedure described above, and the peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S-RAM resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was found to be homogeneous and the purity was found to be better than 95%. The identity of the peptide was confirmed by ES-MS. Yield 19%.

5

21. Peptide synthesis of Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Lys₆-OH (GnRH-Lys₆-OH) on NovaSyn TentaGel

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe Lys₆. The following amino acids forming the GnRH sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC and the couplings were continued for at least 2 hours. The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with
10 DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each)
15 and dried *in vacuo*.

The peptide was cleaved from the resin according to *method c*. The crude freeze dried product was analysed by HPLC and it was found to contain the target peptide together with
20 some impurities. The crude product was purified by preparative reverse-phase HPLC. The purity was found to be better than 98% and the identity of the peptide conjugate was confirmed by ES-MS. Yield 37%.

22. Peptide synthesis of pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys-Glu)₃-OH

25 (GnRH-(Lys-Glu)₃-OH) on NovaSyn TentaGel

Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe (Lys-Glu)₃. The following amino acids forming the GnRH sequence were coupled as preformed Fmoc-protected HOBT
30 esters (3 eq.) in DMF (5 ml) generated by means of DIC and the couplings were continued for at least 2 hours. The acylations were then checked by the ninhydrin test performed at

80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

- 5 The peptide was cleaved from the resin according to *method c*. The crude freeze dried product was analysed by HPLC and it was found to contain the target peptide together with some impurities. The crude product was purified by preparative reverse-phase HPLC. The purity was found to be better than 98% and the identity of the peptide conjugate was confirmed by ES-MS. Yield 43%.

10

23. Peptide synthesis of pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (GnRH-NH₂) NH₂ on TentaGel S-RAM.

Dry TentaGel S-RAM resin (0.25 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml).

- 15 The Fmoc group was removed according to the procedure described above, and the peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S-RAM resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

20

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was found to be homogeneous and the purity was found to be better than 95%. The identity of the peptide was confirmed by ES-MS. Yield 28%.

25

24. Peptide synthesis of H-(Lys)₆-Gln-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (K₆-GnRH-NH₂) NH₂ on TentaGel S-RAM.

Dry TentaGel S-RAM resin (0.25 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml).

- 30 The Fmoc group was removed according to the procedure described above, and the peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S-RAM resins". After completion of the synthesis, the peptide-resin was

06514590 071399

washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and
5 freeze dried from acetic acid. The crude freeze dried product was found to be homogeneous
and the purity was found to be better than 95%. The identity of the peptide was confirmed
by ES-MS. Yield 20%.

25. Peptide synthesis of H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-
10 Cys-Lys-Pro-Gln-Gly-Gly-OH (EMP-1-OH) on TentaGel S-NH₂.

Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-
15 resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was oxidized without further
20 purification, in order to make the disulfide bond according to the procedure described above. The crude cyclized peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 22%.

26. Peptide synthesis of H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val
Cys-Lys-Pro-Gln-Gly-Gly-Lys₆-OH (EMP-1-Lys₆-OH) on TentaGel S-PHB-
Lys(Boc)Fmoc

Dry TentaGel S-PHB-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a
30 polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two
hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above
and the synthesis was continued until finishing the peptide sequence as described under

"Batchwise peptide synthesis on TentaGel S-PHB-Lys(Boc)Fmoc". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

- 5 The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze-dried product was oxidised without further purification in order to make the disulphide bond according to the procedure described above. The crude cyclized peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was
10 found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 27%.

27. Peptide synthesis of H-(Lys)₆-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH (K₆-EMP-1-OH) on TentaGel S-NH₂.

- 15 Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether
20 (3x5 ml, 1 min each) and dried *in vacuo*.

- The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was oxidized without further purification, in order to make the disulfide bond according to the procedure described
25 above. The crude cyclized peptide was purified by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 12%.

- 30 28. Peptide synthesis of H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-OH (GLP-1-(7-36)(Human)-OH) on TentaGel S-NH₂

Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-
 5 resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried peptide was purified twice by
 10 preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 8.7%.

29. Peptide synthesis of H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-
 15 Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys₆-OH (GLP-1-
(7-36)(Human)-Lys₆-OH) on TentaGel S-PHB-Lys(Boc)Fmoc

Dry TentaGel S-PHB-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above
 20 and the synthesis was continued until finishing the peptide sequence as described under "Batchwise peptide synthesis on TentaGel S-PHB-Lys(Boc)Fmoc". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

25 The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was purified twice by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 11 %.

30. Peptide synthesis of H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (PTH(1-34)(Human)-OH) on TentaGel S-NH₂

Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel
5 equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

10

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried peptide was purified twice by preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide
15 was confirmed by ES-MS. Yield 6.1 %.

31. Peptide synthesis of H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Lys₆-OH (PTH(1-34)(Human)-Lys₆-OH) on TentaGel S-PHB-Lys(Boc)Fmoc

20 Dry TentaGel S-PHB-Lys(Boc)Fmoc resin (0.22 mmol/g, 500 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The Fmoc group on the first lysine was removed as described above. And the synthesis was continued until finishing the peptide sequence as described under "Batchwise peptide synthesis on TentaGel S-PHB-Lys(Boc)Fmoc". After completion of the
25 synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was purified twice by
30 preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 98%. The identity of the peptide was confirmed by ES-MS. Yield 5.3%.

32. Peptide synthesis of H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys-Glu)₃-OH (PTH 1-34 human-(Lys-Glu)₃-OH) on NovaSyn TentaGel

- 5 Dry NovaSyn TG resin (0.29 mmol/g, 250 mg) was placed in a polyethylene vessel equipped with a polypropylene filter for filtration and treated as described under "batchwise peptide synthesis on PEG-PS" until finishing the peptide probe (Lys-Glu)₃. The following amino acids forming the PTH sequence were coupled as preformed Fmoc-protected HOBT esters (3 eq.) in DMF (5 ml) generated by means of DIC and the couplings were continued
- 10 for at least 2 hours. The acylations were then checked by the ninhydrin test performed at 80°C as earlier described. After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.
- 15 The peptide was cleaved from the resin according to *method c*. The crude freeze dried product was analysed by HPLC and it was found to contain the target peptide together with impurities. The crude product was purified by preparative reverse-phase HPLC. The purity was found to be better than 98% and the identity of the peptide conjugate was confirmed by ES-MS. Yield 28%.

20

33. Peptide synthesis of H-(Lys)₆-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Lys₆-PTH(1-34)(Human)-OH) on TentaGel S-NH₂

- Dry TentaGel S-NH₂ resin (0.31 mmol/g, 500 mg) was placed in a polyethylene vessel
- 25 equipped with a polypropylene filter for filtration and swelled for two hours in DMF (5 ml). The peptide according to the sequence was assembled as described under "Batchwise peptide synthesis on TentaGel S resins". After completion of the synthesis, the peptide-resin was washed with DMF (3x5 ml, 1 min each), DCM (3x5 ml, 1 min each), diethyl ether (3x5 ml, 1 min each) and dried *in vacuo*.

30

The peptide was cleaved from the resin according to *method b* as described above and freeze dried from acetic acid. The crude freeze dried product was purified twice by

preparative HPLC using the procedure described above. The purified product was found to be homogeneous and the purity was found to be better than 90%. The identity of the peptide was confirmed by ES-MS. Yield 6.2 %.

5 IN VITRO KINETIC MEASUREMENTS

HPLC

Gradient HPLC analysis of samples from *in vitro* kinetic measurements performed as described below was performed using a Hewlett Packard HP 1100 HPLC system consisting of a HP 1100 Binary Pump, a HP1100 Autosampler, a HP1100 Column Thermostat and a HP 1100 Variable Wavelength Detector. A Merck LiChroCART column (125 x 4 mm I.D.) and a LiChroCART precolumn (4 x 4 mm I.D.) packed with Lichrospher RP-18 (5 μ m particles) was used. The column was kept at 25°C or 75°C and the column effluent was measured by UV detection at 215 nm. Separation of the peptide conjugates or the native peptides from degradation products and constituents of the reaction solutions was accomplished using gradient elution of the column with mixtures of mobile phase A (0.1 vol% TFA in water) and mobile phase B (0.085 vol% TFA in acetonitrile) at a flow rate of 1 ml/min. The following linear gradients used are shown in Table 1 below:

Table 1

HPLC Gradient	Peptide / Peptide Conjugate
25 – 40% B in 15 minutes	H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (PTH(1-34)(Human)-OH)
25 – 40% B in 15 minutes	H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys) ₆ -OH

HPLC Gradient	Peptide / Peptide Conjugate
	<i>(PTH(1-34)(Human)-(Lys)₆-OH)</i>
25 – 40% B in 15 minutes	H-(Lys) ₆ -Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH <i>((Lys)₆-PTH(1-34)(Human)-OH)</i>
25 – 50% B in 15 minutes	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-OH <i>(GLP-1(7-36)(Human)-OH)</i>
25 – 50% B in 15 minutes	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-(Lys) ₆ -OH <i>(GLP-1(7-36)(Human)-(Lys)₆-OH)</i>
5 – 50% B in 15 minutes	H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH <i>(EMP-1-OH)</i>
5 – 50% B in 15 minutes	H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys) ₆ -OH <i>(EMP-1-(Lys)₆-OH)</i>
10 – 50% B in 15 minutes	H-(Lys) ₆ -Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH <i>((Lys)₆-EMP-1-OH)</i>
10 – 50% B in 15 minutes	H-(Lys) ₆ -Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys) ₆ -OH <i>((Lys)₆-EMP-1-(Lys)₆-OH)</i>
5 – 40% B in 15 minutes	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂ <i>(Substance P-NH₂)</i>
5 – 40% B in 15 minutes	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys) ₆ -NH ₂

66E F 20" 065TH60

HPLC Gradient	Peptide / Peptide Conjugate
	<i>(Substance P-(Lys)₆-NH₂)</i>
25 – 40% B in 15 minutes	H-(Lys) ₆ -Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂ <i>((Lys)₆-Substance P-NH₂)</i>
40 – 100% B in 15 minutes	H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH <i>(DSIP)</i>
40 – 100% B in 15 minutes	H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu) ₃ -OH <i>(DSIP-(Lys-Glu)₃-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-OH <i>(Leu-Enkephalin)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Lys) ₆ -OH <i>(Leu-Enkephalin-(Lys)₆-OH)</i>
10 – 35% B in 15 minutes	H-(Lys) ₆ -Tyr-Gly-Gly-Phe-Leu-OH <i>((Lys)₆-Leu-Enkephalin-OH)</i>
10 – 35% B in 15 minutes	H-(Lys) ₆ -Tyr-Gly-Gly-Phe-Leu-(Lys) ₆ -OH <i>((Lys)₆-Leu-Enkephalin-(Lys)₆-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Lys) ₁₀ -OH <i>(Leu-Enkephalin-(Lys)₁₀-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Orn) ₆ -OH <i>(Leu-Enkephalin-(Orn)₆-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Dbu) ₆ -OH <i>(Leu-Enkephalin-(Dbu)₆-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-(Dpr) ₆ -OH <i>(Leu-Enkephalin-(Dpr)₆-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-Lys(Glu) ₄ -Lys-OH

HPLC Gradient	Peptide / Peptide Conjugate
	<i>(Leu-Enkephalin-Lys-(Glu)₄-Lys-OH)</i>
5 – 30% B in 15 minutes	H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu) ₃ -(Lys) ₂ -OH <i>(Leu-Enkephalin-Lys-(Glu)₃-(Lys)₂-OH)</i>

HYDROLYSIS KINETICS IN ENZYME SOLUTION

The degradation of the peptide conjugate and the corresponding native peptide were studied at 37°C in a 50 mM phosphate buffer solution at pH 7.4 containing leucine aminopeptidase 5 (25 U/ml) or carboxypeptidase A (1 or 25 U/ml). Experiments were initiated by addition of an aliquot (100 µl) of a stock solution (1 mg/ml) of the peptide conjugate or the native peptide to 900 µl preheated enzyme solution giving a final concentration of ~ 0.1 mg/ml (10⁻⁵ - 10⁻⁴ M) of the peptide conjugate or the native peptide. The peptide/enzyme solution was kept at 37°C using a SHT200D block heater from Stuart Scientific. At appropriate time 10 intervals, samples of 100 µl were withdrawn from the peptide/enzyme solution, mixed thoroughly with 20 µl 25% TFA in acetonitrile in order to stop the enzymatic degradation process and analysed by HPLC as described above. Half-lives (t_{1/2}) for the peptide conjugate and the corresponding native peptide in the enzyme solutions were calculated from plots of the natural logarithm to the concentration of the residual peptide (HPLC peak 15 heights) against time using the formula t_{1/2}=1/k_{obs} x ln(2), where k_{obs} is the apparent first-order rate constant for the observed degradation.

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (PTH(1- 20 34)(Human)-OH)

Hydrolysis kinetics in leucine aminopeptidase

The degradation of H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH 25 (~ 2.4 x 10⁻⁵ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate

constant for the degradation was estimated to $2.1 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to 330 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

- 5 The degradation of H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH ($\sim 2.4 \times 10^{-5} \text{ M}$) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 5.2 min^{-1} and the corresponding half-life
10 calculated to 0.13 min as previously described.

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys)₆-OH
(PTH(1-34)(Human)-(Lys)₆-OH)

15

Hydrolysis kinetics in leucine aminopeptidase

- The degradation of H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys)₆-OH ($\sim 2.0 \times 10^{-5} \text{ M}$) in 50 mM phosphate buffer solutions of pH 7.4 containing
20 leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $1.2 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to 578 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

- 25 The degradation of H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys)₆-OH ($\sim 2.0 \times 10^{-5} \text{ M}$) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $1.5 \times 10^{-2} \text{ min}^{-1}$ and the corresponding half-
30 life calculated to 47 min as previously described.

054150.07139
0651460

The degradation of H-(Lys)₆-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (~ 2.0 x 10⁻⁵ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 3.5 x 10⁻³ min⁻¹ and the corresponding half-life calculated to 198 min as previously described.

15

The degradation of H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-OH ($\sim 3.0 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $3.1 \times 10^{-2} \text{ min}^{-1}$ and the corresponding half-life calculated to 22 min as previously described.

25 The degradation of H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-
Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-OH ($\sim 3.0 \times$
10⁻⁵ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1
U/ml) was studied as described above. The pseudo first-order rate constant for the
degradation was estimated to $4.7 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to
30 148 min as previously described.

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-(Lys)₆-OH (GLP-1(7-36)(Human)-(Lys)₆-OH)

5 Hydrolysis kinetics in leucine aminopeptidase

The degradation of H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-(Lys)₆-OH ($\sim 2.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $1.3 \times 10^{-2} \text{ min}^{-1}$ and the corresponding half-life calculated to 53 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

The degradation of H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-(Lys)₆-OH ($\sim 2.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $8 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to 87 as previously described.

20

H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH (EMP-1-OH)

Hydrolysis kinetics in leucine aminopeptidase

25 The degradation of H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH ($\sim 4.8 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $1.5 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to 462 min as previously described.

30

0944590.0654660

Hydrolysis kinetics in carboxypeptidase A

The degradation of H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH ($\sim 4.8 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. A half-life of more than 50 hours was estimated for the degradation.

H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH (EMP-1-(Lys)₆-OH)

10 Hydrolysis kinetics in leucine aminopeptidase

The degradation of H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH ($\sim 3.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. A half life of more than 100 hours was estimated for the degradation.

15

Hydrolysis kinetics in carboxypeptidase A

The degradation of H-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH ($\sim 3.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. A half-life of more than 20 hours was estimated for the degradation.

H-(Lys)₆-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH ((Lys)₆-EMP-1-OH)

25 Hydrolysis kinetics in leucine aminopeptidase

The degradation of H-(Lys)₆-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-OH ($\sim 3.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. A half life of more than 24 hours was estimated for the degradation.

30

H-(Lys)₆-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH ((Lys)₆-EMP-1-(Lys)₆-OH)

Hydrolysis kinetics in leucine aminopeptidase

- 5 The degradation of H-(Lys)₆-Gly-Gly-Thr-Tyr-Ser-Cys-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys-Lys-Pro-Gln-Gly-Gly-(Lys)₆-OH ($\sim 2.8 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. A half life of more than 100 hours was estimated for the degradation.

- 10 H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ (substance P)

Hydrolysis kinetics in leucine aminopeptidase

- The degradation of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ ($\sim 7.4 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $4.5 \times 10^{-2} \text{ min}^{-1}$ and the corresponding half-life calculated to 16 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

- 20 The degradation of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ ($\sim 7.4 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $2.0 \times 10^{-2} \text{ min}^{-1}$ and the corresponding half-life calculated to 35 min as previously described.

25

H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys)₆-NH₂ (Substance P-(Lys)₆-NH₂)

Hydrolysis kinetics in leucine aminopeptidase

- 30 The degradation of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys)₆-NH₂ ($\sim 4.7 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate

constant for the degradation was estimated to $1.1 \times 10^{-2} \text{ min}^{-1}$ and the corresponding half-life calculated to 66 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

- 5 The degradation of H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-(Lys)₆-NH₂ ($\sim 4.7 \times 10^{-5} \text{ M}$) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $5.5 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to 126 min as previously described.

10

H-(Lys)₆-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ ((Lys)₆-Substance P-NH₂)

Hydrolysis kinetics in leucine aminopeptidase

- 15 The degradation of H-(Lys)₆-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ ($\sim 4.7 \times 10^{-5} \text{ M}$) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $2 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to 347 min as previously described.

20

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH (DSIP)

Hydrolysis kinetics in leucine aminopeptidase

- 25 The degradation of H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH ($\sim 10^{-5} \text{ M}$) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The half-life was calculated to be less than 20 min.

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH (DSIP-(Lys-Glu)₃-OH)**Hydrolysis kinetics in leucine aminopeptidase**

The degradation of H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH ($\sim 10^{-5}$ M) in
 5 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml)
 was studied as described above. The pseudo first-order rate constant for the degradation was
 determined as described earlier and the half-life calculated to be 145 min.

H-Tyr-Gly-Gly-Phe-Leu-OH (Leu-Enkephalin)

10

Hydrolysis kinetics in leucine aminopeptidase

The degradation H-Tyr-Gly-Gly-Phe-Leu-OH ($\sim 1.8 \times 10^{-4}$ M) in 50 mM phosphate buffer
 solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described
 above. The pseudo first-order rate constant for the degradation was estimated to 6.8×10^{-1}
 15 min^{-1} and the corresponding half-life calculated to 1.0 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

The degradation H-Tyr-Gly-Gly-Phe-Leu-OH ($\sim 1.8 \times 10^{-4}$ M) in 50 mM phosphate buffer
 solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described
 20 above. The pseudo first-order rate constant for the degradation was estimated to 9.8×10^{-1}
 min^{-1} and the corresponding half-life calculated to 0.7 min as previously described.

H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH (Leu-Enkephalin-(Lys)₆-OH)**25 Hydrolysis kinetics in leucine aminopeptidase**

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH ($\sim 7.5 \times 10^{-5}$ M) in 50 mM phosphate
 buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as
 described above. The pseudo first-order rate constant for the degradation was estimated to
 $9.7 \times 10^{-3} \text{ min}^{-1}$ and the corresponding half-life calculated to 72 min as previously
 30 described.

666720-0694E50

Hydrolysis kinetics in carboxypeptidase A

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH ($\sim 7.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described
5 above. The pseudo first-order rate constant for the degradation was estimated to 7×10^{-4} min⁻¹ and the corresponding half-life calculated to 990 min as previously described.

H-(Lys)₆-Tyr-Gly-Gly-Phe-Leu-OH ((Lys)₆-Leu-Enkephalin-OH)**10 Hydrolysis kinetics in leucine aminopeptidase**

The degradation H-(Lys)₆-Tyr-Gly-Gly-Phe-Leu-OH ($\sim 7.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 2.6×10^{-2} min⁻¹ and the corresponding half-life calculated to 27 min as previously
15 described.

H-(Lys)₆-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH ((Lys)₆-Leu-Enkephalin-(Lys)₆-OH)**Hydrolysis kinetics in leucine aminopeptidase**

20 The degradation H-(Lys)₆-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH ($\sim 4.8 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. A half life of more than 100 hours was estimated for the degradation.

25 H-Tyr-Gly-Gly-Phe-Leu-(Lys)₁₀-OH (Leu-Enkephalin-(Lys)₁₀-OH)**Hydrolysis kinetics in leucine aminopeptidase**

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Lys)₁₀-OH ($\sim 5.4 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as
30 described above. A half-life of more than 100 hours was estimated for the degradation.

0657420-0657420

Hydrolysis kinetics in carboxypeptidase A

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Lys)₁₀-OH ($\sim 5.4 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 3×10^{-4} min⁻¹ and the corresponding half-life calculated to 2310 min as previously described.

H-Tyr-Gly-Gly-Phe-Leu-(Orn)₆-OH (Leu-Enkephalin-(Orn)₆-OH)**10 Hydrolysis kinetics in leucine aminopeptidase**

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Orn)₆-OH ($\sim 5.7 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 6.4×10^{-3} min⁻¹ and the corresponding half-life calculated to 108 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Orn)₆-OH ($\sim 5.7 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. A half-life of more than 100 hours was estimated for the degradation.

H-Tyr-Gly-Gly-Phe-Leu-(Dbu)₆-OH (Leu-Enkephalin-(Dbu)₆-OH)**Hydrolysis kinetics in leucine aminopeptidase**

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Dbu)₆-OH ($\sim 6.0 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 2.5×10^{-2} min⁻¹ and the corresponding half-life calculated to 28 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

The degradation H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH ($\sim 6.0 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 5×10^{-3} min⁻¹ and the corresponding half-life calculated to 1386 min as previously described.

H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH (Leu-Enkephalin-(Dpr)₆-OH)**Hydrolysis kinetics in leucine aminopeptidase**

- 10 The degradation H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH ($\sim 6.3 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 1.7×10^{-1} min⁻¹ and the corresponding half-life calculated to 4.2 min as previously described.

15

Hydrolysis kinetics in carboxypeptidase A

- The degradation H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH ($\sim 6.3 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 2.4×10^{-2} min⁻¹ and the corresponding half-life calculated to 29 min as previously described.

20

H-Tyr-Gly-Gly-Phe-Leu-Lys(Glu)₄-Lys-OH (Leu-Enkephalin-Lys-(Glu)₄-Lys-OH)**Hydrolysis kinetics in leucine aminopeptidase**

- 25 The degradation H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₄-Lys-OH ($\sim 7.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to 6.5×10^{-2} min⁻¹ and the corresponding half-life calculated to 11 min as previously described.

30

664150 0654460

Hydrolysis kinetics in carboxypeptidase A

The degradation H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₄-Lys-OH ($\sim 7.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $6 \times 10^{-4} \text{ min}^{-1}$ and the corresponding half-life calculated to 1155 min as previously described.

H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₃-(Lys)₂-OH (Leu-Enkephalin-Lys-(Glu)₃-(Lys)₂-OH)

10

Hydrolysis kinetics in leucine aminopeptidase

The degradation H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₃-(Lys)₂-OH ($\sim 7.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing leucine aminopeptidase (25 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $1.2 \times 10^{-1} \text{ min}^{-1}$ and the corresponding half-life calculated to 5.7 min as previously described.

Hydrolysis kinetics in carboxypeptidase A

The degradation H-Tyr-Gly-Gly-Phe-Leu-Lys-(Glu)₃-(Lys)₂-OH ($\sim 7.5 \times 10^{-5}$ M) in 50 mM phosphate buffer solutions of pH 7.4 containing carboxypeptidase A (1 U/ml) was studied as described above. The pseudo first-order rate constant for the degradation was estimated to $8 \times 10^{-4} \text{ min}^{-1}$ and the corresponding half-life calculated to 866 min as previously described.

25 Studies with Enkephalin Analogues***Bioavailability of Leu-enkephalin-OH and Leu-enkephalin-(Lys)₆-OH in mice***

Male mice weighing 20-25 g were given 50 mg Leu-enkephalin-(Lys)₆-OH per kg body weight i.v. or p.o. The compound was dissolved in isotonic NaCl solution. Mice treated with Leu-enkephalin-(Lys)₆-OH, 50 mg/kg p.o. were bled by decapitation at 0, 15, 30, 60, 90, 240, 480, 960 and 1380 minutes after dosing. Mice treated with Leu-enkephalin-(Lys)₆-OH, 50 mg/kg i.v. were bled by decapitation at 5, 15, 30, 60, 180, 240, 370, 720, 1080, and

09344590.0739
66ET20.065TH60

1440 minutes after dosing. Animals treated with the native Leu-enkephalin-OH, 50 mg/kg p.o. or i.v. were bled by decapitation 30 min after dosing. Blood samples were centrifuged immediately (3000 g, 4°C) and serum was isolated and used for activity determination.

- 5 The concentrations of Leu-enkephalin-OH or Leu-enkephalin-(Lys)₆-OH in serum were determined by a bioassay using the vas deferens model from mice. Experiments were carried out essentially as described by Takemori and Porthogese, 1984, *Eur. J. Pharmacol.* 104:101-104. In short: vasa deferentia were isolated from male mice weighing 20-30 g (Møllegaard breeding, DK) and suspended through two electrodes in 10 ml baths at resting
- 10 tension of 1 g. The tissues were bathed with Krebs-bicarbonate solution (physiological buffer solution) maintained at 36-37°C and continuously bubbled with 95 % O₂ and 5 % CO₂. The tissues were stimulated electrically (70 V, 1 ms duration; 0.1 Hz) and contractions were recorded isometrically on a chart recorder. After equilibration of the tissue for at least 20 min, drugs were added in the bath and the maximum effects were measured. Data were
- 15 fitted to the equation % Inhibition = MAX × (1 - [Inh]ⁿ / ([Inh]ⁿ + IC₅₀ⁿ)) + baseline, where MAX is the maximum muscle contraction, [Inh] is the concentration of the inhibitor, n is the Hill slope of the curve and baseline is the muscle contraction insensitive to the compound. Thus, the calculated concentration is a reflection of inhibitory activity in the vas deferens bioassay preparation and not an exact measure of Leu-enkephalin-OH or Leu-
- 20 enkephalin-(Lys)₆-OH in serum.

Values for Leu-enkephalin-OH and Leu-enkephalin-(Lys)₆-OH are mean values ± S.E.M of at least 5 experiments. In assays where the concentration of Leu-enkephalin-(Lys)₆-OH in serum was determined, 100 µl of serum was added to the tissue bath and the % inhibition of

25 the response was determined. The results are shown in Table 2.

66E120 065F4E60

Table 2: Functional activity in serum after p.o. or i.v. administration of Leu-enkephalin-(Lys)₆-OH in mice (n=6-8 serum samples per time point; mean \pm S.E.M.).

p.o. administration		i.v. administration	
Time, min	Activity Leu-enkephalin-(Lys) ₆ -OH (nM)	Time, min	Activity Leu-enkephalin-(Lys) ₆ -OH (nM)
0	0	5	15900 \pm 2400
15	< Detection Limit	15	8500 \pm 1200
30	3000 \pm 800	30	6000 \pm 950
60	6000 \pm 1300	60	1600 \pm 340
90	10900 \pm 3800	180	440 \pm 110
240	10700 \pm 230	240	2500 \pm 320
480	5000 \pm 580	370	31200 \pm 8620
960	2800 \pm 780	720	< Detection Limit
1380	< Detection Limit	1080	< Detection Limit
N/A	N/A	1440	< Detection Limit

N/A: Non Applicable

5

Following an i.v. injection of 50 mg per kg body weight of Leu-enkephalin-(Lys)₆-OH, a rapid increase in activity was observed in serum already after 5 min. Then, activity declined within the following 30 min, but between 240 min (4 hrs) and 720 min (12 hrs), the activity reached a second peak level. The second peak was possibly related to enterohepatic circulation of the drug after i.v. administration. Activity in plasma was below the detection limit at 12, 18 and 24 hours after i.v. administration of Leu-enkephalin-(Lys)₆-OH. After p.o. administration of Leu-enkephalin-(Lys)₆-OH, the activity in serum reached a maximum at 90-240 min (1.5-4 hrs) and activity was detectable after 8, and 16 hrs, but not after 23 hrs. While high activities were observed at 30 min in serum samples from animals treated with Leu-enkephalin-(Lys)₆-OH either p.o. or i.v., no activity was detected 30 min after p.o. or i.v. administration of the native Leu-enkephalin-OH.

These results suggest that Leu-enkephalin-(Lys)₆-OH, but not Leu-enkephalin-OH, is absorbed after p.o. administration and that the elimination rate in serum is substantially reduced relative to the native Leu-enkephalin in mice.

Stability of Leu-enkephalin-OH and Leu-Enkephalin-(Lys)₆-OH in mouse plasma at 37°C

The stability of Leu-enkephalin-OH, Leu-Enkephalin-(Lys)₆-OH, Leu-Enkephalin-(Glu₂-
 5 Lys-Glu₃)-OH, Leu-Enkephalin-(Lys-Glu₄-Lys)-OH, Leu-Enkephalin-(ORN)₆-OH, Leu-
 Enkephalin-(DBU)₆-OH, Leu-Enkephalin-(DPR)₆-OH, and Leu-Enkephalin-(Lys)₁₀-OH in
 mouse plasma at 37°C was examined in the vas deferens bioassay model as described
 above. Prior to addition of the plasma sample, a standard dose-response curve was
 generated in each preparation in order to express the inhibitory activity as concentration of
 10 each test substance. Thus, the calculated concentration is a reflection of inhibitory activity
 in the vas deferens bioassay preparation. Dose-response data were fitted to the equation:

$$\text{Response} = \text{Initial value} \cdot (1 - (\text{conc}/\text{EC50} + \text{conc})) + \text{background}$$

Where initial = initial helically-induced contraction force prior to addition of test substance;
 conc = concentration of test substance; EC50 = concentration of test substance that
 15 produced half maximal inhibition of electrically-induced contraction; background =
 contraction force during maximal relaxation.

All enkephalin analogues were dissolved in Krebs buffer in a concentration of 1 mM. Sixty-
 six µl of each test substance solution (66 nmol enkephalin analog) was incubated with 600
 20 µl plasma at 37°C. At different time points (2-120 min), 10 µl samples were withdrawn for
 analysis of functional activity. Functional activity of each test substance in plasma was
 expressed as the concentration of the test substance that elicited the same inhibition of
 electrically-induced contraction in the vas deferens bioassay. T1/2 was calculated by fitting
 the time-concentration data to the equation:

$$\text{25} \quad \text{conc}(t) = \text{conc}(0) \cdot e^{(-\ln 2/T_{1/2}) \cdot t}$$

where conc(0) = concentration at t=0. The results are shown in Table 3.

Table 3: EC₅₀ and T_{1/2} values for various enkephalin analogues (n=3-4/test substance; mean).

Compound	EC ₅₀ value (nM)	T _{1/2} min
Leu-Enkephalin-OH	65	6.3
Leu-Enkephalin-(Lys) ₆ -OH	160	18.7
Leu-Enkephalin-(Glu) ₆ -OH	140	ND
Leu-Enkephalin-(Lys-Glu) ₃ -OH	350	ND
Leu-Enkephalin-(Lys ₂ -Glu ₃ -Lys)-OH	680	ND
Leu-Enkephalin-(Lys-Glu ₄ -Lys)-OH	357	84.5
Leu-Enkephalin-(orn) ₆ -OH	>20000	ND
Leu-Enkephalin-(Dbu) ₆ -OH	20000	ND
Leu-Enkephalin-(Dpr) ₆ -OH	200	19.8
Leu-Enkephalin-(Lys) ₁₀ -OH	2500	ND

ND: Not determined.

- 5 These data suggest that modifications of Leu-Enkephalin-OH increased the EC₅₀ value and increased the stability in mouse plasma at 37°C.

μ-Receptor binding of Leu-enkephalin-OH analogues

Affinities for μ opioid receptor were determined using [³H](D-Ala²,N-Me-Phe⁴, Gly-ol⁵)

- 10 Enkephalin (DAMGO) (1 nM) as described by Christensen, 1993, Pharmacol. Toxicol. 73:344-345. In short: Bovine brains were placed on ice within minutes after the slaughter. The caudate nuclei were dissected and homogenized in 20 vol. of 0.32 M sucrose. The homogenate was centrifuged at 2000 g for 10 min. The pellet was re-suspended in 10 vol. of 50 mM Tris-HCl buffer 7.4 and stored at -20 °C until use. The synaptic membrane fraction
- 15 was incubated with 1 nM of [3H]DAMGO in the presence of various concentrations of test ligand. Non specifically bound [3H]-DAMGO was established using 1 μM naloxone. Following 15 min. incubation at 36 °C samples were filtered through Whatman GF/C filters and washed with buffer. Radioactivity was determined using conventional techniques.
- 20 As shown in Table 4 below, all compounds were active in this binding assay, indicating that modification of Leu-enkephalin-OH affects receptor affinity.

Table 4: Affinity of Leu-Enkephalin-OH analogues at μ opioid receptors measured as ^3H -DAMGO binding (IC_{50} values (mean \pm SD)).

Compound	IC_{50} values (nM)	
	Time 0 hours	Time 18 hours
Leu-Enkephalin-OH	97 ± 9	80
Leu-Enkephalin-(Lys) ₆ -OH	17 ± 7	32
Leu-Enkephalin-(Glu) ₆ -OH	10,000	5,000
Leu-Enkephalin-(Lys-Glu) ₃ -OH	450 ± 130	900
Naloxone	9.2 ± 1.0	7

- 5 The low affinity of Leu-Enkephalin-(Glu)₆-OH relative to the other test substances may be due to the very low solubility of this compound. Thus, the IC_{50} value of Leu-Enkephalin-(Glu)₆-OH may be lower if tested in a solvent in which the compound is more soluble.

In vivo experiments with EMP-1-K₆ in mice

- 10 To examine the biological efficacy of peroral (p.o.) treatment with EMP-1 and EMP-1-K₆, the hematological responses of an equimolar p.o. dose (956 nmol) of EMP-1 (2 mg) and EMP-1-K₆ (2.56 mg) were examined in male mice (n=8/group). To examine the time course of the hematological responses, a 10 μl venous blood sample was collected from the retroorbital plexus on days 0, 2, and 4. Body weight (BW) and the plasma concentration of
- 15 hemoglobin (P-Hgb), the hematocrit value (Hct), the red blood cell count (RBC), and the mean cell hemoglobin concentration (MCHC) were determined before (Day 0), and 2 and 4 days after administration of EMP-1 or EMP-1-K₆. The results are shown in Table 5.

Table 5: Changes in body weight and in hematological parameters 4 days after p.o. administration of 956 nmol EMP-1 or EMP-1-K₆. Relative changes are presented in parenthesis (mean \pm SEM).

	EMP-1 p.o.	EMP-1-K ₆ p.o.
BW (g)	3.4 \pm 0.2 (16 \pm 1%)	3.4 \pm 0.3 (15 \pm 2%)
P-hgb (mM)	+1.5 \pm 0.5 (+8 \pm 1%)	+2.4 \pm 0.3* (+15 \pm 2%*)
Hematocrit (%)	0.3 \pm 0.8 (0.8 \pm 1.8%)	4.5 \pm 0.9* (12.3 \pm 2.3%*)
RBC (10 ¹² cells/l)	0.6 \pm 0.2 (9 \pm 3%)	1.0 \pm 0.1* (17 \pm 2%*)
MCHC (mM)	2.9 \pm 1.5 (4 \pm 2%)	0.2 \pm 1.5 (0 \pm 2%)

*: p<0.05 vs. EMP-1 p.o.

5

These data show that the p.o. administration of 2.56 mg EMP-1-K₆ produces a significantly greater increase in P-hgb, Hct, and RBC than the equimolar dose of EMP-1 p.o. None of the compounds affected growth or MCHC. These results suggests that EMP-1-K₆ is absorbed after p.o. administration and that it elicits a rapid stimulation of the erythropoiesis in mice.

10

STUDIES WITH PARATHYROID HORMONE (PTH) ANALOGUES

General Procedures

15 Osteoblast retraction assay

Retraction assays were performed with osteoblast prepared from calvaria of 1-day old mice according to published protocols (Miller et al., 1976, Science 192:1340-1343). In brief, osteoblasts were seeded in serum-free minimal essential medium- α (α MEM) at a density of 3000 cells per cm² into 96-well tissue culture plates coated with 50 μ g/ml of type I collagen in phosphate-buffered saline containing 0.1% bovine serum albumin (PBS). One day after plating, PTH compounds were added to a final concentration of 10 nM and incubation was

20

carried out for 1 h. Cells were then fixed and stained with toluidine blue, and the number of retracted cells was counted by visual inspection.

PTH itself is able retract some 64% of the cells compared to blanks where only 10-12 % of the cells are retracted.

5

Enzyme immunoassay (EIA) for human PTH (1-34)

This is a standard EIA assay (EIAS(h)-6101 from Peninsula Laboratories, Inc.)

Biotinylated peptide and peptide competes for binding to PTH (1-34)-antibody. Streptavidin-conjugated Horseradish Peroxidase (SA-HRP) is allowed to bind to the primary antibody/biotinylated peptide complex. 3,3',5,5'-Tetramethyl Benzidine Dihydrochloride (TMB) is allowed to react with the bound HRP. The colour intensity is used to quantification.

10

Specificity of the assay: hPTH(1-34) = 100%; hPTH(1-38) = 100%; hPTH(1-44) = 0%; hPTH(39-68) = 0%; hPTH(1-84) = 0%; ratPTH(1-34) = 0%.

15

The results are shown in Table 6. In the Osteoblast retraction assay, hPTH(1-34) retains approximately 89% of the activity of native, human parathyroid hormone. H-hPTH(1-34)-K₆-OH and H-K₆-PTH(1-34)-OH show 55 and 49%, respectively of the activity of the mother compound hPTH(1-34). The antibody towards hPTH(1-34) used in EIA recognises

20 the two modifications well.

Table 6

Compound / Assay	Retraction assay % Retracted cells	EIA Relative recovery %
Parathyroid Hormone	63.7	-
hPTH (1-34)	58.2	90.8
H-hPTH(1-34)-K ₆ -OH	37.4	61.8
H-K ₆ -PTH(1-34)-OH	34.7	79.1
Blank	11.8	-

Functional activity of Substance P-NH₂ and (Lys)₆-Substance P-NH₂.

25 The functional activity of Substance P-NH₂ and (Lys)₆-Substance P-NH₂ were characterized using the guinea pig ileum. Experiments were carried out essentially as described by

Kristiansen et al., 1992, Br. J. Pharmacol. 58:1150) with the modification that the illeum was not electrically stimulated. Following application of the compounds the induced contraction was measured. Dose-response data were fitted to the equation:

$$\text{Response} = \text{Initial value} \cdot \text{conc}/(\text{EC50} + \text{conc})$$

5

Where initial value = initial electrically-induced contraction force prior to addition of test substance; conc = concentration of test substance; EC50 = concentration of test substance that produced half maximal inhibition of electrically-induced contraction

SubstanceP-NH₂ (EC50 = 40 nM) and (Lys)₆-SubstanceP-NH₂ (EC50= 5 nM) both acted
10 as agonists at the guinea pig illeum.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the
15 scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

20 Various references are cited herein, the disclosure of which are incorporated by reference in their entirety.

25

06574650


WHAT IS CLAIMED IS:

1. A pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising X and Z,

5

wherein X is a pharmacologically active peptide sequence, and

wherein Z is a stabilising peptide sequence, of 4-20 amino acid units covalently bound to X, wherein each amino acid unit in said stabilising peptide sequence, Z is selected from the
10 group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



15 wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and
20 carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

wherein the ratio between the half-life of said peptide conjugate and the half-life of the
25 corresponding pharmacologically active peptide sequence, X, when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when said pharmacologically active peptide X is not orally
30 absorbed, said conjugate is absorbed,

065720-0657250

or a salt thereof, with the proviso that said pharmacologically active peptide conjugate is not selected from

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH,

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Glu)₆-OH,

- 5 H-Tyr-Gly-Gly-Phe-Leu-(Glu)₆-OH and
H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH.

2. A peptide conjugate according to claim 1, wherein Z is covalently bound to X at the C-terminal carbonyl function of X.

10

3. A peptide conjugate according to claim 1, wherein Z is covalently bound to the N-terminal nitrogen atom of X.

4. A peptide conjugate according to claim 1, wherein the first sequence (Z) is covalently
15 bound to X at the C-terminal carbonyl function of X and the second sequence (Z) is covalently bound to the N-terminal nitrogen atom of X.

5. A peptide conjugate according to claim 1, wherein Z is covalently bound to a nitrogen
atom on the side chain of a lysine, arginine or histidine residue or a carbonyl function on the
20 side chain of glutamic acid or aspartic acid of X.

6. A peptide conjugate according to any of the preceding claims, wherein Z consists of 4-15, preferably 4-10, more preferably 4-7, such as 6 amino acid units.

- 25 7. A peptide conjugate according to claim 5 or 6, wherein each amino acid unit in Z is independently selected from the group consisting of Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Orn, 2,4-diaminobutanoic acid, 2,3-diaminopropanoic acid and Met.

8. A peptide conjugate according to claim 7, wherein each amino acid unit in Z is
30 selected from the group consisting of Glu, Lys and Met.

66E T 20" 065TH E 60

9. A peptide conjugate according to any of claims 5 to 8, wherein Z comprises at least one Lys amino acid unit, preferably at least two Lys amino acid units, such as at least three Lys amino acid units, e.g. at least four Lys amino acid units, more preferably at least five Lys amino acid units, such as six Lys amino acid units.

5

10. A peptide conjugate according to claim 9, wherein Z is (Lys)_n, wherein n is an integer in the range from 4 to 15, preferably in the range from 4 to 10, such as in the range from 4 to 8, e.g. in the range from 4 to 6.

10 11. A peptide conjugate according to claim 9, wherein Z is Lys₄, Lys₅ or Lys₆.

12. A peptide conjugate according to claim 11, wherein Z is Lys₆.

13. A peptide conjugate according to any of claims 5 to 9, wherein Z is (Lys-Xaa)_m or
15 (Xaa-Lys)_m, wherein m is an integer in the range from 2 to 7, and each Xaa is independently selected from the group consisting of Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Orn, 2,4-diaminobutanoic acid, 2,3-diaminopropanoic acid and Met.

14. A peptide conjugate according to claim 13, wherein Z is (Lys-Xaa)₃ or (Xaa-Lys)₃,
20 wherein each Xaa is independently selected from the group consisting of Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Orn, 2,4-diaminobutanoic acid, 2,3-diaminopropanoic acid and Met.

15. A peptide conjugate according to claim 15, wherein Z is (Lys-Glu)₃ or (Glu-Lys)₃.

25

16. A peptide conjugate according to any of claims 5 to 9, wherein Z is Lys_p-Xaa_q or
Xaa_p-Lys_q, wherein p and q are integers in the range from 1 to 14, with the proviso that p+q
is in the range of 3-15, and each Xaa is independently selected from the group consisting of
Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Orn, 2,4-diaminobutanoic acid, 2,3-
30 diaminopropanoic acid and Met.

17. A peptide conjugate according to claim 16, wherein Z is Lys₃-Xaa₃ or Xaa₃-Lys₃, wherein each Xaa is independently selected from the group consisting of Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Orn, 2,4-diaminobutanoic acid, 2,3-diaminopropanoic acid and Met.

5

18. A peptide conjugate according to claim 17, wherein Z is Lys₃-Glu₃ or Glu₃-Lys₃.

19. A peptide conjugate according to claims 5-18, wherein Z is Lys-Lys-Lys-Lys, Xaa-Lys-Lys-Lys, Lys-Xaa-Lys-Lys, Lys-Lys-Xaa-Lys, Lys-Lys-Lys-Xaa, Xaa-Xaa-Lys-Lys, Xaa-

10 Lys-Xaa-Lys, Xaa-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys, Lys-Xaa-Lys-Xaa, Lys-Lys-Xaa-Xaa,
Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Xaa, Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Xaa, Xaa-Xaa-
Xaa-Xaa, Lys-Lys-Lys-Lys-Lys, Xaa-Lys-Lys-Lys-Lys, Lys-Xaa-Lys-Lys-Lys, Lys-Lys-
Xaa-Lys-Lys, Lys-Lys-Lys-Xaa-Lys, Lys-Lys-Lys-Lys-Xaa, Xaa-Xaa-Lys-Lys-Lys, Xaa-
Lys-Xaa-Lys-Lys, Xaa-Lys-Lys-Xaa-Lys, Xaa-Lys-Lys-Lys-Xaa, Lys-Xaa-Xaa-Lys-Lys,
15 Lys-Xaa-Lys-Xaa-Lys, Lys-Xaa-Lys-Lys-Xaa, Lys-Lys-Xaa-Xaa-Lys, Lys-Lys-Xaa-Lys-
Xaa, Lys-Lys-Lys-Xaa-Xaa, Lys-Lys-Xaa-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-
Lys-Xaa, Lys-Xaa-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Lys, Xaa-Xaa-
Lys-Lys-Xaa, Xaa-Xaa-Lys-Xaa-Lys, Xaa-Xaa-Xaa-Lys-Lys, Lys-Xaa-Xaa-Xaa-Xaa, Xaa-
Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Xaa, Xaa-Xaa-Xaa-Xaa-Lys,
20 Xaa-Xaa-Xaa-Xaa-Xaa, Lys-Lys-Lys-Lys-Lys-Lys, Xaa-Lys-Lys-Lys-Lys-Lys, Lys-Xaa-
Lys-Lys-Lys-Lys, Lys-Lys-Xaa-Lys-Lys-Lys, Lys-Lys-Lys-Xaa-Lys-Lys, Lys-Lys-Lys-
Lys-Xaa-Lys, Lys-Lys-Lys-Lys-Lys-Xaa, Xaa-Xaa-Lys-Lys-Lys-Lys, Xaa-Lys-Xaa-Lys-
Lys-Lys, Xaa-Lys-Lys-Xaa-Lys-Lys, Xaa-Lys-Lys-Lys-Xaa-Lys, Xaa-Lys-Lys-Lys-Lys-
Xaa, Lys-Xaa-Xaa-Lys-Lys-Lys, Lys-Xaa-Lys-Xaa-Lys-Lys, Lys-Xaa-Lys-Lys-Xaa-Lys,
25 Lys-Xaa-Lys-Lys-Lys-Xaa, Lys-Lys-Xaa-Xaa-Lys-Lys, Lys-Lys-Xaa-Lys-Xaa-Lys, Lys-
Lys-Xaa-Lys-Lys-Xaa, Lys-Lys-Lys-Xaa-Xaa-Lys, Lys-Lys-Lys-Xaa-Lys-Xaa, Lys-Lys-
Lys-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Lys-Lys, Xaa-Xaa-Lys-Xaa-Lys-Lys, Xaa-Xaa-Lys-
Lys-Xaa-Lys, Xaa-Xaa-Lys-Lys-Lys-Xaa, Xaa-Lys-Xaa-Xaa-Lys-Lys, Xaa-Lys-Xaa-Lys-
Xaa-Lys, Xaa-Lys-Xaa-Lys-Lys-Xaa, Xaa-Lys-Lys-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Lys-
30 Xaa, Xaa-Lys-Lys-Lys-Xaa-Xaa, Lys-Lys-Lys-Xaa-Xaa-Xaa, Lys-Lys-Xaa-Lys-Xaa-Xaa,
Lys-Lys-Xaa-Xaa-Lys-Xaa, Lys-Lys-Xaa-Xaa-Xaa-Lys, Lys-Xaa-Lys-Lys-Xaa-Xaa, Lys-
Xaa-Lys-Xaa-Lys-Xaa, Lys-Xaa-Lys-Xaa-Xaa-Lys, Lys-Xaa-Xaa-Lys-Lys-Xaa, Lys-Xaa-

- Xaa-Lys-Xaa-Lys, Lys-Xaa-Xaa-Xaa-Lys-Lys, Lys-Lys-Xaa-Xaa-Xaa-Xaa, Lys-Xaa-Lys-Xaa-Xaa-Xaa, Lys-Xaa-Xaa-Lys-Xaa-Xaa, Lys-Xaa-Xaa-Xaa-Lys-Xaa, Lys-Xaa-Xaa-Xaa-Xaa-Lys, Xaa-Lys-Lys-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Lys-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Lys-Xaa, Xaa-Lys-Xaa-Xaa-Xaa-Lys, Xaa-Xaa-Lys-Lys-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Lys-Xaa, Xaa-Xaa-Lys-Xaa-Xaa-Lys, Xaa-Xaa-Xaa-Lys-Lys-Xaa, Xaa-Xaa-Xaa-Lys-Lys-Lys, Xaa-Xaa-Xaa-Lys-Xaa-Lys, Xaa-Xaa-Xaa-Xaa-Lys-Lys, Lys-Xaa-Xaa-Xaa-Xaa-Xaa, Xaa-Lys-Xaa-Xaa-Xaa-Xaa, Xaa-Xaa-Lys-Xaa-Xaa-Xaa, Xaa-Xaa-Xaa-Lys-Xaa-Xaa, Xaa-Xaa-Xaa-Xaa-Lys-Xaa, Xaa-Xaa-Xaa-Xaa-Xaa-Lys, or Xaa-Xaa-Xaa-Xaa-Xaa-Xaa, wherein each Xaa is independently selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, Met, Orn, and amino acids of the formula I



- wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid (Dbu) and 2,3-diaminopropanoic acid (Dpr).

20. A peptide conjugate according to any of claims 5 to 18, wherein Z consists of L-amino acids only.
21. A peptide conjugate according to any of claims 5-7, wherein Z is (Dbu)_n or (Dpr)_n, wherein n is an integer in the range from 4 to 15, preferably in the range from 4 to 10, such as in the range from 4 to 8, e.g. in the range from 4 to 6.
22. A peptide conjugate according to claim 1, wherein Z is Dpr₆.

23. A peptide conjugate according to any of the preceding claims, wherein said pharmacologically active peptide sequence (X) consists of at the most 75 amino acid units, such as at the most 65, e.g. at the most 60, preferably at the most 55, such as at the most 53, e.g. at the most 50.

5

24. The peptide conjugate according to claim 16, wherein X is selected from the group consisting of enkephalin, Leu-enkephalin, Met-enkephalin, angiotensin I, angiotensin II, vasopressin, endothelin, vasoactive intestinal peptide, neurotensin, endorphins, insulin, gramicidin, paracelsin, delta-sleep inducing peptide, gonadotropin-Releasing hormone, human parathyroid hormone (1-34), truncated erythropoietin analogues, specifically EMP-1, Atrial natriuretic peptide (ANP, ANF), human brain natriuretic peptide (hBNP), cecropin, kinetensin, neurophysins, elafin, guamerin, atriopeptin I, atriopeptin II, atriopeptin III, deltorphin I, deltorphin II, vasotocin, bradykinin, dynorphin, dynorphin A, dynorphin B, growth hormone release factor, growth hormone, growth hormone releasing peptide, oxytocin, calcitonin, calcitonin gene-related peptide, calcitonin gene-related peptide II, growth hormone releasing peptide, tachykinin, adrenocorticotrophic hormone (ACTH), brain natriuretic polypeptide, cholecystokinin, corticotropin releasing factor, diazepam binding inhibitor fragment, FMRF-amide, galanin, gastric releasing polypeptide, gastric inhibitory polypeptide, gastrin, gastrin releasing peptide, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, LHRH, melanin concentrating hormone, melanocyte stimulating hormone (MSH), alpha-MSH, morphine modulating peptides, motilin, neurokinin A, neurokinin B, neuromedin B, neuromedin C, neuromedin K, neuromedin N, neuromedin U, neuropeptide K, neuropeptide Y, pituitary adenylate cyclase activating polypeptide (PACAP), pancreatic polypeptide, peptide YY, peptide histidine-methionine amide (PHM), secretin, somatostatin, substance K, thyrotropin-releasing hormone (TRH), kyotorphin, melanostatin (MIF-1), thrombopoietin analogs, in particular AF 12505 (Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala), insulin-like growth factor I (57-70) (Ala-Leu-Leu-Glu-Thr-Tyr-Cys-Ala-Thr-Pro-Ala-Lys-Ser-Glu), insulin-like growth factor I (30-41) (Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr), insulin-like growth factor I (24-41)(Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr), insulin-like growth factor II (33-40) (Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg), insulin-like growth [tyro] factor II (33-40) (Tyr-Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg), insulin-like growth factor II (69-84)

09344590-071399

- (Asp-Val-Ser-Thr-Pro-Pro-Thr-Val-Leu-Pro-Asp-Asn-Phe-Pro-Arg-Tyr), growth hormone (GH)-releasing peptide-6 (GHRP-6) (His-DTrp-Ala-Trp-DPhe-Lys-NH₂), beta-Interleukin I (163-171) (Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys), beta-Interleukin II (44-56) (Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu), Interleukin II (60-70) (Leu-Thr-Phe-Lys-Phe-Tyr-Met-Pro-Lys-Lys-Ala), exendin-4 (GLP-1 analog) (His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-NH₂), exendin-3 (GLP-1 analog) (His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser),
- 10 [Cys(Acm)_{20,31}] epidermal growth factor (20-31) Cys(Acm)-Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys(Acm), bivalirudin (Hirulog) (D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu), hirulog-1 D-Phe-Pro-Arg-Pro-(Gly)₄-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Tyr-Leu, C-type natriuretic peptide (1-53) (CNP) (Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys; Disulfide bridge: Cys₃₇-Cys₅₃), "Mini ANP" (Met-Cys-His-cyclohexylAla-Gly-Gly-Arg-Met-Asp-Arg-Ile-Ser-Cys-Tyr-Arg, disulfide bridge cys₂-cys₁₃), Melanotan-II (also known as MT-II, alpha-MSH₄₋₁₀-NH₂, or Ac-Nle₄-Asp₅-His₆-D-Phe₇-Arg₈-Trp₉-Lys₁₀), thymosin alpha₁ (TA₁) (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn), orniressin (also known as 8-ornithine-vasopressin, (POR-8), [Phe₂,Ile₃,Orn₈]vasopressin), Cys-Phe-Ile-Gln-Asn-Cys-Pro-Orn-Gly-NH₂, Disulfide bridge: Cys₁-Cys₆), octreotide (201-995) (DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr-ol; disulfide bridge: Cys₂-Cys₇), eptifibatide (INTEGRILIN), calcitonin gene-related peptide (CGRP) (Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH₂; Disulfide bridge: Cys₂-Cys₇), endomorphin-1 Tyr-Pro-Trp-Phe-NH₂; endomorphin-2 Tyr-Pro-Phe-Phe-NH₂, nociceptin (also known as Orphanin FQ, Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln), angiotensinogen (1-13) (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His), adrenomodullin (1-12) (Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg), antiarrhythmic peptide (AAP) (Gly-Pro-Hyp-Gly-Ala-Gly), Antagonist G (Arg-DTrp-(nMe)Phe-DTrp-Leu-Met-NH₂), indolicidin

66ET20 06544590 0344590

(Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH₂), osteocalcin (37-49) (Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val), cortistatin 29 (1-13) (Glp)-Glu-Arg-Pro-Pro-Leu-Gln-Gln-Pro-Pro-His-Arg-Asp), cortistatin 14 Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys; Disulfide bridge: Cys2-Cys13, PD-145065 (Ac-D-Bhg-Leu-Asp-Ile-Ile-Trp), PD-142893 (Ac-D-Dip-Leu-Asp-Ile-Ile-Trp), fibrinogen binding inhibitor peptide (His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val), leptin (93-105) (Asn-Val-Ile-Gln-Ile-Ser-Asn-Asp-Leu-Glu-Asn-Leu-Arg), GR 83074 (Boc-Arg-Ala-DTrp-Phe-DPro-Pro-Nle-NH₂), Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH₂), parathyroid hormone related peptide (107-111) (Thr-Arg-Ser-Ala-Trp), angiotensinogen (1-14) Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn, Leupeptin (Ac-Leu-Leu-Arg-CHO), and any modified or truncated analogue thereof.

25. A peptide conjugate according to any of the previous claims wherein the conjugate is

15 H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Lys₆-NH₂ (GHRH(1-44)(Human)-Lys₆-NH₂);

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-
20 Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Glu₆-NH₂ (GHRH (1-44)(Human)-Glu₆-NH₂);

H- Lys₆-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Lys₆-PTH(1-
25 34)(Human)-OH);

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Lys₆-OH (PTH(1-
30 34)(Human)-Lys₆-OH);

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys₆-OH (GLP-1-(7-36)(Human)-Lys₆-OH);

66E120*065F4E60

H-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly-Lys₆-OH (EMP-1-Lys₆-OH);

5 H- Lys₆-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly-OH (Lys₆-EMP-1-OH);

H- Lys₆-Gly-Gly-Thr-Tyr-Ser-Cys(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys(Acm)-Lys-Pro-Gln-Gly-Gly- Lys₆-OH (Lys₆-EMP-1- Lys₆-OH);

10

H-Aib-His-2-D-Nal-D-Phe-Lys-(Lys)₆-NH₂ (GHRP-(Lys)₆-NH₂);

H-Tyr-Gly-Gly-Phe-Leu-Lys-Lys-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Lys-Glu-Glu-Glu-Lys-OH);

15

H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-Lys-Glu-Glu-Glu-Glu-Lys-OH);

H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys--OH (Leu-enkephalin-(Lys-Glu)₃);

20

H-Tyr-Gly-Gly-Phe-Leu-(Dpr)₆-OH (Leu-enkephalin-(Dpr)₆-OH);

H-Lys₆-Tyr-Gly-Gly-Phe-Leu-OH (H-Lys₆-Leu-enkephalin);

25 H-Tyr-Gly-Gly-Phe-Leu- Lys₆-OH (H-Leu-enkephalin-Lys₆);

H-Lys₆-Tyr-Gly-Gly-Phe-Leu-Lys₆-OH (H-Lys₆-Leu-enkephalin-Lys₆-OH);

Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys)₆-OH (GnRH-Lys₆-OH);

30

Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys-Glu)₃-OH (GnRH-(Lys-Glu)₃-OH); and

66E F 20 " 065 F 4E60

H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys-Glu)₃-OH (PTH 1-34 human-(Lys-Glu)₃-OH).

5

26. A method for the preparation of a pharmacologically active peptide conjugate (X-Z) as defined in claim 2, comprising the steps of:

a) coupling an N- α -protected amino acid or N- α -protected dipeptide in the carboxyl activated form, in the C-terminal activated form to an immobilised peptide sequence H-Z-SSM, thereby forming an immobilised N- α -protected peptide fragment,

10

b) removing the N- α -protecting group, thereby forming an immobilised peptide fragment having an unprotected N-terminal end,

15

c) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of the immobilised peptide fragment, and repeating the removal/coupling step procedure in step b) and c) until the desired peptide sequence X is obtained, and then

20

d) cleaving off the peptide conjugate from the solid support material.

27. A method for the preparation of a pharmacologically active peptide conjugate (Z-X) as defined in claim 3, comprising the steps of:

25

a) coupling an N- α -protected amino acid, or an N- α -protected dipeptide to a solid support material (SSM), thereby forming an immobilised N- α -protected amino acid,

b) removing the N- α -protecting group, thereby forming an immobilised amino acid or peptide fragment having an unprotected N-terminal end,

30

c) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of the immobilised amino acid or peptide fragment, and repeating the removal/coupling step procedure in step b) and c) until the desired peptide sequence X is obtained,

5

d) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of the immobilised peptide fragment, and repeating the removal/coupling step procedure in step b) and d) until the desired peptide sequence Z is obtained, and then

10

e) cleaving off the peptide conjugate from the solid support material.

28. A method for the preparation of a pharmacologically active peptide conjugate (Z-X-Z) as defined in claim 4, comprising the steps of:

15

a) coupling an N- α -protected amino acid in the carboxyl activated form, or an N- α -protected dipeptide in the C-terminal activated form to an immobilised peptide sequence H-Z-SSM, thereby forming an immobilised N- α -protected peptide fragment,

20 b) removing the N- α -protecting group, thereby forming an immobilised peptide fragment having an unprotected N-terminal end,

c) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of
25 the immobilised peptide fragment, and repeating the removal/coupling step procedure in step b) and c) until the desired peptide sequence X is obtained, and then

d) coupling an additional N- α -protected amino acid in the carboxyl activated form, or an additional N- α -protected dipeptide in the C-terminal activated form to the N-terminal end of
30 the immobilised peptide fragment, and repeating the removal/coupling step procedure in step b) and d) until the desired peptide sequence Z is obtained, and then

054450 071390
0551450

- e) cleaving off the peptide conjugate from the solid support material.
29. A method for producing the peptide conjugate of claim 1, comprising
- a) introducing a nucleic acid sequence encoding said conjugate into a host cell;
 - 5 b) culturing said host cell and
 - c) isolating said conjugate from the culture.
30. A method for producing the peptide conjugate of claim 1, comprising
- a) culturing a recombinant host cell comprising a nucleic acid sequence encoding said
 - 10 conjugate under conditions permitting the production of said conjugate; and
 - b) isolating said conjugate from the culture.
31. The method according to claim 29 or claim 30, wherein the nucleic acid sequence encoding said conjugate is contained within a nucleic acid construct or a vector.
- 15 32. A composition comprising a pharmacologically active peptide conjugate as defined in any of the claims 1-25, and a pharmaceutical acceptable carrier.
33. A composition comprising
- 20 H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH,
 - H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Glu)₆-OH,
 - H-Tyr-Gly-Gly-Phe-Leu-(Glu)₆-OH or
 - H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH, and a pharmaceutical acceptable carrier.
- 25 34. A pharmacologically active peptide conjugate as defined in any of claims 1-26 for use in therapy.
35. A pharmacologically active peptide conjugate selected from the group consisting of
- H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Lys-Glu)₃-OH,
 - 30 H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-(Glu)₆-OH,
 - H-Tyr-Gly-Gly-Phe-Leu-(Glu)₆-OH and
 - H-Tyr-Gly-Gly-Phe-Leu-(Lys)₆-OH,

666170"06574660

37. A method for inhibiting neurons from transmitting pain impulses to the spinal cord, comprising administering to a subject in need thereof a conjugate comprising enkephalin
10 and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



25 wherein the ratio between the half-life of said peptide conjugate and the half-life of
enkephalin when treated with carboxypeptidase A or leucine aminopeptidase in about 50
mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at
least about 2, preferably at least about 3, such as at least about 5, more preferably at least
about 7, such as at least about 9, e.g. at least about 10 or when X is inot orally absorbed said
30 peptide conjugate is orally absorbed in an amount effective to inhibit neurons from
transmitting pain impulses.

38. Use of a conjugate comprising enkephalin and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I

5



wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

Wherein the ratio between the half-life of said peptide conjugate and the half-life of enkephalin when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is inot orally absorbed said peptide conjugate is orally absorbed for the manufacture of a pharmaceutical composition for use in treatment of pain.

39. A method for stimulating the release of growth hormone from the pituitary comprising administering to a subject in need thereof a conjugate comprising growth hormone releasing hormone or growth hormone releasing peptide and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



wherein R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} -alkyl, phenyl, and phenyl-methyl, wherein C_{1-6} -alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and
 5 phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C_{1-6} -alkyl, C_{2-6} -alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R^1 and R^2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

10

Wherein the ratio between the half-life of said peptide conjugate and the half-life of growth hormone releasing hormone or growth hormone releasing peptide when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least
 15 about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is inot orally absorbed said peptide conjugate is orally absorbed in an amount effective to stimulate the release of growth hormone.

40. Use of a conjugate comprising growth hormone releasing hormone or growth hormone
 20 releasing peptide and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



25

wherein R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} -alkyl, phenyl, and phenyl-methyl, wherein C_{1-6} -alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents
 30 selected from C_{1-6} -alkyl, C_{2-6} -alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R^1 and R^2 together with the carbon atom to which they are bound form a

cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

wherein the ratio between the half-life of said peptide conjugate and the half-life of growth hormone releasing hormone or growth hormone releasing peptide when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is not orally absorbed, said peptide conjugate is orally absorbed, for the manufacture of a pharmaceutical composition for use in stimulating the release of growth hormone.

41. A method for increasing hemoglobin levels comprising administering to a subject in need thereof a conjugate comprising EMP-1 and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I




20

wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

30 Wherein the ratio between the half-life of said peptide conjugate and the half-life of EMP-1 when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least

about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is not orally absorbed said peptide conjugate is orally absorbed in an amount effective to increase hemoglobin levels.

- 5 42. Use of a conjugate comprising EMP-1 and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and
 15 phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid;

20 wherein the ratio between the half-life of said peptide conjugate and the half-life of EMP-1 when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7,
 25 such as at least about 9, e.g. at least about 10 or when X is not orally absorbed said peptide conjugate is orally absorbed for the manufacture of a pharmaceutical composition for use in treating anemia by increasing hemoglobin levels.

43. A method for preventing or treating bone loss by altering the balance between
 30 osteoclastic and osteoblast activity comprising administering to a patient in need thereof a conjugate comprising parathyroid hormone and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu,

Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



5

wherein R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} -alkyl, phenyl, and phenyl-methyl, wherein C_{1-6} -alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C_{1-6} -alkyl, C_{2-6} -alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R^1 and R^2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

- 15 Wherein the ratio between the half-life of said peptide conjugate and the half-life of parathyroid hormone when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is not orally absorbed
- 20 said peptide conjugate is orally absorbed in an amount effective to treat or prevent bone loss.

44. Use of a conjugate comprising parathyroid hormone and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of

- 25 Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



- 30 wherein R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} -alkyl, phenyl, and phenyl-methyl, wherein C_{1-6} -alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and

phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 5 diaminopropanoic acid; and

Wherein the ratio between the half-life of said peptide conjugate and the half-life of parathyroid hormone when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma
 10 is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10, or when X is not orally absorbed said peptide conjugate is orally absorbed, for the manufacture of a pharmaceutical composition for use in preventing or treating osteoporosis.

15 45. A method for reducing blood glucose levels comprising administering to a subject in need thereof a conjugate comprising glucagon-like peptide-1 and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I

20



wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three
 25 substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 30 diaminopropanoic acid; and

66E T 20 " 065 T 4660

wherein the ratio between the half-life of said peptide conjugate and the half-life of glucagon-like peptide-1 when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is not orally absorbed said peptide conjugate is orally absorbed in an amount effective to reduce blood glucose levels.

46. Use of a conjugate comprising glucagon-like peptide-1 and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



15

wherein R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} -alkyl, phenyl, and phenyl-methyl, wherein C_{1-6} -alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C_{1-6} -alkyl, C_{2-6} -alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R^1 and R^2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

25 wherein the ratio between the half-life of said peptide conjugate and the half-life of glucagon-like peptide-1 when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is not orally absorbed said peptide conjugate is orally absorbed, for the manufacture of a pharmaceutical composition for use in treatment of diabetes.

47. A method for regulating production of sex hormones comprising administering to a subject in need thereof a conjugate comprising gonadotropin releasing hormone and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



- wherein R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} -alkyl, phenyl, and phenyl-methyl, wherein C_{1-6} -alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C_{1-6} -alkyl, C_{2-6} -alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R^1 and R^2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

- wherein the ratio between the half-life of said peptide conjugate and the half-life of gonadotropin when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is not orally absorbed said peptide conjugate is orally absorbed in an amount effective to regulate production of sex hormones.


25

48. Use of a conjugate comprising gonadotropin releasing hormone and a stabilising sequence, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I

30



- wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents
- 5 selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and
- 10 wherein the ratio between the half-life of said peptide conjugate and the half-life of gonadotropin releasing hormone when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10 or when X is
- 15 not orally absorbed said peptide conjugate is orally absorbed and the ratio between the half-life of said peptide conjugate for the manufacture of a pharmaceutical composition for use in regulating the level of sex hormones.
49. A method for treating sleep disorders comprising administering to a subject in need
- 20 thereof a conjugate comprising delta sleep inducing peptide and a stabilising probe, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



- wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and
- 30 phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a

cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

wherein the ratio between the half-life of said peptide conjugate and the half-life of delta-sleep inducing peptide when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C or in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10, or when the pharmacologically active peptide X is not orally absorbed, the conjugate will be orally absorbed, in an amount effective to treat said sleep disorder.

50. Use of a conjugate comprising delta-sleep inducing peptide and a stabilising probe, Z of 4-20 amino acids covalently attached to X, wherein Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I



wherein R¹ and R² are selected from the group consisting of hydrogen, C₁₋₆-alkyl, phenyl, and phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and

wherein the ratio between the half-life of said peptide conjugate and the half-life of Substance P when treated with carboxypeptidase A or leucine aminopeptidase in about 50 mM phosphate buffer solution at about pH 7.4 at about 37°C and in serum or plasma is at least about 2, preferably at least about 3, such as at least about 5, more preferably at least about 7, such as at least about 9, e.g. at least about 10, or when the pharmacologically active

peptide X is not orally absorbed, the conjugate will be orally absorbed, for the manufacture of a pharmaceutical composition for use in treating a sleep disorder

- 5 51. Use of a stabilising peptide sequence (Z) of 4-20 amino acid units for the preparation of a pharmacologically active peptide conjugate as defined in any of claims 1-26,

each amino acid unit in said stabilising peptide sequence Z being independently selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His,

- 10 Met, Orn, or amino acid units of the general formula I



- wherein R¹ and R² independently are selected from hydrogen, C₁₋₆-alkyl, phenyl, and
 15 phenyl-methyl, wherein C₁₋₆-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R¹ and R² together with the carbon atom to which they are bound form a
 20 cyclopentyl, cyclohexyl, or cycloheptyl ring;
 or a salt thereof.

ABSTRACT

The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide
5 sequence (X) and a stabilising petide sequence (Z) of 4-20 amino acid residues covalently bound to X.

SECRET 05/14/80

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
 (Includes Reference to PCT International Applications)

Attorney's Docket Number:

PPT-20479-US

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYME HYDROLYSIS

the specification of which (check only one item below):

☐ is attached hereto

☐ was filed as United States application

Application No.

on _____,

and was amended

on _____

☒ was filed as PCT international application

Number PCT/ DK99/000118

on 9 March 1999,

and was amended under PCT Article 19

on _____

I/We hereby state that I/We have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.


I/We acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, 81.56.

I/We hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign applications(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Denmark	0317/98	9 March 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

66470 065460



COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to PCT International Applications)				Attorney's Docket Number
3	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
4	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
5	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
6	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
7	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
8	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
9	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.</p>				

09-07-99 15:40

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applications)

Attorney's Docket Number:

Signature of Inventor 1

Paul H. H. H.

Signature of Inventor 2

Signature of Inventor 3

Date

9/7/99

Date

Date

Signature of Inventor 4

Signature of Inventor 5

Signature of Inventor 6

Date

Date

Date

Signature of Inventor 7

Signature of Inventor 8

Signature of Inventor 9

Date

Date

Date

Signature of Inventor 10

Signature of Inventor 11

Signature of Inventor 12

Date

Date

Date

09-07-99 16:47



TRADE MARK SERVICE

<212> PRT

$\langle 220 \rangle$ $\langle 220 \rangle$

<222> (2)

 $\langle 220 \rangle$

<222> (5)

<400> 3

1

5

<211> 6

<213> Artificial Sequence

 $\langle 220 \rangle$ $\langle 220 \rangle$

$\langle 222 \rangle$ (2)

<223> D-Pen

<400> 4

1

5

<211> 7

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$ $\langle 220 \rangle$

<222> (2)

<223> D-Pen

 $\langle 220 \rangle$

<222> (5)

<223> D-Pen

<400> 5

Tyr Xaa Gly Phe Xaa Arg Gly
1 5

<210> 6

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DPLCE-Arg-Gly

<220>

<221> MOD_RES

<222> (2)

<223> D-Pen

<400> 6

Tyr Xaa Gly Phe Cys Arg Gly
1 5

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DPDPE-Phe-Ala

<220>

<221> MOD_RES

<222> (2)

<223> D-Pen

<220>

<221> MOD_RES

<222> (5)

<223> D-Pen

<400> 7

Tyr Xaa Gly Phe Xaa Phe Ala
1 5

<210> 8

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DSIP-(Lys-Glu)3

<400> 8

Trp Ala Gly Gly Asp Ala Ser Gly Glu Lys Glu Lys Glu Lys Glu
1 5 10 15

66E720"063T4E69

<400> 13
Cys Tyr Ile Gln Asn Cys Pro Leu Gly
1 5

<220>
<223> Description of Artificial Sequence: AF 12505

```
<210> 15
<211> 14
<212> PRT
<213> Homo sapiens
```

<400> 15
Ala Leu Leu Glu Thr Tyr Cys Ala Thr Pro Ala Lys Ser Glu
1 5 10

```
<210> 16
<211> 12
<212> PRT
<213> Homo sapiens
```

<220>
<223> insulin-like growth factor I (30-41)

<400> 16
Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr
1 5 10

```
<210> 17
<211> 18
<212> PRT
<213> Homo sapiens
```

<220>
<223> insulin-like growth factor I (24-41)

<400> 17
Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro
1 5 10 15

Gln Thr

<210> 18

<211> 8
 <212> PRT
 <213> Homo sapiens

<220>
 <223> insulin-like growth factor II (33-40)

<400> 18
 Ser Arg Val Ser Arg Arg Ser Arg
 1 5

<210> 19
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: insulin-like
 growth [tyro] factor II (33-40)

<400> 19
 Tyr Ser Arg Val Ser Arg Arg Ser Arg
 1 5

<210> 20
 <211> 16
 <212> PRT
 <213> Homo sapiens

<220>
 <223> insulin-like growth factor II (69-84)

<400> 20
 Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg Tyr
 1 5 10 15

<210> 21
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: GHRP-6

<220>
 <221> MOD_RES
 <222> (2)
 <223> D-Trp

<220>
 <221> MOD_RES
 <222> (5)
 <223> D-Phe

<400> 21

552140"0694E60

His Xaa Ala Trp Xaa Lys
1 5

<210> 22
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<223> beta-Interleukin I (163-171)

<400> 22
Val Gln Gly Glu Glu Ser Asn Asp Lys
1 5

<210> 23
<211> 13
<212> PRT
<213> Homo sapiens

<220>
<223> beta-Interleukin II (44-56)

<400> 23
Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu
1 5 10

<210> 24
<211> 11
<212> PRT
<213> Homo sapiens

<220>
<223> Interleukin II (60-70)

<400> 24
Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala
1 5 10

<210> 25
<211> 39
<212> PRT
<213> Heloderma suspectum

<220>
<223> exendin-4

<400> 25
His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

55E40"069T4E50

Ser Gly Ala Pro Pro Pro Ser
35

<210> 26
<211> 39
<212> PRT
<213> Heloderma horridum

<220>
<223> exendin-3

<400> 26
His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> 27
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: modified epidermal
growth factor

<220>
<221> MOD_RES
<222> (1)
<223> Cys (Acm)

<220>
<221> MOD_RES
<222> (12)
<223> Cys (Acm)

<400> 27
Xaa Met His Ile Glu Ser Leu Asp Ser Tyr Thr Xaa
1 5 10

<210> 28
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: bivalirudin

<220>
<221> MOD_RES
<222> (1)

054120-054120

<223> D-Phe

<400> 28

Xaa Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro
1 5 10 15

Glu Glu Tyr Leu
20

<210> 29

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: hirulog-1

<220>

<221> MOD_RES

<222> (1)

<223> D-Phe

<400> 29

Xaa Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro
1 5 10 15

Glu Tyr Leu

<210> 30

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<223> C-type natriuretic peptide (1-53)

<400> 30

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu
1 5 10 15

Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys Gly
20 25 30

Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met
35 40 45

Ser Gly Leu Gly Cys
50

<210> 31

<211> 15

<212> PRT

<213> Artificial Sequence

652120"06374E60

<220>

<223> Description of Artificial Sequence: Mini ANP

<220>

<221> MOD_RES

<222> (4)

<223> cyclohexyl-Ala

<400> 31

Met Cys His Xaa Gly Gly Arg Met Asp Arg Ile Ser Cys Tyr Arg
1 5 10 15

<210> 32

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Melanotan II

<220>

<221> MOD_RES

<222> (1)

<223> Nle

<220>

<221> MOD_RES

<222> (4)

<223> D-Phe

<400> 32

Xaa Asp His Xaa Arg Trp Lys
1 5

<210> 33

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: thymosin alpha 1

<400> 33

Ser Asp Ala Ala Val Asp Thr Ser Ser Glu Ile Thr Thr Lys Asp Leu
1 5 10 15

Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn
20 25

<210> 34

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

6547200621460

```
<220>  
<221> MOD_RES  
<222> (8)  
<223> Orn
```

```
<210> 35
<211> 8
<212> PRT
<213> Artificial Sequence
```

```

<220>
<221> MOD_RES
<222> (1)
<223> D-Phe

```

```
<220>  
<221> MOD_RES  
<222> (4)  
<223> D-Trp
```

```
<220>
<221> MOD_RES
<222> (8)
<223> Thr-ol
```

<400> 35
Xaa Cys Phe Xaa Lys Thr Cys Xaa
1 5

```
<210> 36
<211> 37
<212> PRT
<213> Homo sapiens
```

<220>
<223> CGRP

<400> 36
Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu
1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val
20 25 30

Gly Ser Lys Ala Phe
35

<210> 37
 <211> 4
 <212> PRT
 <213> Homo sapiens

<220>
 <223> endomorphin-1

<400> 37
 Tyr Pro Trp Phe
 1

<210> 38
 <211> 4
 <212> PRT
 <213> Homo sapiens

<220>
 <223> endomorphin-2

<400> 38
 Tyr Pro Phe Phe
 1

<210> 39
 <211> 17
 <212> PRT
 <213> Homo sapiens

<220>
 <223> nociceptin

<400> 39
 Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn
 1 5 10 15

Gln

<210> 40
 <211> 13
 <212> PRT
 <213> Homo sapiens

<220>
 <223> angiotensinogen (1-13)

<400> 40
 Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile His
 1 5 10

<210> 41
 <211> 12

<212> PRT

<213> Homo sapiens

<220>

<223> adrenomedullin (1-12)

<400> 41

Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu Arg
1 5 10

<210> 42

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antiarrhythmic peptide

<220>

<221> MOD_RES

<222> (3)

<223> Hyp

<400> 42

Gly Pro Xaa Gly Ala Gly
1 5

<210> 43

<211> 13

<212> PRT

<213> bovinæ

<220>

<223> indolicidin

<400> 43

Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg
1 5 10

<210> 44

<211> 13

<212> PRT

<213> Homo sapiens

<220>

<223> osteocalcin (37-49)

<400> 44

Gly Phe Gln Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val
1 5 10

<210> 45

<211> 13

<212> PRT

66720-053466

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cortistatin 29 (1-13)

<220>

<221> MOD_RES

<222> (1)

<223> Glp

<400> 45

Xaa	Glu	Arg	Pro	Pro	Leu	Gln	Gln	Pro	Pro	His	Arg	Asp
1				5					10			

<210> 46

<211> 14

<212> PRT

<213> Homo sapiens

<220>

<223> cortistatin 14

<400> 46

Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys	Lys
1				5					10				

<210> 47

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PD-145065

<220>

<221> MOD_RES

<222> (1)

<223> D-Bhg

<400> 47

Xaa	Leu	Asp	Ile	Ile	Trp
1				5	

<210> 48

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PD-142893

<220>

<221> MOD_RES

<222> (1)

<223> D-Dip

666720-053460

Xaa Leu Asp Ile Ile Trp
1 5

<211> 12

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Description of Artificial Sequence: fibrinogen binding inhibitor peptide

His His Leu Gly Gly Ala Lys Gln Ala Gly Asp Val
1 5 10

<211> 13

<212> PRT

<213> Homo sapiens

 $\langle 220 \rangle$

<223> leptin (93-105)

Asn Val Ile Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg
1 5 10

<211> 7

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Description of Artificial Sequence: GR 83074

 $\langle 220 \rangle$

<221> MOD RES

<222> (1)

<223> Boc-Arg

 $\langle 220 \rangle$

<221> MOD RES

<222> (3)

<223> D-Trp

 $\langle 220 \rangle$

<221> MOD RES

<222> (5)

<223> D-Pro

 $\langle 220 \rangle$

<221> MOD_RES

<223> N1e

Xaa Ala Xaa Phe Xaa Pro Xaa
1 5

<211> 4

<213> Homo sapiens

<223> Tyr-W-MIF-1

Tyr Pro Trp Gly
1

$\langle 211 \rangle$ 5

<213> Homo sapiens

<223> parathyroid hormone related peptide (107-111)

Thr Arg Ser Ala Trp
1 5

<211> 14

<213> Homo sapiens

<223> angiotensinogen (1-14)

Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile His Asn
1 5 10

$\langle 211 \rangle$ 4

<213> Artificial Sequence

<223> Description of Artificial Sequence: Stabilising peptide

Lys Lys Lys Lys
1

<210> 56
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<400> 56
 Lys Lys Lys Lys Lys
 1 5

<210> 57
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 57
 Xaa Lys Lys Lys Lys
 1 5

<210> 58
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 58
 Lys Xaa Lys Lys Lys
 1 5

<210> 59
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 59

Lys Lys Xaa Lys Lys
1 5

<210> 60

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 60

Lys Lys Lys Xaa Lys
1 5

<210> 61

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 61

Lys Lys Lys Lys Xaa
1 5

<210> 62

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<400> 62

Lys Lys Lys Lys Lys Lys
1 5

666770-954460

<210> 63
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 63
 Xaa Lys Lys Lys Lys Lys
 1 5

<210> 64
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 64
 Lys Xaa Lys Lys Lys Lys
 1 5

<210> 65
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 65
 Lys Lys Xaa Lys Lys Lys
 1 5

<210> 66
 <211> 6

66T20"053T4E60

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 66
 Lys Lys Lys Xaa Lys Lys
 1 5

<210> 67
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 67
 Lys Lys Lys Lys Xaa Lys
 1 5

<210> 68
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 68
 Lys Lys Lys Lys Lys Xaa
 1 5

<210> 69
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>

66ET/20-05ET4E00

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 69

Xaa Xaa Lys Lys Lys Lys
1 5

<210> 70

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 70

Xaa Lys Xaa Lys Lys Lys
1 5

<210> 71

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 71

Xaa Lys Lys Xaa Lys Lys
1 5

<210> 72

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence

662729-053460

may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 72

Xaa Lys Lys Lys Xaa Lys
1 5

<210> 73

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 73

Xaa Lys Lys Lys Lys Xaa
1 5

<210> 74

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 74

Lys Xaa Xaa Lys Lys Lys
1 5

<210> 75

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<220>

<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 75

66E T 40 " 06234463


```
<210> 76
<211> 6
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

```
<210> 77
<211> 6
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Xaa at various positions throughout the sequence
      may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
      Glu, Arg, His, Met, Orn, Dbu or Dpr
```

```
<210> 78
<211> 6
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Xaa at various positions throughout the sequence
may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 78
Lys Lys Xaa Xaa Lys Lys
1 5

<210> 79
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 79
 Lys Lys Xaa Lys Xaa Lys
 1 5

<210> 80
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 80
 Lys Lys Xaa Lys Lys Xaa
 1 5

<210> 81
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 81
 Lys Lys Lys Xaa Xaa Lys
 1 5

<210> 82
 <211> 6
 <212> PRT
 <213> Artificial Sequence

66E1/0"0534E60

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 82
 Lys Lys Lys Xaa Lys Xaa
 1 5

<210> 83
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<220>
 <223> Xaa at various positions throughout the sequence
 may be Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp,
 Glu, Arg, His, Met, Orn, Dbu or Dpr

<400> 83
 Lys Lys Lys Lys Xaa Xaa
 1 5

<210> 84
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<400> 84
 Lys Glu Lys Glu Lys Glu
 1 5

<210> 85
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Stabilising peptide

<400> 85
 Glu Lys Glu Lys Glu Lys
 1 5

66E1720-0537460

<210> 86
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<400> 86

Lys Lys Lys Glu Glu Glu
 1 5

<210> 87

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Stabilising peptide

<400> 87

Glu Glu Glu Lys Lys Lys
 1 5

<210> 88

<211> 50

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: GHRH (1-44)-Lys6

<400> 88

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln
 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly
 20 25 30

Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu Lys Lys Lys Lys
 35 40 45

Lys Lys
 50

<210> 89

<211> 50

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: GHRH (1-44)-Glu6

662720 05342660

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly
20 25 30

Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu Glu Glu Glu Glu
35 40 45

Glu Glu
50

<211> 40

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Description of Artificial Sequence: Lys6-PTH (1-34)

Lys Lys Lys Lys Lys Lys Ser Val Ser Glu Ile Gln Leu Met His Asn
1 5 10 15

Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys
20 25 30

Lys Leu Gln Asp Val His Asn Phe
35 40

<211> 40

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Description of Artificial Sequence: PTH (1-34)-Lys6

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe Lys Lys Lys Lys Lys Lys
35 40

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: GLP-1 (7-36)-Lys6

<400> 92

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Lys Lys
20 25 30

Lys Lys Lys Lys
35

<210> 93

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EMP-1-Lys6

<220>

<221> MOD_RES

<222> (6)

<223> Cys (Acm)

<220>

<221> MOD_RES

<222> (15)

<223> Cys (Acm)

<400> 93

Gly Gly Thr Tyr Ser Xaa His Phe Gly Pro Leu Thr Trp Val Xaa Lys
1 5 10 15

Pro Gln Gly Gly Lys Lys Lys Lys Lys
20 25

<210> 94

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Lys6-EMP-1

<220>

<221> MOD_RES

<222> (12)

<223> Cys (Acm)

<220>

<221> MOD_RES

<222> (21)

<223> Cys (Acm)

<400> 94

bioRxiv preprint doi: <https://doi.org/10.1101/063446>; this version posted March 1, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Leu Thr Trp Val Xaa Lys Pro Gln Gly Gly
20 25

<220>
<223> Description of Artificial Sequence: Lys6-EMP-1-Lys6

```

<220>
<221> MOD_RES
<222> (21)
<223> Cys (Acm)

```

Leu Thr Trp Val Xaa Lys Pro Gln Gly Gly Lys Lys Lys Lys Lys Lys
20 25 30

<220>
<223> Description of Artificial Sequence: GHRP-(Lys)6

```
<220>  
<221> MOD_RES  
<222> (3)  
<223> 2-D-Nal
```

```
<220>  
<221> MOD_RES  
<222> (4)  
<223> D-Phe
```

Xaa His Xaa Xaa Lys Lys Lys Lys Lys Lys Lys
1 5 10

<211> 11

<212> PRT

 $\langle 220 \rangle$

<400> 97

Tyr Gly Gly Phe Leu Lys Lys Glu Glu Glu Lys
1 5 10

<211> 11

<212> PRT

<220>

<400> 98

Tyr Gly Gly Phe Leu Lys Glu Glu Glu Glu Lys
1 5 10

<211> 11

<212> PRT

 $\langle 220 \rangle$

<400> 99

Tyr Gly Gly Phe Leu Lys Glu Lys Glu Lys Glu
1 5 10

<211> 11

<212> PRT

 $\langle 220 \rangle$ $\langle 220 \rangle$

<221> MOD RES

$$\langle 222 \rangle \quad (6) \quad \bar{\cdot} \cdot (11)$$

<223> Dpr

<400> 100

Tyr Gly Gly Phe Leu Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 101

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Lys6-Leu-enkephalin

<400> 101

Lys Lys Lys Lys Lys Lys Tyr Gly Gly Phe Leu
1 5 10

<210> 102

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Lys6-Leu-enkephalin-Lys6

<400> 102

Lys Lys Lys Lys Lys Lys Tyr Gly Gly Phe Leu Lys Lys Lys Lys Lys
1 5 10 15

Lys

<210> 103

<211> 16

<212> PRT

<213> Homo sapiens

<220>

<223> GnRH-Lys6

<400> 103

Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Lys Lys Lys Lys Lys Lys
1 5 10 15

<210> 104

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: GnRH-(Lys-Glu)3

<400> 104

0044590-01399

Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Lys Glu Lys Glu Lys Glu
 1 5 10 15

<210> 105

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PTH 1-34 (Lys-Glu)3

<400> 105

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe Lys Glu Lys Glu Lys Glu
 35 40

<210> 106

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Leu-enkephalin-(Orn)6

<220>

<221> MOD_RES

<222> (6)..(11)

<223> Orn

<400> 106

Tyr Gly Gly Phe Leu Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10

<210> 107

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Leu-enkephalin-(Dbu)6

<220>

<221> MOD_RES

<222> (6)..(11)

<223> Dbu

<400> 107

Tyr Gly Gly Phe Leu Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10

66E120"06374E60

<210> 108
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Leu-enkephalin-(Dpr)6

<220>
 <221> MOD_RES
 <222> (6)..(11)
 <223> Dpr

<400> 108
 Tyr Gly Gly Phe Leu Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10

<210> 109
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Leu-enkephalin-Lys10

<400> 109
 Tyr Gly Gly Phe Leu Lys Lys Lys Lys Lys Lys Lys Lys Lys
 1 5 10 15

<210> 110
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> DSIP

<400> 110
 Trp Ala Gly Gly Asp Ala Ser Gly Glu
 1 5

<210> 111
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Substance P-Lys6

<400> 111
 Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met Lys Lys Lys Lys Lys
 1 5 10 15

Lys

666720"06514E60

<210> 112
 <211> 11
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Substance P

<400> 112
 Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met
 1 5 10

<210> 113
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Lys6-Substance P

<400> 113
 Lys Lys Lys Lys Lys Lys Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu
 1 5 10 15

Met

<210> 114
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Lys6-GHRP

<220>
 <221> MOD_RES
 <222> (7)
 <223> Aib

<220>
 <221> MOD_RES
 <222> (9)
 <223> 2-D-Nal

<220>
 <221> MOD_RES
 <222> (10)
 <223> D-Phe

<400> 114
 Lys Lys Lys Lys Lys Lys Xaa His Xaa Xaa Lys
 1 5 10

<210> 115
 <211> 10
 <212> PRT
 <213> Homo sapiens

<220>
 <223> GnRH

<220>
 <221> MOD_RES
 <222> (1)
 <223> pGlu

<400> 115
 Xaa His Trp Ser Tyr Gly Leu Arg Pro Gly
 1 5 10

<210> 116
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Lys6-GnRH

<400> 116
 Lys Lys Lys Lys Lys Lys Gln His Trp Ser Tyr Gly Leu Arg Pro Gly
 1 5 10 15

<210> 117
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: EMP-1

<400> 117
 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly
 20

<210> 118
 <211> 30
 <212> PRT
 <213> Homo sapiens

<220>
 <223> GLP-1-(7-36)

<400> 118

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
 20 25 30

<210> 119

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<223> PTH (1-34)

<400> 119

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe

<210> 120

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
 Leu-enkephalin-Lys-(Glu)3-(Lys)2

<400> 120

Tyr Gly Gly Phe Leu Lys Glu Glu Glu Lys Lys
 1 5 10

<210> 121.

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<223> Leu-enkephalin-(Glu2-Lys-Glu3)

<400> 121

Tyr Gly Gly Phe Leu Glu Glu Lys Glu Glu Glu
 1 5 10

Sequence